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Group B Streptococcus (GBS, Streptococcus agalactiae) has been recognized as an impor-
tant cause of neonatal infection and early neonatal mortality within the first seven days of 
life.(1-3)
Vertical transmission of GBS from mother to child occurs during labor. The gastrointesti-
nal tract of the mother has been recognized as the source of vaginal GBS colonization. The 
frequency of GBS colonization ranges from 10% to 35% in women of reproductive age.(4;5) 
Studies on vertical GBS transmission in colonized mothers during labor report incidences 
of colonization of the infant between 16 and 69%.(6-11) Early-onset group B streptococcal 
disease (GBS-EOD) occurs in approximately 1% of newborns who are colonized with GBS 
and typically presents with sepsis, pneumonia or meningitis.(12) Risk factors for acquir-
ing GBS-EOD are prelabor rupture of membranes, preterm labor, intrapartum fever, GBS 
bacteriuria during pregnancy or a previous child with GBS.(13)
Clinical trials in the USA during the 1980s showed that GBS-EOD may be prevented by 
administering antibiotics during labor to mothers who are colonized with GBS.(14) After 
introduction of national guidelines in 2002, in which culture based screening of all pregnant 
women and intrapartum antibiotic prophylaxis (IAP) in all GBS carriers was recommended, 
the incidence of GBS-EOD in the USA has declined from 1.8 per 1000 live births to 0.32 
cases per 1000 live births in 2003.(5;15) Overall mortality from GBS-EOD, as high as 50% 
in 1970s, fell to 5% in 2003.(1;16-18)
In Europe little data have been published on national incidence rates of GBS-EOD. The inci-
dence of neonatal early-onset GBS disease in some European countries varies from 0.5 to 
1.15 per 1000 live born infants.(19-21) In the United Kingdom, studies reported incidence 
rates of GBS-EOD of 0.5 per 1000 live births in the absence of screening,(19;22) with a 
case-fatality rate of 10.6%.(22)
In the Netherlands, the incidence of GBS-EOD before implementation of a nationwide 
guideline during a 2-year period (1997-1998) was 1.9 per 1000 live born infants. This is 
the total incidence of proven sepsis and probable sepsis. In proven sepsis, streptococci 
are isolated from blood and/or from cerebrospinal fluid combined with physical signs of 
infection in the neonate. In probable sepsis GBS is detected in serious ill children at various 
sites, but not in blood and/or cerebrospinal fluid. The incidence of proven GBS-EOD alone 
was 0.54 per 1000 live births. After the Dutch Society of Obstetrics and Gynecology and the 
Dutch Society of Paediatrics approved modified risk factor based guidelines for prevention 
in 1998, there has been a limited decrease in the incidence of proven GBS-EOD in the 
Netherlands from 0.54 per 1000 live births to 0.36 per 1000 live births.(22) There was no 
decrease in the incidence of probable early-onset GBS sepsis, meningitis or case fatality 
rate. According to the Netherlands Perinatal Registry, incidences of (proven and probable) 






15 reported cases in 2008. In 2009 an unexplained increase was seen, with 172 cases 
of GBS-EOD (0.93 per 1000 live births). Between 2000 and 2009 a case fatality rate for 
GBS-EOD of 6.3% was found.
Since the overall effect of the Dutch guideline on the incidence of GBS-EOD is disappoint-
ing, revision of the Dutch guidelines was considered in 2006. Because of the presumed 
lack of evidence to change towards an alternative strategy, the Dutch prevention strategy 
remained as it was. However, given the on-going burden of GBS-EOD, adaptation of the 
Dutch guidelines should be reconsidered, particularly concerning the fact that perinatal 
mortality in the Netherlands is high compared to other European countries.(23) The aim 
of this thesis is to contribute to the information needed for the establishment of an optimal 
prevention strategy for GBS-EOD.
BACkGround And SCoPe
The Pathogen
Group B streptococcus (GBS, Streptococcus agalactiae) has been known as a human 
pathogen since 1938.(24) GBS are facultative anaerobic Gram-positive cocci growing in 
chains or as diplococci.(Figure 1) On sheep blood agar they cause a characteristic zone of 
beta-hemolysis around colonies, because of destruction of red blood cells.(Figure 2).
With serological techniques using capsular polysaccharides as type-specific antigens, 
GBS can be distinguished from other types Streptococci (A, C, D and G). When using sur-
face proteins as additional antigenic markers, GBS can be divided into nine serotypes (Ia, Ib 
and II-VIII). Recently a tenth serotype has been proposed.(25)
 
Figure 1  GBS: Gram-positive cocci growing in 
chains
 
Figure 2  Blood Agar Plate with Streptococcus 
Agalactiae and typical haemolytic zone 
around colonies
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Differences in the expression of polysaccharides and surface proteins account for differ-
ences in the pathogenesis of infections.(26) Factors playing a role in the development of an 
asymptomatic or invasive infection have not yet fully been elucidated. Capsular polysac-
charides expressed by GBS assist in bacterial evasion of host defense by interfering with their 
ingestion by phagocytes. More virulent strains of GBS can produce increased amounts of 
polysaccharides. Another important virulence factor of GBS is related to its ability to attach 
to endothelium and epithelium, particularly of vaginal tissue and chorionic membranes 
and to the neonatal lungs.(27) The more virulent invasive strains of GBS have been found 
to have a greater capacity for adherence to endothelium and epithelium, and this has been 
particularly evident in studies of serotype III GBS.(27;28)
GBS disease is caused mainly by serotypes I, II and III.(27) Serotype III is the most preva-
lent serotype in asymptomatic carriers.(30-32)
Colonization and transmission
The gastrointestinal tract is the human reservoir of GBS. Women may carry GBS temporary, 
intermittent or persistent.(33-36) Colonization has not always been studied with the use of 
optimal microbiologic methods such as specific growth medium in a cohort that was studied 
over months. Detection methods for GBS that were used in earlier studies might have missed 
lightly colonized women.(28)
A cross-sectional study among healthy male and non-pregnant female students reported 
on colonization with group B Streptococcus. With adequate detection methods, GBS was 
isolated from one or more sites (vaginal, anal and urine specimens) in 34% of women 
and 31% of men. The prevalence was associated with sexual activity, tampon use, milk 
consumption, and hand washing done < 4 times per day.(29) Although GBS can be sexu-
ally transmitted, colonization has not been associated with frequency of sexual activity or 
numbers of partners.(30).
Since in the USA Caribbean Hispanics and black women were reported to be GBS car-
riers more frequently than white women, a role for ethnic or genetic factors is presumed.
(33;40)
Colonization with GBS is described to occur in 10-35% of pregnant women.(4;5)
Studies on vertical GBS transmission in colonized mothers during delivery report inci-
dences of colonization of the infant between 16 and 69%.(6-11) The majority of infants who 
are exposed to GBS are colonized on skin or mucous membranes but remain asymptomatic.
Of the colonized newborn infants, 1-2% develops serious neonatal infection.







Intrauterine infection of the fetus results from ascending spread of GBS from the vagina 
of colonized women into the uterine cavity. This vertical transmission from mother to child 
usually occurs after rupture of the membranes, when GBS enters the amniotic fluid and 
colonizes the skin and mucocutaneous areas of the fetus. Aspiration of infected amniotic 
fluid may cause pneumonia, and when GBS entries the bloodstream, sepsis may occur. Entry 
in the cerebrospinal fluid after hematogenous spread may cause meningitis. (Figure 3)
The ability of GBS to attach and invade the chorioamniotic membranes has been demon-
strated in vitro.(32) GBS may also penetrate the intact chorionic membranes, leading to 
cases of intra-amniotic infection or abortion.(33)
Figure 3:  Hypothesized pathogenesis of GBS-EOD (Designed by Vincent Khouw, VMK- designs) 
1 Colonization in the rectovaginal compartment; 2 Rupture of the membranes; 3 GBS enters the 
amniotic fluid; 3a GBS colonization of skin and mucocutaneous areas; 4 Aspiration of infected 
amniotic fluid; 5 Infected amniotic fluid causes pneumonia (if the bacterial load is high enough); 
6 Entry of GBS in the bloodstream (sepsis or bacteraemia); 7 Entry in cerebrospinal fluid after 
hematogenous spread (meningitis). Derived from thesis A.E. Muller; Population pharmacokinetics of 
antibiotics to prevent group B streptococcal disease: from mother to neonate; 2009
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Intra-amniotic bacterial colonization or progression to infection depends on the number 
and pathogenicity of the colonizing bacteria and the effectiveness of the amniotic fluid 
antibacterial mechanisms.(34) In addition, it is conceivable that maternal genetic variation 
plays a role in the response to occurrence and severity of intra-uterine infections. Romero 
et al. speculated that it is not the presence of the bacterial organism itself, but the response 
of the host that is the critical step in this chain of events. When the host defence system is 
inadequate, bacterial growth may become excessive and lead to an ascending infection into 
the uterus.(35)
GBS disease in the newborn
Neonatal GBS is diagnosed as culture-proven if streptococci are isolated from blood and/
or from cerebrospinal fluid combined with physical signs of infection in the neonate. The 
diagnosis probable GBS-EOD is used for cases of serious neonatal disease when GBS is 
detected at various sites, but not in blood and/or cerebrospinal fluid.(36) A different group 
is the “asymptomatic” GBS bacteriemia, defined as positive blood cultures for GBS in neo-
nates without clinical signs of infection.(37-39)
Most infections in newborns occur in the first week of life and are designated early-onset 
GBS disease (GBS-EOD). The majority of cases of GBS-EOD occur within 24 hours after 
delivery(22) and present as a rapidly progressive septicaemic illness (Figure 4).






Newborns with GBS-EOD usually present with sepsis or pneumonia, and less often contract 
meningitis, osteomyelitis, or septic arthritis.(18;27)
In late-onset neonatal GBS infections (GBS-LOD), illness occurs between 8 and 90 days after 
birth. In contrast to GBS-EOD, late-onset infection is not always acquired from the mother. 
Horizontal transmission during the perinatal period may occur from mother to infant or 
from nosocomial or community sources. GBS-LOD is more often associated with localized 
infections (especially meningitis and pneumonia), which are less rapidly progressive than 
GBS-EOD. The incidence of meningitis in late onset disease is approximately 30%.(15)
Case reports demonstrate that maternal milk, in cases of either clinical or subclinical masti-
tis, may be a source of GBS infection resulting in either late onset or recurrent neonatal GBS 
disease.(40-44) GBS may initially colonize the neonatal oropharynx mucosa during delivery, 
infecting maternal ducts during breastfeeding. The organism multiplies in the milk ducts and 
as the microbial concentration increases in the milk, the infant might be reinfected during 
breastfeeding.(40)
There is significant long-term morbidity after GBS-EOD and GBS-LOD.(45) Survivors may 
suffer from hearing or visual loss, uncontrolled seizures, impaired psychomotor develop-
ment and/or mental retardation.(46;47) A prospective study with 5-year follow-up showed 
that GBS meningitis results in children with neurological deficiencies in 34.8% of cases 
ranging from partial sensory loss to profound mental retardation, blindness and deafness.
(48)
Incidence and causes of neonatal sepsis
The reported incidence of overall neonatal sepsis varies from 7.1(49) to 38(50) per 1000 live 
births in Asia, from 6.5(51) to 23(52) per 1000 live births in Africa and from 3.5(53) to 8.9 
per 1000 live births(54) in South America and the Caribbean. Incidence rates reported in the 
United States and Australia range from 1.5 to 3.5 per 1000 for early onset sepsis (EOS) and 
up to 6 per 1000 live births for late onset sepsis (LOS), a total of 6-9 per 1000 for neonatal 
sepsis.(55-58)
Neonatal surveillance in developed countries generally identifies GBS and E. coli as the 
dominant EOS pathogens and coagulase negative staphylococci (CONS) followed by 
GBS and Staphylococcus Aureus as the dominant LOS pathogens.(55;57) The pathogens 
most often implicated in neonatal sepsis in developing countries differ from those seen in 
developed countries. Overall, Gram-negative organisms are more common in developing 
countries and are mainly represented by Klebsiella, E.coli, Pseudomonas and Salmonella. 
Of the Gram-positive organisms in developing countries, Staphylococcus Aureus, coagulase 
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negative staphylococci, Streptococcus pneumoniae and Streptococcus pyogenes are most 
commonly isolated.(59;60)
The difference in occurrence of invasive pathogens in developed and developing coun-
tries might be explained by true differences in pathogens across the world, but might also 
be explained by an epidemiological bias linked to the fact that most EOS babies in develop-
ing countries die at home before reaching health care facilities and they do not appear in 
the statistics.(59) In a review of studies from developing countries reporting on etiology of 
community-acquired infections, authors stated that hospital-based studies suggest that most 
infections in the first week of life are due to Gram-negative pathogens, and many may be 
environmentally rather than maternally acquired, owing to unhygienic delivery practices.
(60)
risk factors for GBS-eod
In general and for several reasons neonates are at risk for infections, and this is in particular 
for preterm neonates.(61;62) In the first place, preterm babies are at risk for infections 
because of decreased barrier function of skin and mucocutaneus tissue. Necessary invasive 
treatment of preterm neonates, such as intravenous and umbilical venous infusion, may 
contribute to infection. Secondly, the immune system in neonates is impaired. Consider-
ing the humoral immune response, adequate numbers of B lymphocytes are present, but 
antibody production is delayed compared with the adult. Decreased levels of complement 
components contribute to the increased vulnerability to infection of neonates. Infection is 
a major problem for infants born before 28 weeks. Their serum IgG antibody levels are low 
and the deficiencies in complement levels and chemotactic responses noted in full-term 
neonates are even more marked and persist for longer.(63)
For cellular immune response, compared with older children and adults, neonates have 
an intrinsic limitation in their capacity to produce neutrophils and a subsequent suscep-
tibility to exhaustion of marrow reserves during times of increased use, such as sepsis.
(64) In addition, the neutrophils have impairments of numerous functions important to the 
clearance of microbes, including marrow egress, adhesion to the microvascular endothe-
lium, chemotaxis and antibacterial function.(61;64-67) Deficiencies in circulating levels 
of GBS-specific antibody in the context of neutrophil dysfunction heighten the neonatal 
susceptibility to GBS infection.(61)
Both host related factors and bacterial properties may increase the risk on GBS-EOD. A 
number of factors are known to increase the risk of neonatal early-onset infection in the 

































































Prematurity < 37 weeks
















































































































































































































































































































































Preterm delivery (before 37 weeks of gestation)
The excess risk of GBS-EOD in preterm and LBW infants has been well recognized for many 
years. Early reports noted that preterm and low- birth-weight infants were overrepresented 
among infants with early-onset disease.(68;69) This is confirmed by more recent case-
control studies.(70;71)There is a progressive increase in risk for neonatal sepsis in general 
with decreasing gestational age.(72) Reported odds ratio’s for GBS-EOD in prematurity differ 
from 3.89 (95% CI 2.08-7.27)(73;74) to 10.4 (95% CI 3.9-27.6).(13)
Prolonged rupture of the membranes (more than 18-24 hours)
Prolonged rupture of the amniotic membranes for > 18(72;75) to 20(76) hours before deliv-
ery substantially increases the risk of neonatal GBS-EOD.(77)
Odds for GBS-EOD in prolonged rupture of the membranes vary from 7.28 (95% CI 
4.42-12) to 25.8 (95% CI 10.2-64.8).(13;74)
Intrapartum fever 
Intrapartum temperature > 37.5°C(75) or fever without additional definition of temperature 
are associated with an increased risk of neonatal GBS infection.(27)There are no objective 
data to quantitate that higher maternal fever confers a higher risk. Odds of 4.1 (1.2-13.4) to 
10.0 (95% CI 2.4-40.8) for GBS-EOD in patients with intrapartum fever were reported, but 
studies differ in definition of fever (either > 37.5°C or > 38°C).(13;56;73;74)
Chorioamnionitis
Intrapartum fever accompanied by two or more additional signs of chorioamnionitis, includ-
ing fetal tachycardia, uterine tenderness, foul-smelling vaginal discharge, or maternal leuko-
cytosis is associated with higher neonatal GBS attack rates.(72;78-81) One study provided 
sufficient data for estimation of OR, which was 6.42 (95% CI 2.32-17.8).(74)
One case control study reported that at least one of the risk factors preterm delivery, intra-
partum fever and membrane rupture of at least 18 hours is found in 49% of GBS-EOD cases.
(56)
Maternal GBS bacteriuria
The incidence of GBS in quantities >105 colony forming units (cfu) /ml urine in pregnant 
women has been reported to be between 0.4 and 7%.(82-84) Infants born to women with 
GBS bacteriuria during pregnancy are more frequently and more heavily colonized with 
GBS and may be at increased risk for invasive GBS disease.(85;86)
Two studies investigating the relation between bacteriuria and genital colonization 
reported a positive predictive value of GBS bacteriuria in the first trimester of pregnancy for 






In another study urine was sampled at admission for labor. Of 1786 women whose urine 
was sampled during labor, GBS were isolated from 128 (7%), in 22 of whom (1% of the 
total) GBS were present in quantities greater than or equal to 104 colony forming units (cfu)/
ml urine. Neonates born to women with greater than or equal to 104 cfu GBS/ml urine were 
apparently at greater risk for neonatal infection, as they were more commonly and more 
heavily colonized than were the newborns of women with lower quantities of GBS in urine.
(84) 
It has been shown that only 60% of bladder punctured pregnant women whose urine 
specimens contained >105 cfu/ml urine harboured GBS in the bladder.(84) Therefore, a high 
quantity of GBS in urine is assumed to reflect heavy colonization of urethra, vulva and 
vagina instead of cystitis. However, there are no studies with quantative cultures to confirm 
this assumption.
History of a previous child with invasive neonatal GBS disease. 
Although having had a sibling with invasive GBS disease is widely accepted as a risk fac-
tor for GBS-EOD, only few reports show neonatal GBS infection followed more than one 
pregnancy in the same mother.(89-91) In some but not all of the cases, mothers received 
antibiotics during a subsequent pregnancy and delivery. Therefore it is difficult to determine 
what the exact risk for GBS-EOD in a subsequent pregnancy is. 
Women may remain colonized with the same strain of a virulent subtype of GBS for 
prolonged periods and may fail to develop protective levels of type specific serum antibod-
ies despite long term colonization.(92;93)
To conclude, there may be an increased risk of GBS-EOD in subsequent pregnancies in 
women who have had a child with GBS-EOD disease, but this risk has not been quantified.
Other factors
Bacterial virulence properties might influence the risk on GBS-EOD(94), as well as low 
levels of maternal antibodies.(95) Race or ethnicity,(96;97) maternal age,(96;97) neonate 
gender, multiple gestation, (98-101) internal monitoring> 12 hours, (72) increased number 
of vaginal exams, (56) meconium staining,(77) asphyxia(70) and fetal acidosis(102) may be 
associated with increased risk. These variables may be covariant with GBS colonization, 
gestational age at delivery, duration of ruptured membranes or other factors. Therefore, their 
independent contributions are not delineated readily.
However, 30-40% of GBS-EOD occurs in the absence of one of the five major risk factors 
(prelabor rupture of membranes, preterm labor, intrapartum fever, GBS bacteriuria during 
pregnancy or a previous child with GBS).(18;103)
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GBS isolation and detection
The detection rate of GBS from clinical specimens depends on several factors. Culturing 
specimens from both the anorectum and the vaginal introitus increases the likelihood of 
GBS isolation by 5-27% over vaginal culture alone.(75;104;105) Internal examination or 
visualization of the cervix by speculum examination should not be performed for collection 
of screening cultures, since studies show much lower isolation rates from cervical swabs 
than low vaginal swabs.(5;106;107)
After collection of swabs, it is important that Group B streptococci from rectovaginal 
swabs will survive during shipment from satellite clinics to a central microbiology laboratory.
In 1967, Amies published about a transportation device that would preserve clinical 
samples from collection sites to the testing lab that could be many hours or even days away.
(108) Until today, this “Amies transport medium” is internationally recommended for throat, 
wound and genital tract samples.(109) Amies broth with charcoal is a non-nutritional, 
phosphate buffered type medium used to maintain the viability of microorganisms without 
a significant increase in growth. Charcoal was added to the formulation to neutralize the 
toxic effects of fatty acids that are toxic to microorganisms. 
The CDC guidelines state specifically that the viability of GBS can be maintained for up 
to 4 days in appropriate transport medium.(109) There are few data, which support this state-
ment. One study showed that there will be a loss of positive culture results if the GBS colony 
density is low or if the room ambient temperature is relatively high (> 300C).(110) GBS was 
recovered from 92-100% of swabs containing 10 or more colony forming units (cfu) when 
stored either 30C or 240C for 4 days. However, GBS recovery decreased significantly when 
the swabs were stored at 300C. After 6 days, sensitivity of 96-100% was observed only for 
the swabs held at 40C and 240C and containing the high density of 100 or more cfu.(110)
Another study showed that among initially positive swabs kept at 210C in Amies transport 
medium, GBS were recovered after 24h, after 48 h, after 72 h and after 96 h in 95%, 88%, 
85% and 71% of the specimens respectively.(111)
To conclude, viability of GBS is not fully preserved by storage of vaginorectal swabs in 
Amies transport medium. There are effects of time and temperature and these effects are 
greater for lower GBS concentrations.
When swabs arrive in a laboratory and culturing starts, the use of selective broth medium 
(i.e. a broth containing antimicrobial agents to inhibit competing organisms) is essential 
because it can increase the yield of screening cultures by as much as 50%.(112;113) 
Examples of selective enrichment broths include Todd-Hewitt broth supplemented either 
with gentamicin (8 microgram/ml) and nalidixic acid (15 microgram/ml) (called TransVag 







 Although TransVag and Lim broth media are often available without blood, the addition 
of 5% sheep blood can increase the recovery of GBS. Selective enrichment broth can also 
contain chromogenic substrates that provide for a change in color in the setting of beta-
hemolytic GBS; however, nonhemolytic isolates will not be detected by these broths alone.
(115-120)
rapid tests 
Nowadays, several non-culture-based tests are available which enable rapid point-of care 
diagnostics for intrapartum screening, allowing optimal targeting of IAP to women carrying 
GBS. 
As well as being accurate, the ideal test should be rapid enough to allow adequate time 
for IAP to be effective, and should require minimal preparatory steps and be easily interpre-
table to enable routine use on busy delivery suites. 
Polymerase chain reaction
Polymerase chain reaction (PCR) involves the logarithmic amplification of specific areas of 
the bacterial chromosome using an iterative process of hybridisation of replication primers, 
amplification from these primers of the target DNA and separation of the nascent DNA so 
that the process can be repeated. Real-time detection of the amplified DNA is by incorpora-
tion of a fluorescent marker, which is quantitatively measured within a PCR thermocycler. 
The net effect of this is to reduce the results turnaround time from 12–24 hours to less 
than 2 hours. One of the main disadvantages of current PCR technology is that laborious 
preparative steps are required to extract DNA before the thermocycling process can be 
undertaken.(121)
Optical immunoassay
In the optical immunoassay (OIA) an antibody specific to a GBS surface carbohydrate is 
coated on a sample well. In the presence of GBS carbohydrate the optical substrate of 
the test well reflects differently and can be detected visually using a luminometer. Again a 
preparative step is needed, to extract the carbohydrate antigen from GBS.(121)
DNA hybridisation
Nucleic acid hybridization tests are based on the ability of complementary nucleic acid 
strands to specifically align and associate to form stable double-stranded complexes. Com-
mercially available kits use a single-stranded DNA probe with a chemiluminescent label 
that is complementary to GBS ribosomal RNA. A preparatory step releases the RNA from the 
organism, to which the labeled DNA probe combines to form a stable DNA:RNA hybrid. 
A specific reagent enables the differentiation of hybridized probe from unhybridized probe 
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and measurement in a luminometer, with a positive result being one that is greater than a 
predefined threshold.(121)
Enzyme-linked immunosorbent assay
Similar to the OIA, the enzyme-linked immunosorbent assay (ELISA) employs antibodies to 
GBS surface carbohydrate, both coated on a sample well and in soluble form linked to an 
enzyme. The GBS binds first to the sample well and then the soluble form of the antibody 
binds to the GBS. The enzyme then produces a reaction in a colored substrate, which can 
be detected by eye or quantitated in a luminometer.(121)
Latex agglutination
The most easy to use of all the available rapid tests is based on antibodies bound to latex 
particles. If GBS is present, the antibodies bind to its surface and the attached latex aggluti-
nates into visible clumps.
Each of the tests currently available has advantages and disadvantages. Even laboratory-
based use of these tests is limited, and there has been no proper evaluation of any of these 
tests in the point-of-care setting.(121)
Accuracy of rapid tests for GBS
In a recent systematic review on rapid tests for GBS colonization in laboring women 23 
relevant papers of 29 test accuracy studies assessing a total of six tests were analyzed.(122)
This review shows that many of the GBS tests, with the exception of real-time PCR and 
optical immunoassay (OIA) either took too long to produce a result on time or were not of 
sufficient accuracy to be feasible for maternal intrapartum testing. The review focused on 
studies in which selective media were used for gold standard culture. PCR had a median 
sensitivity and specificity of 96% (Range 88–99%) and 98% (Range 96–98%) respectively. 
Median sensitivity for optical immunoassay (OIA) was 48% (Range 37–72%) and median 
specificity was 97% (Range 95–97%). Positive likelihood ratio for PCR was 38.80 (95% CI 
6.05-248.720), negative likelihoodratio was 0.06 (95% CI 0.03-0.11). The positive likeli-
hood ratio for OIA was 14.7 (95% CI 10.6-20.3) and negative likelihood ratio was 0.47 
(95% CI 0.31-0.73).
Although OIA seems less accurate than PCR, it was more rapid (30 minutes compared 
to 40 minutes) and less complex to perform, making it more feasible as a near-patient test. 
However, the real time PCR was only evaluated in 2 relatively small studies. Authors state 
that with regard to the poor methodological quality of the existing studies and the impreci-
sion of the evidence for PCR, a robust technology assessment comparing the most promising 






Recently, in a primary test accuracy study swabs were obtained at the onset of labor from 
1400 women from two large maternity units to compare the results of vaginal and rectal PCR 
and OIA (index tests) with the reference standard of enriched culture of combined vaginal 
and rectal swabs.(121) PCR was significantly more accurate than OIA for the detection 
of maternal GBS colonization. The sensitivity for PCR was 84% (95% CI 79-88%), with a 
specificity of 87% (95% CI 85-89%). Authors conclude that PCR performed better than OIA, 
but results of their economic analysis demonstrate that both rapid tests should not yet be 




Vaccination of pregnant women offers the opportunity for primary prevention of GBS dis-
ease of the newborn by two mechanisms. First, a vaccine that induces mucosal immunity 
would decrease maternal colonization and consequently the risk of transmission to the 
fetus. Second, and potentially more important would be the transplacental transmission 
of protective antibodies to the baby. Babies with high concentrations of antibodies to GBS 
proteins have an OR of 0.002 (95% CI 0.000-0.57) of developing GBS-EOD compared with 
those with low levels.(123) Protective maternal antibodies are believed to persist in the fetus 
for about 3 months after birth affording additional passive protection against GBS late onset 
disease.(124)
The search for a suitable candidate molecule for vaccination has been ongoing for 
two decades, but a vaccine has yet to be licensed for use and evaluated for effectiveness in 
reducing neonatal GBS disease. Initial developments involved carbohydrate-based vaccines of 
which immunogenic efficacy has been demonstrated in women.(124) The problem with each 
vaccine is that there are five major, and several minor, serotypes of GBS, each with a differ-
ent outer carbohydrate. The current vaccine preparations for GBS are based on the serotypes 
prevalent in the USA and Europe. However, these vaccine preparations are not as effective in 
women of other regions of the world because of the prevalence of different serotypes express-
ing a different repertoire of surface proteins. To ensure effective vaccine development, it will 
be important to monitor the distribution pattern of the prevalent serotypes and sequence types 
in all regions of the world, thereby ensuring the inclusion of the most relevant components in 
a global GBS vaccine.(124) Any vaccine would have to be multivalent and appropriate to the 
serotype prevalence within the population. Focus therefore shifted to an ubiquitous protein 
that is present on the outer surface of all GBS serotypes.(125) Protein-based antigens are inher-
ently more immunogenic than carbohydrates, are less likely to cross-react with human tissues 
and can more readily be manipulated by molecular techniques. 
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Chlorhexidine
Vaginal disinfection with chlorhexidine during labor has been suggested as a simple, cheap 
and safe alternative for IAP to prevent vertical transmission and subsequent GBS-EOD. 
Chlorhexidine is without risk of bacterial resistance and with no risk of allergic complications.
In a systematic review in 2004, analysis of 5 studies (including 2190 term and preterm 
infants) comparing vaginal disinfection with chlorhexidine during labor versus no treatment 
or placebo resulted in a statistically significant reduction in GBS colonization of neonates 
(RR 0.72, 95% CI 0.56 to 0.91), but the studies were not large enough to draw conclusions 
regarding reduction of GBS infections.(126) There was no statistically significant reduction 
in EOD including GBS infection, GBS pneumonia, GBS meningitis or mortality.
In a randomized controlled study with 244 GBS colonized mothers at term (screened at 36-38 
weeks), the efficacy of intrapartum vaginal flushings with chlorhexidine was compared with 
ampicillin intravenously (IV) in preventing GBS transmission to neonates. The rate of neonatal 
GBS colonization was not statistically different in both groups (chlorhexidine, 15.6%; ampicil-
lin, 12%). However, colonization with Escherichia coli was significantly more prevalent in the 
ampicillin (7.4%) than in the chlorhexidine group (1.8%, p < 0.05).(127)
In a large trial in Soweto, South Africa, 8011 women were randomized to chlorhexidine 
vaginal wipes or external genitalia water wipes during active labor, and their babies were 
assigned to full body (intervention) or foot (control group) washes with chlorhexidine at 
birth, respectively.
Rates of neonatal sepsis did not differ between the groups. Rates of colonization with 
GBS in newborn babies born to mothers in chlorhexidine and control groups did not differ.
(128)
In conclusion, studies with chlorhexidine showed promising results regarding reduction of 
transmission of GBS colonization but a definite conclusion on the effect of this treatment on 
the incidence of GBS-EOD cannot be drawn.(126;129;130)
Antibiotic treatment of the mother
Since vaginal re-colonization from the gut may occur, antibiotic treatment of GBS carriers 
during pregnancy is inadequate as prophylaxis.(5) In addition, prolonged prophylactic treat-
ment can result in resistance of other microorganisms and disturbance of the intestinal and 
vaginal flora. 
In a small double-blind randomized controlled trial, prenatal oral amoxicillin (500 mg 2 
times daily during 5 days) or placebo was given to GBS carriers identified by rectovaginal 






amoxicillin compared to placebo was 43% and 67% of the women at the time of labor 
(difference statistically not significant).(131)
Intrapartum antibiotic prophylaxis (IAP) of the mother during delivery is regarded as the 
most effective method to reduce the number of neonatal GBS infections.(14) 
In the absence of IAP in vaginal deliveries, neonates born from GBS colonized mothers 
were colonized in 16%-69% at one or more surface areas.(6-11;132;133) After administra-
tion of IAP with ampicillin in randomized studies, a lower neonatal colonization rate has 
been found after vaginal delivery, varying from 0% to 10%.(9;14;133;134)
The most direct indicator for efficacy of IAP is the bacterial load in neonatal blood cultures. 
Recently, the Cochrane collaboration conducted a systematic review on the impact 
of maternal intrapartum antibiotics for maternal Group B streptococcal colonization on 
neonatal GBS infection. Only three randomized controlled trials, evaluating the effects of 
IAP versus no treatment, conducted more than 20 years ago in three different countries and 
enrolling a total of 500 women have been published.(14;132;135)
Overall quality of the included studies was poor and the risk of bias high. No study 
reported on a pre-set sample size and no placebo was used in the three studies comparing 
one antibiotic versus no treatment; care-givers and researchers were not blinded to group 
assignment.(9) 
Despite serious concerns about bias in the three included trials, studies were combined. 
A statistically significant reduction in GBS-EOD was found. (RR 0.17, 95% CI 0.04-0.74) 
The authors concluded that IAP reduces GBS-EOD, but there is lack of evidence from recent 
well designed and conducted trials to recommend IAP to reduce GBS-EOD.(11)
Antibiotics and dosing regimens
There are only a few well designed studies in which the efficacy and side effects of different 
antibiotics and dosing regimens have been examined. Adequate antibiotic concentrations 
in amniotic fluid are likely to be involved in eradication of GBS from surface areas. Since 
there is some time needed to achieve adequate amniotic fluid concentrations and eradicate 
GBS from these areas, the time interval between IAP and delivery is essential. De Cueto et 
al. found for ampicillin that when this interval is at least 2 hours, vertical transmission of 
GBS was minimized to 1.5%.(133)
Muller et al collected blood samples from mothers in labor, umbilical cord and neonates 
after administration of an intrapartum dose of amoxicillin of 2 gram. With these data a 
multicompartment model to describe the overall concentration versus time profile in mater-
nal plasma, umbilical cord and neonatal plasma was developed. Peak concentrations in 
umbilical cord and neonatal serum were lower and delayed compared to the maternal peak 
concentration. Approximately one hour after the start of the antibiotic administration the 
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neonatal concentration reached its highest level, and thereafter exceeded the concentra-
tions in venous umbilical cord. Simulation of a 2 gram infusion on basis of the developed 
pharmacokinetic model demonstrated that amoxicillin concentrations in maternal, venous 
umbilical cord and neonatal serum exceeded the minimal inhibitory concentration for > 
90% of the dosing interval of 4 hours.(136)
The CDC guideline advises intravenous prophylaxis with 5 million IU penicillin G or 2 
gram amoxicillin or ampicillin, followed by respectively 2.5 million IU penicillin or 1 gram 
amoxicillin or ampicillin every four hours until delivery.(5) Dutch guidelines deviate from 
this guideline, advising an initial dose of 2 million Units benzylpenicillin and subsequent 
doses of 1 million Units every four hours. (Table 2)
Muller et al. described in a simulation model in women with PPROM that a dosing regimen 
of bolus injections of 1 gram amoxicillin every 6 hours was predicted to be adequate for the 
prevention of GBS infection in pregnant patients.(137) This regimen was described as the 
usual regimen in a former review of the Cochrane Library(138), which now is withdrawn. 
The new Cochrane review on this topic doesn’t describe recommendations for antibiotic 
dosing regimens anymore. A two gram loading dose does not seem to be beneficial and the 
1 gram doses can safely be administered by bolus injection increasing the comfort of the 
patient and facilitating prophylaxis.(137)
Penicillin is the first choice because of the narrow spectrum and less risk of selection of 
resistant bacteria.(139) Resistance to penicillin in GBS has been described (140;141), but 
is very rare. Resistance to erythromycin and clindamycin has been reported in 7.4% and 
3.4% of invasive GBS isolates respectively.(142;143) This has clinical consequence as these 
agents are recommended for intrapartum prophylaxis in women with a history of penicillin 
allergy. For this reason in the last report of the CDC the recommendation has been changed. 
In case of penicillin allergy with low risk of anaphylaxis, cefazolin instead of erythro-
mycin or clindamycin is recommended. In case of allergy to penicillin with high risk of 
anaphylaxis, clindamycin or erythromycin is given after susceptibility to one of these agents 
is proven. In case of allergy to penicillin with high risk of anaphylaxis and resistance to 
clindamycin and erythromycin, vancomycin can be given.
Dutch guidelines advise either clindamycin or erythromycin in case of history of penicil-
lin allergy without establishing low or high risk of anaphylaxis or the susceptibility of GBS 
to one of these antibiotics. (Table 2)
Antibiotic treatment of the neonate
Complete absence of GBS-EOD was reported as an unexpected benefit of a policy of routine 






(144;145) Subsequent observational studies have suggested that the administration of intra-
muscular penicillin to the newborn immediately following delivery may be an effective 
strategy to reduce the incidence of GBS-EOD. However, these studies were uncontrolled, 
retrospective and non-randomized.(146-149) A Cochrane review on intramuscular penicillin 
for the prevention of early onset group B streptococcal infection in newborn infants included 
only one study. In this randomized controlled trial of 1187 infants of birth weight 501 to 
2000 grams, there were no significant differences found for the outcomes of GBS-EOD (RR 
0.73, 95% CI 0.32-1.62) or neonatal mortality (RR 0.78, 955 CI 0.55-1.11). Other outcomes 
such as GBS-LOD, neonatal sepsis and secondary outcomes such as neurodevelopmental 
status and length of hospital stay could not be assessed.(150)
Adverse effects of antibiotics
The administration of antibiotics as prophylaxis against GBS-EOD should have minimal 
risks for both mother and child. For the mothers, an important adverse effect of an increased 
use of antibiotics is the increasing incidence of potential severe adverse reactions including 
anaphylaxis to penicillin.(151;152) The incidence of anaphylaxis after administration of 
penicillin is estimated to be 0.01% with a mortality rate of 9%.(153;154) 
Table 2 Antibiotic Dosing regimen as recommended by the CDC(5)
Antibiotic Initial dose Subsequent dose dosing Interval Patients
Benzylpenicillin 5 million Units* 2.5 million Units* 4 hours Not penicillin allergic
Ampicillin 2 g 1 g 4 hours Not penicillin allergic
Cefazolin** 2 g 1 g 8 hours Allergic to Penicillin;
Low risk of anaphylaxis
Clindamycin - 900 mg 8 hours Allergic to Penicillin;
High risk of anaphylaxis,
susceptibility to 
clindamycin proven
Erythromycin - 600 mg 6 hours Allergic to Penicillin;
High risk of anaphylaxis,
susceptibility to 
erythromycin proven
Vancomycin** 1g 12 hours Allergic to Penicillin;
High risk of anaphylaxis,
resistant to clindamycin 
and erythromycin
* Dutch guidelines differ from these CDC guidelines, advising an initial dose of 2 million Units and 
subsequent doses of 1 million Units
** Dutch guidelines do not mention cefazolin nor vancomycin as alternatives for Benzylpenicillin in 
case of allergy
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Neonatal risks include an increase in incidence of non-GBS-EOD. The use of ampicillin 
rather than penicillin for intrapartum GBS prophylaxis has been reported to be associated 
with an increase in the incidence of neonatal sepsis caused by ampicillin-resistant Gram-
negative micro-organisms.(55;155;156)
One study reported an association between the use of intrapartum antibiotics and LOD.
(157) The incidence of postnatal yeast infections may increase with the use of intrapartum 
antibiotics(158) and possibly acquired abnormalities in early-life bacterial colonization may 
affect the development of the immune system and change the pattern of initial colonization 
of the gut in the first days of life which may be linked to later development of allergic 
disease.(157;159-161)
Burden of the disease
The incidence of GBS-EOD before implementation of prevention strategies ranged from 0.2 
to 3 or even more cases per 1000 live births with substantial geographical variations.(162) 
In Europe, prior to 2000, incidence varied between 0.2 and 0.3 in Denmark(21) to 0.76 
in Finland(163), 0.69 to 4.5 in France(164), 1.9 in the Netherlands(18), 3.25 in the Czech 
Republic(165) and 2.4 in Spain.(166) 
Wide variations in incidence could be correlated with differences in women’s GBS 
carriage rate, with differences of ethnic or racial susceptibility to GBS infection, with differ-
ences in definition of diagnosis of GBS-EOD and with differences in virulence among the 
prevalent GBS strains.
evolution of Guidelines for prevention of GBS-eod
During the past two decades, various initiatives have been established to prevent GBS-
EOD. These were mainly promoted in the USA and transferred and adapted into national 
guidelines in some European countries.
Clinical trials in the 1980s showed that GBS-EOD can be prevented by administering 
intrapartum antibiotic prophylaxis (IAP) to mothers who are colonized with GBS.(14;17) 
Prevention starts with a strategy to identify mothers at risk for having a baby with GBS-
EOD. 
The simplest strategy, IAP in all deliveries, has not been considered because of unneces-
sary exposure to antibiotics.
In the USA, two different options of IAP, either based on the presence of maternal factors 
associated with increased risk of GBS-EOD (risk factor based screening) or on maternal 
antenatal GBS-positive screening cultures (culture based screening), were established in 
1996.(46) Although neither option was optimal or properly implemented, surveillance stud-






In the risk factor based approach, women presenting at the time of labor with clinical risk 
factors for disease (ie preterm delivery before 37 weeks of gestation, prolonged rupture of 
the membranes, intrapartum temperature > 37.5°C, maternal GBS bacteriuria during preg-
nancy and a history of a previous child with GBS-EOD) are offered intrapartum antibiotic 
prophylaxis. 
In the screening approach, women are screened for carriage of group B streptococcus 
between 35 and 37 weeks of gestation, and IAP is offered to all carriers as well as in case of 
unknown GBS carriage and delivery at < 37 weeks gestation or amniotic membrane rupture 
> 18 hours.
In both strategies, antibiotics are given during labor to women who had group B strepto-
coccal bacteriuria during their current pregnancy, or who have had an infant with GBS-EOD 
previously.(46)
In 2002, a population-based retrospective study of 5144 births, including 312 in which 
the newborn had GBS-EOD, showed that culture based screening was 50% more effective 
in prevention of GBS-EOD compared to risk factor based screening.(167) In this study, to 
identify candidates for intrapartum prophylaxis, either screening of pregnant women for 
GBS colonization by means of cultures (screening approach) or assessing clinical risk factors 
(risk factor approach) was used as both recommended by the former CDC guidelines in the 
USA.(46) Antenatal screening was documented for 52 percent of the mothers in the study. 
The risk of GBS-EOD was significantly lower among the infants of screened women than 
among those in the risk factor group (RR 0.46, 95% CI 0.36-0.60).
Thereafter, national guidelines in the USA were changed, shifting from a recommendation 
of either of these strategies to a recommendation of only culture based screening at 35-37 
weeks of gestation for all pregnant women and IAP for any woman with GBS colonization. 
The risk factor based approach was reserved for women in labor with an unknown maternal 
colonization status.(5) Culture based screening was expected to result in further declines in 
the incidence of GBS-EOD.(167) 
Since the end of the 1990’s, in several European countries a culture based screening strategy 
has been recommended, including Spain (1998 and 2003), Italy (1996), France (2001), 
Belgium (2003), Germany (1996, 2008) Switzerland (2007), Poland(2008) and Czech 
Republic (2008). The risk factor based strategy has been recommended in the UK and in 
the Netherlands. In some other European countries, for example in Bulgaria and Denmark, 
there are no guidelines.(168)
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epidemiology
In the USA, after widespread implementation of prevention strategies, the incidence 
decreased from 1.8 cases per 1000 live births in 1993 to 0.6 per 1000 live births in 1998 
and 0.32 cases per 1000 live births in 2003.(17;109;169) 
In European countries in which a prevention strategy was adopted, an important drop of 
the incidence of GBS-EOD was observed as well. In Spain for example, incidence declined 
from 2.4 cases per 1000 live births in 1996 to 0.59 in 2005.(166) Table 3 shows GBS colo-
nization during pregnancy and incidence of GBS-EOD in various European countries after 
2000. 
The initial reported case fatality rate associated with GBS-EOD in the USA dropped from > 
50% in the 1970s to 4-10% in recent years.(1;16-18;109;170-173)
Intrapartum administration of antibiotic prophylaxis (IAP) to the mother may have contrib-
uted to above named declines, by the antibiotic effect on the infant and by decreasing 
the severity of the disease. It is unclear to what extent the decrease in GBS-EOD can be 
attributed to the administration of antibiotics. Other factors may contribute as well, among 
which are early recognition of infection and improved neonatal care(174), as well as natural 
changes in prevalence of maternal colonization and variation in GBS subtype distribution.
From Norway an, unexplained, marked increase in case fatality was reported. In this country 
a risk factor based strategy is applied. From an average of 5.8% in 2000-2005 a significant 
increase to 33% in the first 6 months of 2006 and a slightly increased incidence of invasive 
GBS disease in neonates using a risk factor based strategy has been reported.(175) Such 
changes in case fatality rates without alterations in antibiotic policy might be explained by 
changes in the virulence characteristics of circulating GBS.
In all countries the case fatality rate in preterm born infants remains substantially higher than 
in term born infants, with case-fatality rates of approximately 20% - 30% among infants born 
before 33 weeks’ gestation, compared with 2%-3% among term born infants.(173;176;177)
remaining burden of the disease
In 2009, evaluation of the implementation of the screening guidelines in the USA was 
performed over the period 2003-2004. This revealed that the rate of screening for GBS 
during pregnancy increased from 48.1% in 1998-99 to 85% in 2003-2004; the percentage 
of infants exposed to IAP increased from 26.8% to 31.7%.(169)
IAP was given in 87.0% of the women who were screened positive for GBS and who 







The overall incidence of GBS-EOD in the USA in 2004 was 0.31 cases per 1000 live 
births. Preterm infants had a higher incidence of GBS-EOD than term infants (0.73 vs. 0.26 
cases per 1000 live births). However, 74.4% of the cases of GBS disease occurred in term 
infants. Missed screening (i.e. “forgot to screen” at 35-37 weeks of gestation and no IAP) 
among mothers who delivered at term accounted for 13.4% of group B streptococcal dis-
ease. (34 of the 254 cases) A total of 61.4% of the term infants with GBS disease were born 
to women who had tested negative for GBS before delivery.(169)
Table 3 GBS colonization during pregnancy and incidence of GBS-EOD in various European 
countries after 2000. Derived from Trijbels-Smeulders et al(168), Barcaite et al(4) and Edmond et al(3)
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Germany 2006 16(186) 2005 0.21(171)
United Kingdom 2006 21.3(187) 2011 0.67(188)




Denmark 2004 36(192) 2004 0.34(193)
Iceland 2003 24.3(194)











From 2003 to 2006, an increase in GBS-EOD in the USA was seen towards 0.40 per 1000 
live births. When stratified by race, incidence among black infants increased significantly 
(0.53 to 0.86 cases per 1000 live births), whereas incidence among white infants did not 
change significantly (0.26 to 0.29 cases per 1000 live births.(178) The reason for this differ-
ence remains unexplained.
Strategy for prevention and incidence of GBS-eod in the netherlands
In the Netherlands, the Dutch Society of Obstetrics and Gynecology (NVOG) and the Dutch 
Society of Pediatrics (NVK) approved the guidelines for prevention of GBS-EOD in 1998. 
These guidelines do not recommend universal screening nor prophylaxis in case of risk 
factors for GBS-EOD alone, but were based on a sort of the risk factor based approach.
(46) IAP is recommended following a previous delivery of an infant with GBS-EOD, or 
heavy maternal GBS colonization (which may present as GBS urinary tract infection or 
GBS bacteriuria during current pregnancy). In the case of onset of labor before 37 weeks 
of gestation or prolonged rupture of membranes (>18 hours before delivery), screening for 
GBS carriage is performed first, followed by prophylaxis when the culture is positive. When 
delivery occurs before the result of the culture is available, the gynecologist should decide 
about antibiotic prophylaxis, based on the severity of the risk factor(s). (Figure 5) In this 
approach, the Dutch strategy differs from the risk factor based strategy. The choice for this 
risk factor-based strategy in 1998 was made with the intention to reduce the number of 
women that receives prophylactic antibiotics, taking into account the Dutch organisation of 
obstetrical care with approximately 30% home deliveries. 
The Dutch guidelines advise to discontinue prophylactic administration of antibiotics 
to the mother after delivery, unless symptoms of maternal infection persist. In that case 
prophylaxis is changed to therapy with a change of antibiotic strategy.
A differentiated sequential management of newborn infants of GBS carriers who had an 
indication for antibiotic prophylaxis seems to be justified. It should be established whether 
adequate prophylaxis was given during delivery. Despite lack of evidence for existing dosing 
schedules, IAP is regarded as adequate if the antibiotics were given intravenously in the 
right dosage and at least 4 hours before delivery, so that two doses have been given. After 
adequate prophylaxis, observation during 48 hours, of which at least 24 hours in hospital, 
is recommended. If no or inadequate prophylaxis was given and gestation was more than 
35 weeks, the same strategy is followed. If no or inadequate prophylaxis was given and 
gestation was less than 35 weeks, a culture is taken from blood and cerebrospinal fluid and 
treatment for sepsis is started. If the cultures of blood and of cerebrospinal fluid are negative 
and no clinical signs of infection are present, treatment can be stopped.
If clinical signs of infection exist, an extensive diagnostic approach for infection is 
indicated and the infant is treated as in sepsis, independently of the prophylaxis and the 






After the introduction of above named prevention guidelines based on risk factors in 
1999, there has only been a limited decrease in the incidence of proven GBS-EOD from 
0.54 per 1000 live births to 0.36 per 1000 live birth in the Netherlands.(22)
There was no decrease in the incidence of probable early-onset GBS sepsis, respectively 
1.3 and 1.4 per 1000 live births. In the small category of late onset GBS sepsis (> 7 days after 
birth), there was no decrease in the incidence of proven cases.(22)
Table 4 shows incidence figures of GBS meningitis and GBS sepsis and Table 5 shows 
deaths due to perinatal GBS infections in the Netherlands between 2000 and 2009, as 
registered by the Netherlands Perinatal Registry. This registration is estimated to cover 70% 
of the total population of the Netherlands and data therefore only show a trend over years. 
Incidences of (proven and probable) GBS sepsis and GBS meningitis seemed to be stable 
until 2008, with respectively 108 and 15 reported cases in 2008. In 2009 an unexplained 
increase was seen, with 172 cases of GBS-EOD (0.93 per 1000 live births). Between 2000 
and 2009 a case fatality rate for GBS-EOD of 6.3% was found. 
Revision of the Dutch guidelines was considered in 2006, but recommended prevention 
strategy remained as it was. Because of the ongoing burden of GBS-EOD, adaptation of the 
Dutch guidelines should be reconsidered, particularly with regard to the fact that perinatal 
mortality in the Netherlands is high compared to other European countries.(23)
Figure 5:  Scheme on prevention strategy of GBS-EOD in the Netherlands
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ouTLIne oF The TheSIS
The aim of this thesis is to contribute to the information needed for the establishment of an 
optimal preventive strategy for GBS-EOD.
In chapter 2 a study is described that was performed to determine the prevalence of GBS 
and to identify risk factors for GBS carriage in a multicultural population of pregnant women 
in The Hague in the Netherlands. Several factors are known to increase the risk of perinatal 
GBS-infection in women that carry GBS. In chapter 3 we report on the relationship between 
prolonged rupture of membranes (PROM, >24 hours) and labor before 37 weeks of gestation 
and GBS, to evaluate whether occurrence of these risk factors can predict prenatal GBS 
status. In GBS strains from the studied multicultural obstetric population, phenotypic and 
genotypic antibiotic susceptibility patterns and putative epidemicity was assessed, which is 
described in chapter 4.
Chapter 5 describes the results of a systematic review in which the relation between 
maternal colonization with Group B Streptococcus and preterm birth was determined and 
Figure 6: Postdelivery management of newborn infants of GBS carriers who received IAP as 






in chapter 6 we present results of a meta-analysis to assess the best timing of antenatal cul-
tures, which may help to establish optimal prevention of GBS-EOD in neonates. With regard 
to the remaining burden of disease in the world, we list opportunities for improvement of 
prevention of GBS-EOD in chapter 7, followed by considerations in finding an optimal 
prevention strategy for the Netherlands in chapter 8. Finally, conclusions of earlier chapters 
are summarized and future perspectives and directions of research in the prevention of 
GBS-EOD are discussed in chapter 9.
Table 4 Incidence of GBS meningitis and GBS sepsis in the Netherlands, as registered by the 
Netherlands Perinatal Registry
Year number of cases 











Total 2000-2009 209 1344
Table 5 Deaths due to perinatal GBS infections in the Netherlands between 2000 and 2009, as 
registered by the Netherlands Perinatal Registry
diagnosis number of deaths Percentage
GBS meningitis (n=209) 12 5.7%
GBS sepsis (n=1344) 87 6.5%
GBS meningitis or GBS sepsis (n=1171) 92 6.3%
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objective This study was performed to determine the prevalence of GBS and to identify GBS 
colonization risk factors in a multicultural population of pregnant women in the Netherlands. 
We calculated predictive values of cultures in pregnancy for intrapartum GBS carriage.
Study design From a total of 1702 women visiting several antenatal outpatient departments, 
rectovaginal swabs were collected at 35-37 weeks’ gestation. In 761 women swabs were 
repeated at time of delivery. Carriage of GBS late in third trimester and at time of delivery 
was analysed in relation to age, parity, ethnicity and socio-economic status. 
results Twenty-one percent was GBS carrier late in pregnancy. Compared to Europeans, 
African women were at a higher risk (29%) and Asian women were at lower risk (13%) for 
GBS carriage. No differences in colonization were found between women with respect 
to age, parity or socio-economic background. Positive predictive value of GBS carriage at 
35-37 weeks’ gestation for carriage at time of parturition was 79% and negative predictive 
value was 93%.
Conclusions It is impossible to identify a group of pregnant women at high risk for GBS 
colonization. Predictive values of antenatal genital group B streptococci cultures at 35-37 
weeks’ gestation for intrapartum GBS carriage are lower than previously reported.
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InTroduCTIon
Since the 1970s, Group B Streptococcus (GBS, Streptococcus agalactiae) has been recog-
nized as the most important infectious cause of morbidity and mortality in newborn infants. 
Despite the decrease in mortality during the last decades, early-onset GBS disease remains 
a serious neonatal condition, which may cause severe neurological damage. In the Neth-
erlands, the incidence of early-onset GBS disease in 1997-1998 was estimated at 1.9 per 
1000 live births, with a case fatality rate of 5%(1). GBS transmission is vertical from mother 
to child. The gastrointestinal tract is the source of vaginal GBS colonization and many adults 
are colonized with GBS without showing symptoms. Approximately 10%-30% of women 
of childbearing age carries GBS in the rectovaginal compartment(2-4). The prevalence may 
vary due to differences in the culture technique, the location and number of sites cultured 
and the population studied(2). A role for ethnic or genetic factors is presumed, since Carib-
bean Hispanics and black women were reported to be GBS carriers more frequently(2;5;6).
Dutch data originate from studies by Gerards in 1985 and Adriaanse in 1995, in which 
overall carrier rates of 14% in the 16-20th week of pregnancy(7) and 20% at delivery(8) have 
been described. 
In the United States, revised consensus guidelines regarding the management of GBS 
were published in 2002. These guidelines recommend screening of all pregnant women for 
GBS carriage at 35 to 37 weeks’ gestation and intrapartum treatment of those women with 
positive cultures(9).
The Dutch Society of Obstetrics and Gynaecology and the Dutch Society of Pediatrics(10) 
recommend intrapartum maternal administration of antibiotics in women with intrapartum 
temperature > 38ºC, in women with GBS bacteriuria during current pregnancy and in 
women who previously gave birth to an infant with early-onset GBS disease, irrespective to 
their GBS status. In women presenting with any of the other risk factors associated with early 
onset GBS disease, i.e. delivery at <37 weeks’ gestation or rupture of membranes for more 
then 24 hrs, screening for GBS carriage is performed first, followed by chemoprophylaxis 
when the culture is positive. In case the delivery occurs before the result is available, the 
obstetrician should decide about antibiotic prophylaxis, based on the severity of the risk 
factor(11). The choice for this risk factor-based strategy was made in 1998, with the intention 
to reduce the number of women that receives prophylactic antibiotics(11), taking account 
of the Dutch organisation of obstetrical care with approximately 30% home deliveries. The 
disadvantages of this strategy are, that 30%-40% of neonatal early-onset GBS infections may 
occur in the absence of risk factors(1) and that in most cases delivery occurs before culture 
results are available. 
The best preventive strategy maximises treatment in women who need it, and minimises 
treatment in women who do not need it. To be able to optimise the strategy it is essential to 






may have changed due to recent changes in demographics, in particular with regard to 
ethnic background of women living in major cities. The aim of this study was to ascertain 
GBS carrier-rate late in pregnancy in a multicultural, urban population in the Netherlands, 
to find out if a group of high risk for GBS colonization could be identified and to calculate 
positive and negative predictive values for intrapartum carriage, based on results of the 
cultures at 35-37 weeks’ gestation.
MeThodS
In The Hague, approximately 8000 deliveries take place annually. Almost all hospitals and 
a part of midwifery practices joined this study. Between July 2000 and December 2002, 
physicians and midwives at their discretion non-selectively asked women at 35-37 weeks of 
pregnancy to participate in the study. All these women attended either the outpatient depart-
ment of obstetrics and gynaecology at the Medisch Centrum Haaglanden, the Leyenburg 
Hospital, the Rode Kruis Hospital or one of the six participating midwifery practices in The 
Hague, the Netherlands.
After informed consent, the physician or midwife collected a rectovaginal swab for GBS 
culture by initially swabbing the vaginal introïtus and thereafter the rectum (through the 
anal sphincter). Swabs were placed in a transport medium (Amies transport medium with 
charcoal) and sent to one of the participating laboratories. Inoculation took place at 35-37°C 
for 18-24 hours into a selective broth medium (Todd-Hewitt supplemented with gentamycin 
(8 micrograms/ml) and nalidixid acid (15 micrograms/ml)). The broth was subcultured onto 
a blood agar under anaerobic circumstances and GBS suspected colonies were then Gram-
stained. A catalase reaction was performed for all Gram-positive cocci. On all catalase 
negative colonies, a streptococcus grouping latex agglutination test (PathoDx group B, 
Diagnostic Products Corporation, Los Angeles, USA) was performed to identify GBS. The 
results were reported to the participating antenatal clinics and midwifery practices. Colo-
nized women received intrapartum antibiotics only when one or more of the risk factors 
associated with early onset GBS disease was present. The initial intention was to repeat GBS 
cultures during labour in all GBS positive women and in 400 of GBS negative women.
All women were asked to complete a questionnaire about ethnic, demographic and 
socio-economic factors and obstetric details. Age, parity, postal code and the country of 
birth of both the woman and her parents were registered. The participants were grouped into 
different demographic and socio-economic categories by using the classification systems of 
the Municipal Information Centre of The Hague and the Central Commission for Statistics 
in the Netherlands (Statistics Netherlands/CBS) and into different ethnic categories by using 
publications published by the Ministry of the Interior and Kingdom Relations (BZK) and 
information acquired from the United Nations. The country of birth was used to classify the 
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women into ethnic groups according to the Dutch standard identification method(12). These 
ethnic groups are Class A: Born in the Netherlands or coming from one of the developed 
countries; Class B: Coming from any less developed country (Table 2B).
A protocol was formulated to screen 2100 women from The Hague, classified into differ-
ent ethnic and socio-economic groups:
Group 1: Class A and living in the inner city (lower socio-economic group),
Group 2: Class B and living in the inner city, 
Group 3: Class A and living in the suburbs (higher socio-economic group) and 
Group 4: Class B and living in the suburbs.
Although we initially planned to include 2100 women, we found that after 2 years and 5 
months 1700 women were included, and that no additional information would be gained 
by continuation of the inclusion period.
We estimated the prevalence of positive cultures as the proportion of positive testing 
women over all women, with 95%-confidence intervals based on a binomial distribution. 
These calculations were performed for various subgroups, and prevalences were compared 
by calculating relative risks (prevalence ratios), with 95%-confidence intervals based on a 
Poisson distribution of the positive tests.
Positive and negative predictive values for intrapartum carriage, based on the results of 
the cultures collected at 35-37 weeks pregnancy, were calculated.
The medical ethics committees of the participating hospitals approved the protocol for 
this study.
reSuLTS
During the study period, a total of 1702 pregnant women were enrolled. Mean age was 30.5 
years, median was 31 years (range 14 to 45 years). Four hundred and sixty-six women were 
primigravida and 1225 women were multigravida, while data about parity were missing in 
11 cases. Six hundred and ninety-two women were Dutch and had parents who were both 
born in the Netherlands, the remaining women had at least one parent born in a foreign 
country or were born in another country themselves. The ethnic origin of 53 women was 
unknown. Of the 1702 women, 365 (21%) had positive cultures for Group B Streptococcus 
at 35-37 weeks of gestation. There was no relationship between colonization and age, parity 
or miscarriages (Table 1). Table 2 shows the breakdown of women by classification in group 
A or B, living in the inner city or the suburbs and the percentage of GBS carriage found per 
group. The prevalence of GBS carriage in Classes A and B were identical: 21%. We then 
analysed whether the place where women lived (inner city or the suburbs) affected the 






Table 1 Age, parity, history of abortions and GBS culture results
Age N % GBS positive 95% CI
< 20 41 32 0.18-0.46
20-29 663 17 0.14-0.20
30-39 905 24 0.21-0.27
>= 40 92 25 0.16-0.34
Unknown 1 100
Parity
0 663 21 0.18-0.24
1 645 19 0.16-0.22
2 232 29 0.23-0.35
3 or more 181 22 0.16-0.28
Unknown 11 18
History of Abortions
0 1163 21 0.20-0.21
1 or 2 470 22 0.18-0.26
3 or more 58 22 0.11-0.33
Unknown 11 18
Table 2A GBS carrier rates according to origin and where people lived in The Hague 
(The Netherlands)
Rate % 95% CI
Class A Inner City 29/174 17 0.11-0.23
Suburb 129/569 23 0.19-0.26
Unknown 1/2
Total 159/745 21 0.18-0.24
Class B Inner City 104/471 22 0.18-0.26
Suburb 88/427 21 0.17-0.25
Unknown 2/6
Total 194/904 21 0.18-0.24




Total Inner City 134/657 20 0.17-0.23
Suburb 225/1032 22 0.19-0.23
Unknown 6/13
Total 365/1702 21 0.19-0.23
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lived in the suburbs. Prevalence in these groups was 20% and 22%, respectively. The place 
of residence of 13 women was unknown. 
Participating women originated from 72 different countries. When using United Nations 
world region classifications to cluster these countries, differences in GBS carriage between 
the women of these various countries of birth become apparent. (Table 3). In women 
originating from countries in Europe and Latin America we found a colonization rate of 
21% compared to colonization rates of 29% in African women and 13% in Asian women. 
Women born in Africa had an increased risk for colonization compared with European 
women (RR 1.4, CI 1.1 – 1.7), whereas Asian women had a reduced risk for GBS carriage 
compared to European women (RR 0.6, CI 0.4 - 0.8). In 173 of the 365 GBS positive women 
and in 588 of the 1337 GBS negative women, cultures were repeated at delivery. In 174 
(23%) of these 761 women, cultures were positive at this time.
Table 4 shows the proportion of women with positive and negative intrapartum cultures 
in relation to the results of the first swab taken between 35 - 37 weeks’ pregnancy. Of all the 
pairs of cultures, 136 of 173 women who were positive at 35-37 weeks gestation were also 
positive at delivery (Positive Predictive Value 79%) and 550 of 588 women who were ini-
tially negative, remained negative at delivery (Negative Predictive Value 93%). Thirty-eight 
women acquired GBS in the last weeks of pregnancy, whereas cultures in 37 previously 
positive women were negative at delivery.
CoMMenT
In this study we show that in the multicultural, urban population of pregnant women in 
The Hague, the Netherlands, the GBS carrier rate is 21%. We showed differences between 
colonized and non-colonized women in ethnicity, but we could not demonstrate differences 
between colonized and non-colonized women with respect to age, parity or socio-economic 
background. Positive predictive value of GBS carriage at 35-37 weeks’ gestation for carriage 
at time of parturition was 79% and negative predictive value was 93%.
Table 2B Classification in Class A or B according to country of birth
Country
Class A Netherlands, Belgium, Canada, Denmark, Germany, Finland, France, Greenland, United 
Kingdom, Ireland, Iceland, Israel, Japan, Channel Islands, Liechtenstein, Luxembourg, Monaco, 
Dutch East Indies, Dutch Newguinea, Newfoundland, New-Zealand, Norway, Austria,United 
States of America, Sweden, Switzerland.
Class B All other countries
Class A: Women of Dutch origin or coming from one of the developed countries






The large number of women in our study distinguishes this study from other GBS 
prevalence studies. Table 5 presents other studies in which pregnant women were cultured 
rectovaginal at about 35-37 weeks’ gestation with the use of selective broth media. 
In previous studies, GBS carriage prevalences between 1,6% and 30,4% have been 
described(2-5;7;8;13-26). The differences in these prevalences can probably be explained 
by the different gestational ages at culturing, differences in culture site and in the use of 
different culture techniques. 
Table 3 World regions and GBS culture results
Continent of native 
Country
n % GBS positive 95% CI
Africa 240 29 0.23-0.35
Asia 256 13 0.09-0.17
Latin America 245 22 0.17-0.27
Europe 907 21 0.18-0.24
Other 10 30 0.015-0.58
Unknown 44 27 0.14-0.40
Total 1702 27
Table 4 Cultures at 35-37 weeks’ gestation compared to intrapartum cultures*
Culture at 35-37 weeks Intrapartum Intrapartum Total
Positive Negative
Positive 136 37 173
Negative 38 550 588
Total 174 587 761
* In 761 of 1702 cases intrapartum GBS cultures were performed
PPV was 79%, NPV was 93%
Table 5 Studies with Rectovaginal GBS cultures on selective broth medium in third trimester of 
pregnancy
Author Year Country n Prevalence GBS
Dillon et al 1982 United States 754 28%
Easmon et al 1985 United Kingdom 895 19.8%
Sunna et al 1991 Jordan 500 30.4%
Yancey et al 1996 United States 826 26.5%
Grimwood et al 2002 New Zealand 240 22%
This study 2003 The Netherlands 1702 21%
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Characteristics of the population studied can also explain differences in prevalence rates. 
Women of Caribbean origin and black women were previously reported to be at greater 
risk of colonization than those of Mexican origin and white women(2;5;6), which suggests 
a role for ethnic or genetic factors. However, other small studies(27-29) have reported no 
differences in group B streptococcal prevalence between any ethnic groups. The women in 
our study originated from 72 different countries. Differences were found in the prevalence 
rates between European, Asian and African women. These results are in accordance with 
the findings of others(2;5;6).
Differences in GBS carriage rates may also be explained by differences in the socio-
economic status of the study group. A study in New Zealand women showed an increased 
risk for GBS carriage in the socially advantaged(3), whereas Regan et al(2) found GBS was 
less common among women with a higher education. In our study, we registered postal 
codes and related socio-economic status to the neighbourhood. Even when calculating 
prevalences for the poor and wealthy neighbourhoods separately and using different levels 
of income, we could not find any relation between socio-economic status and GBS carriage. 
An explanation for this might be that in our population the higher income group was quite 
small compared to the other groups. 
Numerous studies have documented that the accuracy of prenatal screening cultures in 
identifying intrapartum colonization status can be enhanced by careful attention to the tim-
ing of cultures, the anatomic sites swabbed and the laboratory procedures used for culture 
and detection of the organisms(9). Swabbing both the lower vagina and the rectum (through 
the anal sphincter) substantially increases the yield compared with sampling only the cervix 
or sampling the vagina without swabbing the rectum(30). Isolation rates will be increased 
by approximately 10%-15% if the lower genital and anorectal areas are sampled rather than 
only the upper vagina and cervix(31). 
Yow(14), Kubota(23) and others(15;25) performed only vaginal or cervicovaginal swabs 
and found prevalences between 6% and 14.2%, whereas rectovaginal cultures done in sev-
eral other studies(3;8;16;21;24;26) revealed higher rates between 19.4% and 31%, similar 
to the 21% found in our study.
Since vaginal and in particular rectal flora contains numerous micro-organisms, the use 
of selective enrichment broth is recommended to maximise the isolation of GBS and to 
avoid the overgrowth of other organisms. When direct agar plating is used instead of selec-
tive enrichment broth, as many as 50% of woman who are GBS carriers have false-negative 
culture results(32). Ferrieri(13) and Kubota(23) did not use selective culture medium and 
only found prevalence rates of 5,6% and 11.4% respectively, whereas studies that used 






Discordant results are reported regarding the effects of age and parity on GBS preva-
lence(5;14;27;28;33;34). In various studies(27;29;35;36) no significant differences in colo-
nization rates were noted on the basis of age or parity, but increasing age(5) and parity(5;14) 
have also sometimes been associated with lower rates of carriage. However, Regan(2) 
described GBS carriage as being more common among older women and women of lower 
parity. In our study we found no association between colonization and age or parity. 
Although the importance of infection as a cause of preterm delivery is gaining recognition, 
little is known about the role of GBS infection in miscarriages. McDonald et al.(37) stated 
that GBS was a key pathogen in unsuspected intrauterine infections underlying spontaneous 
midgestation abortions. The study of Daugaard(38) demonstrated an association between 
the occurrence of group B streptococci in the urine and cervix and late spontaneous abor-
tions, but El Kersh et al.(24) found no correlation with a history of repeated spontaneous 
miscarriages. We did not find any relation between women who had a history of miscar-
riages and GBS carriage, but at this point our population is selected since we only screened 
almost term pregnant women.
Collection of cultures between 35 and 37 weeks’ gestation is recommended to improve 
the sensitivity and specificity of the identification of women who are colonized at the time 
of delivery(4;31). 
Serial cultures done in antenatal patients suggest that women may be intermittent carriers 
of Group B streptococci and demonstrate that concordance with intrapartum culture status 
improves as the interval between antenatal cultures and delivery is shortened(4). Yancey 
et al(4) found in a population with 26,5% carriage a positive predictive value of 87% and 
a negative predictive value of 96%, when cultures were done within six weeks before 
delivery. To improve the accuracy of antenatal cultures, the Centres for Disease Control and 
Prevention has suggested that the collection of these cultures should occur at 35-37 weeks’ 
gestation instead of earlier in pregnancy(39). In our study we cultured 761 women again on 
admission for delivery and then calculated the positive and negative predictive values of the 
first culture for carriage during labour. The intention to reculture all GBS positive women 
and 400 of GBS negative women during labour was not fulfilled, probably because of hectic 
in the labourrooms and lack of attention to the studyprotocol. 
The PPV of 79% and the NPV of 93% in our study is low compared to other studies and 
probably would have been higher if we recultured all initially GBS positive women during 
labour. Both our results and the somewhat higher but still low predictive values of others 
underline the need for rapid tests to detect GBS colonization status. These bedside-tests 
might obviate the need for antenatal culture based screening if their sensitivity and specitiv-
ity are comparable to culture in selective broth media and they yield results rapidly enough 
to permit the administration of adequate intrapartum antibiotic prophylaxis to women 
detected as carriers(9). Thus far, these tests have not been reliable enough to be used as an 
alternative to rectovaginal cultures.
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In the USA, the screening based strategy is recommended since 2002(9). This recommenda-
tion is based on data found in a recent study of comparison of screening based and risk 
factor based strategies. The conclusion of this study was that the screening based strategy 
was over 50% more effective than the risk-factor based strategy(40). Management strategy 
depends on local factors like the percentage of GBS carriers and the percentage of pregnant 
women with perinatal risk-factors within the population, the organisation of perinatal care 
and the local availability of laboratory facilities. 
The choice for a preventive strategy should be based on rationality, cost-effectiveness 
and the current knowledge and possibilities(11). Since the GBS prevalence found in our 
Dutch studypopulation is more or less similar to prevalences in the USA, the present Dutch 
recommended risk factor based strategy for GBS disease prevention should be reconsidered.
We show that it is not possible to identify a group of pregnant women at high risk for 
GBS colonization with regard to age, parity or socio-economic factors. There are ethnic 
differences between colonized and noncolonized women. We demonstrated that positive 
and negative predictive values of antenatal genital group B streptococci cultures at 35-37 
weeks’ gestation for intrapartum GBS carriage are lower than previously reported. 
Results of this study can be useful in the process of finding the best preventive strategy for 
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Preterm labor and/or prolonged rupture of membranes is not 
associated with antenatal carriage of Group B Streptococcus 
(GBS)












Background Up to 36% of pregnant women is colonized with GBS. Labor before 37 weeks 
of gestation, rupture of membranes for more than 18-24 hours, intrapartum temperature of 
> 38°C, maternal GBS bacteriuria during pregnancy and a history of a previous child with 
invasive neonatal GBS disease are established risk factors for early onset neonatal GBS 
disease (GBS-EOD). Dutch guidelines do not recommend general screening, but in case 
of preterm labor and prolonged rupture of membranes, they advise to start intrapartum 
antibiotic prophylaxis if GBS cultures are positive. However, childbirth frequently occurs 
before culture results are available and therefore opportunities for prevention of GBS-EOD 
can be missed.
objective The objective of this study was to evaluate whether the occurance of labor before 
37 weeks of gestation or prolonged rupture of membranes can predict maternal GBS car-
riage.
Study design From 1702 pregnant women rectovaginal swabs were collected at 35-37 
weeks’ gestation, with the assumption that GBS status at 35-37 weeks is a good indicator for 
GBS status during labor.
Risk factors for GBS-EOD were registered during labor. To assess whether the occurrence 
of preterm labor or prolonged rupture of membranes was associated with GBS carriership, 
four-fold prognostic tables were constructed.
results Prevalence of GBS colonization in our population was 21.4%. At least one of the 
five established risk factors for GBS-EOD was present in 12.2% of women. For preterm labor 
and for prolonged rupture of membranes odds ratios for GBS colonization were RR 1.35 
(95% CI 0.77-2.37) and RR 0.82 (95% CI 0.55-1.21) respectively. Women with one of these 
risk factors alone or in combination do not show a higher risk on GBS colonization.
Conclusions Prevalence of GBS colonization in pregnant women in our population is 
21.4%. The risk factors preterm labor between 35 and 37 weeks of pregnancy and prolonged 
rupture of membranes after 35 weeks separately or combined do not show association with 
GBS carriage at 35-37 weeks. Occurrence of one of these risk factors during labor does not 
predict GBS carriage and is therefore not helpful in identifying mothers at higher risk for a 
baby with GBS-EOD.
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InTroduCTIon
Despite decline in incidence of neonatal group B streptococcal disease (GBS-EOD) over 
the past 10 years, GBS continues to be an important cause of neonatal infections and early 
neonatal mortality within the first seven days of life.(1-4) The gastrointestinal tract of the 
mother is the source of vaginal GBS colonization. Tansmission from mother to child occurs 
during labor. Prevalence of GBS colonization in women of reproductive age ranges from 
10% to 36%.(5;6) GBS colonization can be transient, intermittent or persistent.(7-9) GBS 
cultures at gestational age of 35-37 weeks are predictive for GBS carriage during labor.
(10;11) Established risk factors for GBS-EOD are preterm birth (before 37 weeks of gestation)
(12-18), prolonged rupture of the membranes(17-22), intrapartum temperature > 38°C(16-
18;21;23;24), maternal GBS bacteriuria during pregnancy(25;26) and a history of a previous 
child with GBS-EOD.(27-29)
Intrapartum antibiotic prophylaxis (IAP) given to women at risk of transmitting GBS to 
their baby can prevent GBS-EOD.(30;31) Identifying these mothers at risk may be performed 
by screening (taking a culture during pregnancy to detect maternal colonization) and/ or by 
identifying women during pregnancy with one of the established risk factors for GBS-EOD. The 
Centres for Disease Control and Prevention (CDC) have recommended screening of all pregnant 
women in the United States at 35-37 weeks’ gestation and IAP during labor for all carriers.(32) 
In the Netherlands, the Dutch Society of Obstetrics and Gynaecology (NVOG) and the Dutch 
Society of Pediatrics (NVK) approved a modified risk factor based guideline for prevention of 
GBS-EOD in 1998. This guideline advises IAP for women with intrapartum fever (>38°C), GBS 
bacteriuria during pregnancy or a previous child with GBS disease, as is performed worldwide in 
both screening based and risk factor based strategies. In women with preterm labor (< 37 weeks) 
or prolonged rupture of membranes (>24 hours) (PROM), a culture is taken, followed by IAP 
when the culture is GBS-positive. Culture results take 24 to 48 hours. If labor occurs before the 
result of the culture is available, the obstetrician should decide about IAP, based on the severity 
of the risk factor(s). After introduction of these guidelines, there only has been a limited decrease 
in the incidence of proven GBS-EOD (i.e.: streptococci are isolated from blood and/or from 
cerebrospinal fluid combined with physical signs of infection) in the Netherlands.(33) There is a 
continuous debate for improvement or change of guidelines, particularly with regard to perinatal 
mortality in the Netherlands, which is high compared to other European countries.(34) 
Limited effectiveness of the present guideline might be explained by the fact that in case of 
occurrence of preterm labor or prolonged rupture of membranes, opportunities for prevention 
can be missed because of delay in obtaining culture results. If women with these risk factors 
are at higher risk to carry GBS, Dutch guidelines could be improved by advising direct treat-
ment of women with these risk factors instead of waiting for culture results before start IAP.
In hospitals and midwifery practices in The Hague (the Netherlands), a prevalence study was 






describes a secondary analysis of our cohort of 1702 women to evaluate whether labor before 
37 weeks of gestation or prolonged rupture of membranes can predict prenatal GBS carriage.
MeThodS
Between July 2000 and December 2002, physicians and midwives at their discretion, but 
without selecting specific groups, asked women at 35-37 weeks of pregnancy to participate 
in the study. All these women attended either the outpatient Department of Obstetrics and 
Gynecology at the Medical Centre Haaglanden, the Leyenburg Hospital, the Rode Kruis 
Hospital (nowadays together Haga Hospital) or one of the six participating midwifery prac-
tices in The Hague, the Netherlands.
After informed consent, the physician or midwife collected a rectovaginal swab for GBS 
culture by initially swabbing the vaginal introïtus and thereafter the rectum (through the 
anal sphincter). Swabs were placed in a transport medium (Amies transport medium with 
charcoal) and sent to one of the participating laboratories. Inoculation took place at 35-37°C 
for 18-24 hours into a selective broth medium (Todd-Hewitt supplemented with gentamycin 
(8 micrograms/ml) and nalidixic acid (15 micrograms/ml)). The broth was subcultured onto 
a blood agar under anaerobic circumstances and GBS suspected colonies were then Gram-
stained. A catalase reaction was performed for all Gram-positive cocci. On all catalase 
negative colonies, a streptococcus grouping latex agglutination test (PathoDx group B, 
Diagnostic Products Corporation, Los Angeles, USA) was performed to identify GBS. The 
results were reported to the participating antenatal clinics and midwifery practices.
During labor, the main risk factors for GBS-EOD (Labor before 37 weeks of gestation, 
rupture of membranes for more than 24 hours, intrapartum temperature of > 38°C, maternal 
GBS bacteriuria during pregnancy and a history of a previous child with invasive neonatal 
GBS disease) were registered.
Local GBS protocol in all attending hospitals during the study advised to start IAP in case 
of intrapartum temperature above 37.8°C, GBS bacteriuria during pregnancy or a previous 
child with GBS-EOD. 
In case of preterm labor or prolonged rupture of membranes (> 24 hours), IAP was given 
in both GBS colonized women and to women with unknown GBS culture results.
When registration was incomplete, the missing patient data were obtained from the 
National Obstetric Registration or the obstetric chart of the patient. To assess whether the 
occurrence of preterm labor or prolonged rupture of membranes was associated with GBS 
carriage, we calculated Odds Ratio’s for frequency data by cross-tabulation with 95% con-
fidence intervals based on binomial/ Poisson distributions.
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reSuLTS
During the study period a total of 1702 pregnant women were enrolled in the study. Of these 
women, 365 (21.4%) had GBS positive cultures. Table 1 presents patient characteristics in 
relation to GBS carriage at 35-37 weeks of gestation. Epidemiologic data from this cohort 
were previously reported by Valkenburg et al.(35)
Rupture of membranes for more than 24 hours and preterm labor (35-37 weeks of gesta-
tion) were registered in 6.5% and 1.5% of the study population respectively. Focusing on 
these risk factors in which the obstetrician must judge whether antibiotics should be started, 
we found that for preterm labor and for prolonged rupture of membranes odds ratios for GBS 
colonization were RR 1.35 (95% CI 0.77-2.37) and RR 0.82 (95% CI 0.55-1.21) respectively. 
(Table 2 and Table 3). Women with one of these risk factors alone or in combination do not 
show a higher risk on GBS colonization. (Table 4)
dISCuSSIon
In the Netherlands, in women at labor with high risk of delivering a baby with GBS-EOD 
and unknown GBS status, in some cases the caregiver will decide whether or not to pre-
scribe antibiotics. For risk factors such as intrapartum temperature of > 38°C, maternal GBS 
bacteriuria during pregnancy and a history of a previous child with invasive neonatal GBS 
disease, there is worldwide consensus to start IAP during labor. However, in case of preterm 
labor or prolonged rupture of the membranes there is no consensus. Therefore we focused 
on these risk factors. In our analysis of preterm labor and prolonged rupture of membranes 
in relation to prenatal GBS carriage in a Dutch cohort of pregnant women, we found that 
preterm labor and prolonged rupture of membranes do not predict maternal GBS carriage.
In the Dutch modified risk factor based strategy for prevention of GBS-EOD, opportunities 
for prevention can be missed in case of prolonged rupture of membranes or in case of 
preterm labor, because of delay in obtaining culture results. We hypothesized that if women 
with these risk factors are at higher risk to carry GBS, Dutch guidelines could be improved 
by advising direct treatment of women with these risk factors instead of waiting for culture 
results before start IAP.
However, occurrence of these two risk factors separately or combined does not show 
association with GBS carriage and is therefore not helpful in identifying mothers at higher 
risk for a baby with GBS-EOD. This has implications for a risk factor based prevention strat-
egy. If all women with these risk factors during labor would receive antibiotics, this would 
result in the unnecessary exposure to antibiotics of a large group of women (eighty percent 






Table 1 Patient characteristics of study population. Age, parity, history of abortions, continent of 
native country and presence of risk factors for GBS-EOD (risk factor alone or in combination with 
another risk factor) in relation to GBS carriage at 35-37 weeks of gestation
n % GBS positive 95% CI
Total Population 1702 21 0.19-0.23
Age
< 20 41 32 0.18-0.46
20-29 663 17 0.14-0.20
30-39 905 24 0.21-0.27
>= 40 92 25 0.16-0.34
Unknown 1 100
Parity
0 663 21 0.18-0.24
1 645 19 0.16-0.22
2 232 29 0.23-0.35
3 or more 181 22 0.16-0.28
Unknown 11 18
history of Abortions
0 1163 21 0.20-0.21
1 or 2 470 22 0.18-0.26
3 or more 58 22 0.11-0.33
Unknown 11 18
native country in:
Africa 240 29 0.23-0.35
Asia 256 13 0.09-0.17
Latin America 245 22 0.17-0.27
Europe 907 21 0.18-0.24
Other 10 30 0.015-0.58
Unknown 44 27
risk factor for GBS-eod
Rupture of Membranes > 24 hrs 123 18 0.12-0.26
Preterm labor (< 35 weeks’gestation) 31 29 0.16-0.47
GBS-bacteriuria 27 67 0.48-0.81
Fever during labor 25 32 0.17-0.51
Sibling with GBS-EOD 15 47 0.25-0.70
No risk factor present 1466 21 0.18-0.22
Risk Factor unknown 33 15
Thirty-three (1.9%) women of the study population were excluded because of missing data.
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since particularly in case of preventive interventions, it is necessary to pay attention to 
the increasing potential maternal and neonatal risks and side effects of antibiotics and the 
emergence of resistant GBS strains.(36-39) For mothers, an important adverse effect of an 
increased use of antibiotics is the increasing incidence of potential severe adverse reactions 
including anaphylaxis to penicillin.(40;41) Neonatal risks include an increase in incidence 
of non-GBS-EOD.(42-44)
In a previous report we showed non-significant ethnical differences between GBS 
colonized and non-colonized women, but we could not demonstrate differences between 
colonized and non-colonized women with respect to age, parity or socio-economic back-
ground. Results of this study show that it is not possible to identify a subgroup of pregnant 
women that is at higher risk for GBS colonization.(35) If it was, defining riskgroups for GBS 
Table 2 PROM > 24 hrs alone or in combination with another risk factor.
Presence of rupture of membranes for > 24 hours (prolonged rupture of membranes,
PROM) during delivery in relation to GBS carriage at 35-37 weeks gestation
GBS + GBS - Total
PROM 22 101 123
No PROM 338 1208 1546
Total 360 1309 1669
RR 0.82 95% CI 0.55-1.21
Table 3 Preterm Labor (PL) alone or in combination with another risk factor.
Presence of preterm labor in relation to GBS carriage at 35-37 weeks gestation
GBS + GBS - Total
Preterm Labor 9 22 31
No Preterm Labor 351 1287 1638
Total 360 1309 1669
RR 1.35 95% CI 0.77-2.37
Table 4 Prolonged rupture of membranes (> 24 hours) (PROM), Preterm labor (gestational age < 37 
weeks of gestation) and combination of both in relation to GBS carriage at 35-37 weeks gestation in 
patients were there is no other risk factor for GBS-EOD
ProM PL GBS + GBS- Total or (95% CI)
No No 334 1196 1530 Reference
No Yes 5 20 25 0.89 (0.33-2.40)
Yes No 18 91 109 0.71 (0.42-1.19)
Yes Yes 3 2 5 5.3 (0.90-32.28)
Total PROM and/or PL 26 113 139 0.82 (0.53-1.28)






carriage could be usefull in daily laborroom decisionmaking to start IAP in case screening 
results were not available yet.
Although our study shows interesting results, there are some limitations. First, bacterial 
cultures were taken at 35 to 37 weeks’ gestation, with the assumption that GBS carriage 
at 35-37 weeks is a good indicator for GBS status during labor. In a systematic review 
we confirmed the recommendations to screen pregnant women for colonization of GBS at 
35-37 weeks gestation(32), since the positive predictive value (PPV) of GBS cultures for GBS 
carriage during labor decreases when the interval between antenatal culture and delivery 
culture increases, especially when it is more than six weeks.(11) Negative predictive values 
(NPV) remain constant and are therefore unrelated to the gestational age at which the culture 
is performed. However, predictive values of GBS cultures at gestational age of 35-37 weeks 
have never been reported to be 100%.
Second, women who delivered before 35 weeks of gestation were not included in the 
analysis, which makes the present rate of preterm birth low. Third, we have studied the risk 
for, but not the true incidence of GBS-EOD. Finally, we need to mention that international 
definitions define PROM as rupture of membranes for more than 18 hours,(19-22;32) while 
Dutch guidelines during current study used to define PROM as more than 24 hours. In 
international guidelines on GBS prevention, intrapartum temperature of > 38°C is a reason 
to start intrapartum antibiotic therapy, whereas Dutch guidelines at time of study advised to 
start antibiotics in women with an intrapartum temperature of 37.8°C.
Figure 1 Risk factors for GBS-EOD during delivery
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Since the introduction in 1998 of a Dutch national guideline on prevention of GBS-EOD 
there has been a limited decrease in the incidence of proven GBS-EOD in the Netherlands 
from 0.54 per 1000 live births to 0.36 per 1000 live births.(33) There was no decrease in 
the incidence of probable early-onset GBS sepsis, meningitis or case fatality rate. According 
to the Netherlands Perinatal Registry, GBS sepsis and GBS meningitis seemed to be stable 
until 2008, with respectively 108 and 15 reported cases in 2008. In 2009 an unexplained 
increase was seen, with 172 cases of GBS-EOD (0.93 per 1000 live births).
It is clear that the current Dutch guideline is not effective and a new strategy to prevent 
GBS-EOD is justified, particularly with regard to perinatal mortality in the Netherlands, 
which is high compared to other European countries.(34) The present study showed that 
occurrence of labor before 37 weeks of gestation or prolonged rupture of membranes do not 
predict GBS colonization of the mother.
Depending the results of a bedside screening test during delivery, further cost-effective-
ness-and implementation studies are needed to compare different prevention strategies for 
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objectives To describe prevalence of phenotypic and genotypic macrolide-resistance 
among GBS isolates in pregnant women and explore the possibility of clonal spread of 
resistant GBS isolates in a multicultural population.
Study design Antimicrobial resistance patterns of 107 GBS isolates obtained from asymp-
tomatic pregnant women were determined using Etests.
Macrolide resistance genes mef(A), erm(TR) and erm(B) were determined with PCR and a 
subset of 39 isolates, including the 8 isolates harbouring macrolide resistance genes, was 
subjected to RAPD analysis to detect clonal spreading.
results Resistance to erythromycin and clindamycin was found in 8% and 7%, respectively. 
Macrolide resistance genes mef(A), erm(TR) and erm(B) were found in 1, 2 and 5 isolates, 
respectively; only five of these eight isolates exhibited both genotypic as well as phenotypic 
resistance. One genotype occurred in 36% of the subset.
Conclusions Earlier reports on prevalence of phenotypic resistance were confirmed. Among 
the susceptible isolates one clonal type of GBS was clearly predominant; one of the resistant 
isolates shared its genotype. When such clonal types acquire resistance traits in the future, 
GBS disease may become harder to control.
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InTroduCTIon
Neonatal infection with group B streptococci (GBS, Streptococcus agalactiae) is a universal 
cause of neonatal morbidity and mortality. To prevent GBS acquisition of the child during 
labor and delivery, intrapartum antibiotic prophylaxis is applied, usually with benzylpenicillin 
or, otherwise, with cefazolin, clindamycin, erythromycin or vancomycin. Emergence of resis-
tance against these antimicrobials would decrease prophylactic efficacy. Resistance against 
erythromycin and clindamycin has been found in 0.7%-29% and 1.7%-21% of the strains, 
depending on geographical origin and temporal trends.(1-4) Fortunately, decreased suscep-
tibility to benzylpenicillin has been scarcely reported(4;5), but clonal dissemination of such 
strains of decreased susceptibility would be worriesome.(6) Clonal diversity of erythromycin-
resistant strains was documented in Portugal(3) and Spain.(7) Purpose of the present study was 
to assess phenotypic and genotypic antibiotic susceptibility patterns and putative epidemicity 
of GBS strains from a multicultural obstetric population in The Hague (the Netherlands).
MATerIALS And MeThodS
GBS isolates were obtained from rectovaginal cultures from asymptomatic women in the 
third trimester of pregnancy (January 2002 - February 2003). Isolates were kept in Amies 
transport medium. Incubation took place at 35-37°C for 18-24 hours in Todd-Hewitt broth 
with gentamycin (8 μg/ml) and nalidixic acid (15 μg/ml). Bacterial isolates were subcultured 
on 5% sheep blood agar in 5% CO2. Suspect GBS colonies were subjected to Gram-staining. 
Catalase activity was assayed for Gram-positive cocci. GBS strains were identified by Path-
oDx group B® (DPC, Los Angeles, USA) and stored at -80ºC in glycerol containing media.
Antibiotic susceptibility and presence of macrolide resistance genes were determined for 
107 isolates from as many women. A subset of 39 strains was included in RAPD genotyp-
ing. This selection included all 8 isolates showing phenotypic macrolide resistance and 31 
randomly selected isolates. Patient records revealed the countries of birth of the women. 
Prior to susceptibility testing, GBS isolates were grown on 5% sheep blood agar plates 
for 18-24 hours in 5% CO2. Dilutions of 0.5 McFarland were swabbed on Mueller-Hinton 
agar plates with 5% horse blood. E-tests (AB Biodisk, Solna, Sweden) for benzylpenicillin, 
cephalothin, erythromycin and clindamycin were performed according to the manufactur-
ers’ instructions. Cephalothin was tested as a representative first-generation cephalosporin. 
Cultures were incubated for 24 hours at 35-37°C in 5% CO2. The MIC was recorded as 
indicated by the NCCLS guidelines for streptococci. 
For molecular typing, bacterial DNA was extracted using lysostaphin treatment, the Bac-
terial DNA kit III and the MagnaPure Robot (Roche Diagnostics, Almere, The Netherlands). 






using primers and protocols as described by Sutcliffe et al.(8) and Seppala et al.(9) PCR 
results were scored on the basis of the absence or presence of the correctly sized amplicon 
after agarose gel electrophoresis. No positive control isolates were included, allthough 
all of the individual PCR runs showed positive results. Negative controls involved water 
samples. Genotyping by RAPD was performed according to Ahmed et al.(10) using prim-
ers 12/13 (AAGTAAGTG-ACTGGGGTGAGCG), 46 (GGTTGGGTGAGAA-TTGCACG). 48 
(GGCCATAGAGTG-TTGCAGACAAACTGC), 50 (GCGATCCCA) and 52 (GTGGATGCGA) 
DNA fingerprints were scored by two independent individuals and any change in banding 
pattern led to definition of a novel genotype. In case of discrepant interpretations consensus 
was sought through intervention of a third examiner. This resolved all discrepancies. Geno-
types were defined for all separate RAPD tests, the combination of all five types led to the 
composite, overall RAPD genotype.(11) Finally, PCR ribotyping was performed according 
to Martirosian et al.(12)
reSuLTS And dISCuSSIon
Samples were obtained from 1702 pregnant women between 35 and 37 weeks of preg-
nancy. In 365 (21%) samples GBS was cultured. From this isolate collection, we randomly 
selected 107 isolates. Of all 107 isolates, over 84% were susceptible to all antimicrobials 
tested (Table 1). Of the 9 isolates not susceptible to erythromycin, resistance or intermediate 
susceptibility to clindamycin was present in seven cases. Macrolide resistance genes were 
detected in 8 of 107 strains. Phenotypic and genotypic data for the subset of 39 strains are 
summarized in Table 2. No strain contained more than one macrolide resistance gene. Out 
of these 8 strains, 5 showed phenotypic resistance towards macrolides on lincosamides. In 
two phenotypically macrolide-resistant or -intermediate strains resistance genes were not 
detected. PCR ribotyping produced a single PCR fragment of which the nucleotide sequence 
precisely matched the sequence of the reference strain 2603 V/R (results not shown), con-
firming GBS identity. Per GBS-isolate 5 separate RAPD reactions were performed. When 
Table 1 Susceptibility patterns of 107 tested GBS strains 
Antibiotic* Susceptible (S) Intermediate (I) resistant (r)
Benzylpenicillin 107 (100%) 0 (0%) 0 (0%)
Cephalothin 107 (100%) 0 (0%) 0 (0%)
Erythromycin 98 (92%) 2 (2%) 7 (6%)
Clindamycin 100 (93%) (1%) 6 (6%)
*MIC breakpoints (μg/mL) used in our study are as recommended by NCCLS(8) for benzylpenicillin: S 
=< 0.12, I = 0.25-2, R >= 4, cephalothin: S =< 8, I = 16, R >= 32, erythromycin: S=< 0.25, I = 0.38-
0.75, R >= 1, clindamycin: S =< 0.25, I = 0.38-0.75, R >= 1. 
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Table 2 Summary of typing data obtained from a subset of GBS isolates from The Hague









































12/13 46 48 50 52
1 0.032 0.094 0.064 0.064 A A A A B *
2 0.047 0.064 0.047 0.094 B B B B G * 
3 0.032 0.094 0.047 0.047 A A C A H *
4 0.032 0.094 0.047 0.047 A A C A A *
5 0.047 0.094 0.047 0.094 A A D A A I
6 0.047 0.125 0.094 0.19 A A E A A *
7 0.032 0.125 0.094 0.064 A A F A A II
8 0.064 0.125 0.125 0.125 A A G A A *
9 0.032 0.094 0.125 0.19 A A F A A II
10 0.047 0.094 0.125 0.094 A C * A A *
11 0.047 0.094 2 0.064 + A C H A A * 
13 0.047 0.064 0.016 0.047 A A F A A II
14 0.032 0.094 0.125 0.094 A A D A B III
15 0.047 0.064 0.047 0.064 A A D C A *
16 0.047 0.094 0.064 0.094 A A D C B *
23 0.047 0.094 0.064 0.094 + A A D A B III 
36 0.064 0.094 >256 >256 + A D F A A * 
44 0.064 0.094 0.50 12 A A D A A I
45 0.047 0.064 4 >256 A E D A A IV
59 0.032 0.094 1.5 0.19 + B F * B C * 
68 0.023 0.047 >256 Ra + A A D A D * 
72 0.047 0.094 >256 >256 + A G D A E * 
76 0.064 0.064 0.50 0.50 C D F A F *
78 0.064 0.064 0.19 0.094 + C H F A C * 
91 0.047 0.094 0.016 0.064 + D H * D G * 
92 0.094 0.094 0.094 0.094 E A F A A *
96 0.064 0.064 0.094 0.19 F A D E A *
97 0.047 0.125 0.016 0.032 G F * E C * 
98 0.032 0.094 0.064 0.064 C A D A A V
99 0.032 0.094 0.047 0.047 A A D A A I






the amplimers were analysed by gel electrophoresis on avarage 5 DNA fragments were 
visible per fingerprint. This amounts to an approximate number of 25 scorable fragments 
per isolate. Per RAPD assay a type was assigned and a single band difference led to another 
type designation.
Overall, 27 RAPD genotypes were identified (Table 2), 5 of which occurred more than 
once (I: 8/39 (21%) ; II: 3/39 (8%) ; III: 2/39 (5%) ; IV: 2/39 (5%) ; V: 2/39 (5%)). The 
AA*AA type occurs 14 times (36%), showing that certain (sub)clones may spread more 
efficiently than others. These subclonal types, sharing 4 out of 5 individual RAPD test results, 
shared >80% band identity. Data on the countries of birth of the patients in the subset were 
obtained: 18 were born in the Netherlands and the others were from 10 different countries, 
showing the heterogeneity of the population. As expected in this small study group, no 
association between country of birth and phenotypic resistance or RAPD type was found.
All phenotypically macrolide-resistant isolates were RAPD-unique, but isolate 44 shared 
the epidemic genotype AA*AA with antibiotic susceptible GBS isolates.









































12/13 46 48 50 52
101 0.064 0.125 0.047 0.094 C A D A A V
102 0.094 0.19 0.047 0.094 A C D A E *
103 0.094 0.125 0.047 0.094 A A D A A I
104 0.064 0.125 0.032 0.094 A A D A A I
105 0.094 0.125 0.047 0.064 A E D A A IV
106 0.094 0.125 0.047 0.064 A A D A A I
107 0.094 0.125 0.064 0.094 A A D A A I
108 0.064 0.125 0.047 0.094 H A D A A *
The overall RAPD genotype combines the outcome of the five assays as defined by the different 
primers listed in Methods. This led to the identification of 27 genotypes. Note that strains sharing the 
AA*AA genotype (* any other type) may also form a clonal cluster. Only types occurring more than 
once have been given a serial Roman cluster code, all others are unique. Resistant isolates are marked 
in bold and intermediate susceptible isolates in italic.
a Resistance to clindamycin was inducible
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ConCLuSIonS
The prevalence of macrolide resistance among our isolates agrees with recent reports.(2;4;5) 
Several discrepancies between the phenotypic resistance and the presence of resistance 
genes are identified. Phenotypic resistance without erm or mef genes may be due to the 
fact that also other genes are involved in macrolide resistance.(9;13) In addition, erm(B) 
expression, often needs to be induced.(14) Furthermore, genetic variation in the erm and 
mef genes may also lead to false-negative PCR results. All phenotypically macrolide resistant 
strains were RAPD typed as unique genotypes. But among the susceptible isolates, we found 
a predominant GBS clone. One of the resistant isolates shared the genotype with this pre-
dominant clone, but the presence of resistance within the predominant clone is still limited 
to a single GBS isolate. The existence of a major antibiotic-susceptible GBS clone indicates 
that epidemic expansion of resistant variants could easily happen even in a heterogenous 
population. When resistance would expand in such epidemic isolates, efficient spread of 
antimicrobial resistance could take place. Continuous surveillance for resistance and its 
clonal spread is therefore needed, especially in the light of the increased use of antibiotics 
for prophylactic indications. In addition, the spread of this clone beyond the limited geo-
graphic area we analyzed in this study should be monitored by modern genotyping methods 
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Background Up to 36% of pregnant women is colonized with GBS, most often without 
having symptoms. Preterm delivery in GBS colonized mothers is a recognized risk factor for 
early onset neonatal GBS disease (GBS-EOD), but whether maternal GBS genital coloniza-
tion is related to preterm delivery is unclear.
objective The objective of this review was to determine the relationship between maternal 
colonization with Group B Streptococcus and preterm delivery. 
Study design Pubmed searches and reference lists of all selected publications were used to 
find studies reporting on the relationship between maternal GBS colonization and preterm 
delivery. Study characteristics were abstracted, and validity scores were performed. To assess 
the relationship between GBS colonization and pregnancy outcome, four-fold prognostic 
tables were constructed for each study.
results Out of more than 60 full-text articles, 16 follow-up studies and four case control 
studies were included in this review. Follow-up studies were divided into ‘cohort studies’, in 
which cultures were taken early in pregnancy and which reported on pregnancy outcome, 
and ‘cross-sectional studies’, in which cultures were collected during delivery. Studies dif-
fered widely in methods, validity score and GBS prevalence. The combined estimate from a 
random effect meta-analysis of the eleven cohort studies was 1.06 (95%CI 0.95-1.19) and 
for the five cross-sectional studies 1.75 (95%CI 1.43-2.14). For the case control studies the 
pooled odds ratio was 1.59 (95% CI 1.03-2.44).
Conclusions This systematic review did not show an association between maternal GBS 
colonization during pregnancy and preterm delivery. However, in case of preterm delivery, 
there is an increased risk of subsequent maternal GBS colonization. 
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InTroduCTIon
Despite major advances in perinatal care, preterm delivery is still the predominant cause 
of perinatal mortality and a major cause of neurological morbidity in surviving infants. 
Although the determinants of preterm delivery are uncertain, evidence suggests maternal 
genital tract colonization with specific organisms can play a role in preterm rupture of mem-
branes and preterm delivery. Bacterial products such as phospholipases A2 and C, endotoxin, 
and induction of the cytokine cascade can stimulate the prostaglandin pathway and initiate 
labour. (1;2) Reproductive tract infections or colonization associated with preterm delivery 
include Chlamydia trachomatis (3) and bacterial vaginosis. (4-6)
Up to 36% of pregnant women is colonized with GBS, most often without having symp-
toms.(7-10) Preterm delivery in GBS colonized mothers is a recognized risk factor for early 
onset neonatal GBS disease (GBS-EOD)(11), but whether maternal GBS genital colonization 
is related to preterm delivery is unclear.
The objective of this study was to critically review the literature to find any association 
between maternal GBS colonization and preterm delivery.
MeThodS
The review process of our study, including methods of reporting outcomes was based on 
recommendations of Stroup et al.(12)
Search for studies 
The selection process for studies reporting on GBS colonization and the outcome of pregnancy 
involved several steps following the guidelines provided by the book Systematic Reviews in 
Health Care.(13) Pubmed was searched for potentially relevant articles on the predictive value 
of positive GBS-cultures for preterm delivery published from 1966 to December 2008. 
The search strategy included the terms Streptococcus agalactiae, streptococcus group B, 
premature, preterm, labor, labour, delivery, birth, pregnancy outcome, infant, and combina-
tions of all these search terms.
Selection process, selected studies and validity 
All possibly relevant articles were selected on the basis of title and abstract by two research-
ers (AV, AS) and were retrieved for more detailed examination. The selected articles had to 
meet met the following inclusion criteria:
1. They were published in English, French, Italian, Spanish or German.
2. They reported pregnancy outcome in GBS carriers and non-GBS carriers.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4. It was possible to formulate a fourfold table with well defined outcome numbers. 
The bibliographies of all relevant articles were searched for additional references. All the 
retrieved articles were screened by the two researchers to ensure that the articles described 
original research and met the inclusion criteria mentioned above. In case of disagreement, 
the articles or abstracts were re-examined and discussed until consensus was achieved. 
Duplicate reporting from a single institution was excluded.
A validity score was calculated according to the criteria described by the Evidence-Based 
Medicine Working Group.(14) To determine the validity of selected studies, each study was 
graded on the basis of 7 criteria for prospective studies (range 0-11) or 4 criteria for case 
control studies (range 0-6). The following criteria of validity were used: adequate descrip-
tion of study population, well defined moment of antenatal cultures, use of selective broth 
medium and chosen culture-site(s), completeness of follow-up and/or clear description of 
dropouts and adjustment for prognostic factors. 
data extraction and statistical analysis
From each report, two researchers (AV, AS) extracted information about the study location 
and design, study population, number of patients, inclusion and exclusion criteria, study 
objectives, methods for GBS screening, timing of cultures, culture-site, completeness of 
follow-up, frequency of GBS colonization, and frequency of preterm delivery. A selection 
form based on the above criteria was constructed and filled in independently by both 
researchers. Both filled in a fourfold prognostic table based on the available data. In cases 
of disagreement, articles were re-examined and discussed until consensus was achieved.
We used Review Manager (Update Software, Oxford) to calculate relative risks and 95% 
confidence intervals, which were graphically displayed in Forest Plots.
reSuLTS
Selection of articles
After screening more than 150 citations, 60 full-text articles were retrieved. Nineteen articles 
describing 20 studies were included in this review. Four of the studies were case control 
studies(15-18) and 16 were follow-up studies (15;19-33) (see Table 1). One of the 19 articles 
described both a case control study and a cohort study, which we analyzed separately.(15) 
Follow up studies were divided into ‘cohort studies,’ in which cultures were taken at a well 
defined moment in pregnancy and reported on pregnancy outcome (n=11)(15;19-28) and 
‘cross-sectional studies,’ in which patients were only cultured at time of delivery, preterm 
or term (n= 5).(29-33) Case control studies matched patients with preterm delivery with 
patients with the same gestational age but not in labour. From three studies, only the results 
of well described subgroups were included in this review.(20;22;23)
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Review articles and articles which did not represent original research were excluded. 
(34-45) Articles were also excluded if they did not deal with our research question or did not 
report outcomes according to our definition(4;6;46-60), if they reported patients received 
antibiotics at any time during pregnancy (5;61-65), if they overlapped with another publica-
tion included in our review(66;67), if the reported outcome numbers were inconsistent(68), 
or if the study population was unclear.(69)
description of selected studies
The 20 studies included 45,888 patients living in ten different countries. Results of data-
extraction are listed in Table 1. The overall prevalence of GBS colonization varied from 
1.7%-28% (mean 12.2%, median 10.8%). In only nine studies GBS was cultured on a 
selective broth medium, which is reported to be an important factor for adequate detection 
of GBS. In twelve studies either vaginal or rectal or cervical cultures were taken, and in four 
studies vaginal cultures were combined with rectal cultures. In three other studies, urine 
specimens were cultured, and in one study (18) samples were taken from both urine, rectum 
and urethra, but the study did not specify which sample was positive in patients with preterm 
delivery. The reported prevalence of adverse outcome varied from 1.8%-16% (mean 7.6%, 
median 6.8%). However, the studies did not define adverse outcome consistently. Outcome 
measures included so-called preterm delivery (n=7), preterm labour (n=3), premature onset 
of labour (n=2), delivery < 37 weeks (n=3), preterm birth (n=1), premature delivery (n=1) 
prematurity (n=1), premature labour (n=1) and ‘premature’ (n=1). The studies also do not 
always give a clear definition of outcome; not all studies indicate whether deliveries were 
spontaneous or elective, what gestational age was defined as ‘term,’ and whether mem-
branes were intact or not. 
Validity
Table 2A shows total validity scores for the follow-up studies (maximum validity score: 
11), and Table 2A shows them for the case control studies (maximum validity score: 6). All 






Table 2A Characteristics and results of original studies according to the validity in prospective studies











































1 0 1 ND ND 0 0 2
Regan
1981
0 0 1 ND NA 0 0 1
Dawodu 
1983
0 0 1 1 NA NA 0 2
Gerards
1982
0 0 2 1 0 0 0 3
Minkoff
1984
0 2 1 0 0 1 0 4
Moller
1984
0 0 0 0 0 0 0 0
White
1984
0 0 0 0 ND 0 0 0
Joshi 
1987
0 0 1 0 NA NA 0 1
Hastings
1986
0 0 2 1 0 0 0 3
McDonald
1992
1 2 1 1 ND 0 2 7
Mc Kenzie
1994
1 2 0 0 0 0 2 5
Chua
1995
0 0 1 0 0 1 0 2
Citernesi 
1996
0 0 1 0 NA NA 0 1
Regan
1996
0 2 1 1 0 1 0 5
Feikin
2001
1 0 1 0 0 1 2 5
Hakansson
2008
1 0 2 1 NA NA 0 4
 NA= Not applicable  ND= Not described
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relation between GBS colonization and preterm delivery
Relative risks for preterm delivery in women colonized with GBS are shown graphically 
in Forest Plots. Figure 1 presents all cohort studies and Figure 2 all cross-sectional studies. 
Figure 3 shows all case control studies with odds ratios.
For cohort and cross-sectional studies, the combined estimates from a random effect 
meta-analysis were 1.06 (95%CI 0.95-1.19) and 1.75 (95%CI 1.43-2.14), respectively. The 
pooled odds ratio of case control studies for colonization given preterm delivery was 1.59 
(95% CI 1.03-2.44). 
Pooling cross-sectional studies and case control studies revealed odds of 1.76 (95%CI 
1.44- 2.15) (not shown in table).
Interpretation of results
The search strategy yielded studies with different study designs and different study periods, 
from countries with different prevalence of GBS colonization and preterm delivery. Preterm 
delivery seems positively associated with GBS colonization at the time of delivery, but 
colonization during pregnancy does not seem to be associated with preterm delivery.
Table 2B Characteristics and results of original studies according to the validity in Case Control studies






















Lamont 1986 0 2 1 0 3
Martius 1988 1 1 1 0 3
Feikin 2001 1 1 0 0 2
Persson 1986 0 1* 1 0 2
* Persson 1986: Rectal, urethral and urine specimens were cultured, from the text it is not clear which 






Figure 1 GBS colonization and preterm delivery in cohort studies
Figure 2 GBS colonization and preterm delivery in cross-sectional studies
Figure 3 GBS colonization and preterm delivery in case control studies
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dISCuSSIon
To the best of our knowledge, this is the first systematic review on this topic containing 
studies from different parts of the world. This review analysed 19 publications covering 20 
studies that dealt with the association between maternal GBS colonization and preterm 
delivery. In only one follow-up study was an association between GBS colonization during 
pregnancy and preterm delivery described.(27) Moller et al. found a higher risk of preterm 
delivery in women who had GBS in their urine, but their study had a low validity score. 
Cross-sectional studies during delivery and case control studies showed positive GBS cul-
tures more frequently in patients with preterm delivery.
The results of the present study are in concordance with those of Romero et al.(39) They 
reviewed seven studies on genital colonization and three on asymptomatic bacteriuria 
with GBS in relation to preterm delivery. Genital colonization was examined in one cross-
sectional study (tested at the time of admission), two case control studies, and four cohort 
studies. Romero et al. concluded that there was no evidence of an association between GBS 
colonization of the maternal genital tract and preterm delivery. The studies which examined 
asymptomatic GBS bacteriuria indicated that GBS bacteriuria in early pregnancy seems to 
be a risk factor for premature delivery. However, a major problem in literature is inconsis-
tency of definition of asymptomatic bacteriuria.
Romero suggested that asymptomatic bacteriuria may be a marker of the most severe 
form of GBS genitourinary tract colonization. The incidence of GBS in quantities >105 
colony forming units (cfu) /ml urine in pregnant women has been reported to be between 
0.4 and 5%.(70;71) It has been shown that only 60% of bladder punctured pregnant women 
whose urine specimens contained >105 cfu/ml urine harboured GBS in the bladder.(18) 
Thus, a high quantity of GBS in urine is assumed to reflect heavy colonization of urethra, 
vulva and vagina. It remains unclear whether heavy GBS colonization by itself influences 
pregnancy outcome or whether the urinary tract infection is responsible.
Gibbs et al.(72) found no relationship between maternal genital tract GBS colonization 
and preterm delivery. However, in three of the four studies they described, there was a 
significant association between maternal genital group B streptococci colonization and 
premature rupture of membranes.
Recently, Colbourn and Gilbert(73) described the natural history of GBS-EOD in the UK. 
In a meta-analysis of eleven studies, three of which were case control studies, the pooled 
odds ratio for preterm delivery in mothers with GBS colonization during delivery was 1.53 
(95% CI 1.14-2.05).
The vaginal microbial ecosystem in pregnant women has been shown to be an equilib-
rium of antagonistic and synergistic organisms.(74;75) Disruption of the normal vaginal 






amniotic fluid, initiating preterm labour. It is generally accepted that amniotic fluid infection 
caused by microorganisms is associated with preterm delivery. 
In a review of the association between maternal GBS colonization and preterm delivery, 
Kubota et al.(45) postulated that GBS was a marker of a lactobacilli-reduced vaginal envi-
ronment, which would increase the risk of bacterial vaginosis. However, so far no empirical 
evidence of an association between GBS colonization and lactobacilli-reduced flora has 
been found.(76)
Intra-amniotic bacterial colonization or progression to infection depends on the effec-
tiveness of the amniotic fluid antibacterial mechanisms and the number and pathogenicity 
of the colonizing bacteria. (77) It is conceivable that maternal genetic variation in response 
to these infections also plays a role in the risk of intra-uterine infection. Romero et al. specu-
lated that it is not the presence of the organism itself, but the response of the host that is the 
critical step in this chain of events. When the host defence system is inadequate, bacterial 
growth may become excessive and lead to an infection ascending into the uterus. As part of 
its uncontrolled proliferation, the organism may penetrate the urinary tract and be detected 
as asymptomatic GBS bacteriuria.(39)
A review such as this one is hampered by the wide variation in the published reports, 
with different methods, incomplete information on follow-up, regional differences in GBS 
prevalence, adjustment for other risk factors, and different definitions of preterm delivery. 
The validity of the studies also varied widely, from 0-7 points out of 11, and the control 
studies in particular considered only very small groups of patients.
Approximately 6-36% of pregnant women carry GBS in the rectovaginal compartment.
(9;10;78;79) The detected prevalence depends on the culture technique used, the locations 
tested, the culture media, the number of body sites cultured, and on the population studied. 
(80) Using selective broth media and sampling several culture sites (i.e., vagina and rectum) 
improves recovery of GBS up to 50%(81), but only seven of the studies did both. Few studies 
performed urine cultures to detect GBS. 
Epidemiological studies on preterm delivery should adjust for known risk factors. Race, 
Social Economic Status (SES), age at beginning of pregnancy, duration of pregnancy, and 
multifetal gestation have been reported to influence GBS colonization. (9;81-84) Therefore, 
differences in reported prevalence of GBS can be a reflection of different risk profiles, which 
could also include different risk profiles for preterm delivery.
Risk factors for preterm delivery have been described, such as history of preterm delivery 
(RR 2,6: 95%-BI 2,0-3,4), ethnicity, age < 16 years (OR 1,7; 95%-BI 1,1-2,8)(85), cigarette 
smoking(86), use of cocaine(87), uterine malformation, cervical conization(88), DES exposi-
tion in utero, and multifetal gestation. Only three of the studies considered in this review 
described adjustments for prognostic risk factors for preterm delivery.
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Finally, when we want to solve a problem, we should clearly distinguish cause and con-
sequences. Although all the studies considered in this review described patients admitted 
to hospital because of contractions before 37 weeks of gestational age, most studies did not 
make it clear whether deliveries were spontaneous, whether membranes were intact or not, 
and whether preterm contractions led to preterm delivery or not. In addition, it is not known 
whether researchers were aware of the results of cultures. All of this might influence how 
follow-up studies are interpreted.
ConCLuSIon
In this review we did not find a causal relationship between maternal GBS colonization and 
preterm delivery. However, in cases of preterm delivery, there is a significantly increased 
prevalence of GBS colonization. To understand the effect of GBS on pregnancy, large obser-
vational studies are needed, with clearly defined outcomes, and with prognostic risk factors 
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Timing of GBS screening in pregnancy: A systematic review













Background Group B Streptococcus (GBS, Streptococcus agalactiae) is an important cause 
of early-onset neonatal sepsis. Guidelines include the advice to collect cultures at 35-37 
weeks’ gestation and to administer intrapartum antibiotic prophylaxis (IAP) in case of GBS-
positive cultures, as well as in all preterm deliveries. Improved effectiveness of antenatal 
cultures might help to further decrease GBS-early onset disease (GBS-EOD).
objectives The objective of our review was to determine the best timing of antenatal cul-
tures, which may help to establish optimal prevention of perinatal GBS infection in both 
term and preterm neonates.
Search Strategy Pubmed and Embase databases and reference lists were searched for rel-
evant articles published from 1966 to February 2009.
Selection criteria Nine articles were included. Information about study features and predic-
tive values of antenatal cultures were abstracted. 
data collection and analysis From each study, study characteristics and inclusion and exclu-
sion criteria were abstracted by two researchers. To assess the predictive value of the GBS 
test in each study, the researchers independently constructed four-fold prognostic tables. 
Main results Positive predictive values for antenatal GBS cultures ranged from 43-100 % 
(mean 69%) and negative predictive values from 80-100% (mean 94%). GBS cultures col-
lected in late pregnancy had high positive predictive values for colonization during delivery. 
The negative predictive value was high and relatively constant regardless of gestational age. 
Conclusions This systematic review confirms recommendations to screen pregnant women 
for colonization of GBS at 35-37 weeks gestation, but one should be aware of the limitations 
of screening, with 6% of GBS carriers remaining undetected in antenatal cultures. There 
are two possible ways to prevent GBS-EOD in premature deliveries: either to give IAP in all 
premature deliveries or to screen all pregnant women both early in pregnancy and again 
later in pregnancy.
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InTroduCTIon
Even with the increased use of intrapartum antibiotic prophylaxis, Group B Streptococcus 
(GBS, Streptococcus agalactiae) disease is an important cause of morbidity and mortality 
in newborn infants in developed countries.(1;2) For neonates, the source of colonization 
or GBS-infection is the mother. The maternal gastrointestinal tract is the source of vaginal 
GBS colonization. GBS has been found to be present in the rectovaginal compartment of 
6-45% of pregnant women, (3-8) though in general it is asymptomatic.(9;10) The prevalence 
of positive GBS cultures varies due to the dynamics of GBS, culture techniques, sampling 
techniques, and the populations studied.(9;11) 
Vertical transmission from colonized mothers to their infants during labor is 50-65%.
(12;13) In GBS-colonized neonates, 1-2% of term infants and 8% of preterm infants will 
develop group B streptococcal early onset disease (GBS-EOD). Mortality rates vary from 5 
to 20% and are higher in preterm infants.(3;12) 
Intrapartum antibiotic prophylaxis (IAP) to GBS carriers reduces the incidence of GBS-
EOD.(14-18) However, prevention strategies for GBS disease are currently based on two 
different approaches: risk factor based and screening based.
Since known risk factors for perinatal GBS infections (preterm labor, preterm or pro-
longed rupture of membranes, intrapartum fever, chorioamnionitis, and signs of heavy GBS 
colonization, such as a previous infant with GBS disease or GBS bacteriuria during the 
current pregnancy) only occur in 40-50% of all GBS cases, the Centers for Disease Control 
and Prevention in the United States advises rectovaginal cultures during the antenatal period 
at 35-37 weeks gestational age and offering IAP during delivery to all pregnant women with 
positive GBS cultures.(19) The choice to screen at this moment was based on studies by 
Yancey et al.(20) and Boyer et al.(12), who found that cultures accurately predicted GBS 
colonization status at delivery when obtained in the late antenatal period.
In cases of preterm labor, prevention strategies advise antibiotic prophylaxis. By the end 
of the last decade, 30% of women delivering in US maternity units involved in a large 
multicenter study received intravenous antibiotics during labor.(21) 24% of women received 
antibiotics for vaginal colonization of group B streptococci, in order to reduce the risk of 
GBS-EOD. Screening for GBS and intrapartum prophylactic antibiotics contributed to a 
decline of the incidence of GBS-EOD during the 1990s, but this stabilised in the US at 0.2 
to 0.5/1000 live births in the mid to late 1990s.(22;23) 
Thus, despite the considerable effort and economic resources spent on IAP for GBS-EOD, 
cases continue to occur. Puopolo reported that the majority of remaining GBS-EOD occurred 
in infants whose mothers screened negative for GBS colonization.(24) Predictive values of GBS 
cultures at gestational age of 35-37 weeks have never been reported to be 100%, and screening 






GBS-disease in neonates is most dangerous.(25;26) Improving the effectiveness of GBS screen-
ing and awareness of its limitations might help to further decrease the prevalence of GBS-EOD. 
Our objective was to review the literature on the timing of GBS screening in pregnancy 
to determine the best moment to screen for GBS colonization, which may help to establish 
optimal prevention of perinatal GBS infection both in term and preterm neonates.
MeThodS
The review process, including the method of reporting outcomes, was based on recom-
mendations given by Stroup et al(27) in their article “Meta-analysis of Observational Studies 
in Epidemiology.”
Search for studies 
Relevant articles were selected in several steps, following the guidelines provided by Systematic 
Reviews in Health Care.(28) First, Pubmed and Embase databases were searched for potentially 
relevant articles published from 1966 to February 2009. The search strategy is presented in 
Table 1.
Selection process, selected studies and validity 
Articles were selected on the basis of title and abstract by two researchers (AV, RR) and were 
retrieved for more detailed examination, based on the following criteria: 
1) The article represented original research. 
2) The article reported the outcome of maternal antenatal and intrapartum GBS-cultures.
2) The results allowed a positive and negative predictive value to be calculated.
Studies were excluded when the study population received antibiotics prior to cultures 
being taken (i.e., during pregnancy or labor), or when it was unclear whether antibiotics 
were administered. 
All selected articles were searched for additional references. Both researchers screened all 
retrieved articles to ensure they met the inclusion criteria mentioned above. In case of disagree-
ment, articles or abstracts were re-examined and discussed until consensus was achieved. 
To determine the validity of selected studies, each study was graded by the two research-
ers (AV, RR) on the basis of eight criteria (see Table 3). A validity score was calculated 
(range:0-9) according to the criteria for prognostic studies described by the Evidence-Based 
Medicine Working Group (29). The following validity criteria were used: adequate descrip-
tion of study population, well-defined point of inclusion in study, well-defined moment 
of antenatal cultures, use of selective medium and chosen culture site(s), completeness of 
follow-up and/or clear description of dropouts, and the possibility to formulate a fourfold 
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table. Poor validity is defined as a validity score below five and good validity as a score of 
five or higher, with a maximum possible score of nine.
data extraction & statistical analysis
The two researchers independently extracted information on study design, methods of GBS 
screening, culture sampling, timing of antenatal culture(s), prevalence and numerical follow-
up data from each study. To assess the predictive values of the GBS test in each study, a fourfold 
prognostic table was constructed to show the relation between antenatal test results and GBS 
culture outcome at delivery for several points in gestation. Positive predictive value (PPV) is 
defined as the proportion of pregnant women with a positive antenatal GBS culture in whom 
Table 1 Search strategy in Medline and Embase (up to February 2009)
Search Query




















20 #16 OR #17 OR #18 OR #19
21 Colonised OR colonized
22 #15 OR #21
23 #22 AND #8 AND # 1 AND #20
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the GBS culture remained positive during labor. Negative predictive value (NPV) is defined 
as the proportion of pregnant women with negative GBS cultures, both antenatal and intra-
partum. For studies which included more than one antenatal culture sample, several fourfold 
prognostic tables were constructed. The following numerical data was considered: positive 
and negative predictive values, sensitivity, and specificity, all at 95% confidence intervals. 
reSuLTS
Selection 
Medline and Embase searches yielded 365 and 53 potentially relevant references, respec-
tively (Table 1). After assessing these articles on the basis of title and abstracts, twenty-five 
of these publications were retrieved for more detailed examination. Searching the reference 
lists of these articles resulted in eight additional articles. Of these 33 articles, nine studies 
met our inclusion criteria.(3;12;20;25;26;30-33) Twenty-four articles were excluded, eight 
because they did not include original research,(13;34-40) five because no culture was per-
formed at delivery,(5;11;41-43) one because the cultures taken early in pregnancy were not 
from same site as those taken during labor,(44) nine because it was impossible to construct 
a fourfold prognostic table using the data presented in the article,(4;17;45-51) and one 
because antibiotics were used during labor before an intrapartum GBS culture was taken 
(n=1).(52) The remaining nine articles were used for data extraction and analysis. 
description 
The nine remaining articles studied a total of 25,664 women, 8,898 of whom were cultured 
for GBS both in the antenatal period and during delivery. Results of data extraction are listed in 
Tables 2a and 2b. Positive predictive values for all GBS cultures ranged from 43-100 % (mean 
69%) and negative predictive values from 80-100% (mean 94%). All data were separated 
into prospective studies (Group A, n=7) and retrospective studies (Group B, n=2). In Group 
A, GBS cultures were taken at one or more points during gestation and were repeated during 
delivery. All seven of these studies identify the gestational age at which antenatal cultures were 
taken.(3;25;26;30-33) The mean positive and negative predictive values (PPV and NPV) for the 
studies in Group A were 63.3% (range: 46-89%) and 94.2% (range: 87-97%), respectively, 
with medians of 61% and 95% (Table 2a). Dividing these results into early cultures (collected 
before 35 weeks gestational age [GA] and delivered at term) and late cultures (collected after 
35 weeks GA and delivered at term), these results are 58.8% and 70.2% for PPV (mean), 
respectively, and 93.0% and 95.2% for NPV (mean), respectively.
In group B, study data were collected according to the interval (in weeks) between antena-
tal culture and the culture taken during delivery (counted retrospectively).(12;20) The mean 






medians of 72% and 95% (Table 2b). Dividing into early and late cultures, mean PPV was 
63.5% and 93.2%, respectively, and mean NPV 90.2% and 97.5%.
Antenatal cultures in the studies in Group A were performed at a mean gestational age of 
30.6 weeks (range: 10-40 weeks). Term delivery occurred in >90% in studies which reported 
gestational age at delivery (four out of six studies).(3;20;26;32) The prevalence of GBS colo-
nization varied from 6-29% (mean 18%) in the antenatal period, and 8-27% (mean 20%) 
at delivery (Tables 2a and 2b), based on data from eight studies.(3;20;25;26;30-33) Data on 
prevalence from Boyer et al. could not be taken into account, because they did not distinguish 
between antenatal prevalence and prevalence at delivery.(12) In 7 out of 9 studies, GBS was 
cultured on a selective broth medium, which is reported to be an important factor for adequate 
detection of GBS.(20;53;54) In two studies, only vaginal cultures were taken,(30;31) and in 
five studies vaginal cultures were combined with rectal cultures.(3;12;20;25;26)(Tables 2a 
and 2b). Five studies reported follow-up data of the study population;(12;20;30-32) in three 
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compare them, since PPV is dependent on the prevalence. 
The type of broth medium used and the culture site(s) 
can influence the prevalence. Using selective broth media 
and sampling several culture sites (i.e. both vagina and 
rectum) improves recovery of GBS up to 50%  [37] . Other 
factors could also affect prevalence and predictive values: 
e.g. ethnicity, socioeconomic status, age at beginning of 
pregnancy, duration of pregnancy, or multiparity. In oth-
er words, differences in the prevalence of GBS could be a 
reflection of the different risk profiles in the study popu-
lation  [3, 9, 13, 37, 45] .
 The differences mentioned above are reflected in the 
differences in the validity of the studies ( table 3 ;  fig. 1 ). 
The validity score reflects both the quality of the specific 
studies and the comparability between the studies. All 
studies showed methodological limitations, with validity 
varying from 4 to 8 (with 9 being the maximum score). A 
strong correlation between validity scores and predictive 
values was not found.
 To compare these studies, we divided them into two 
groups: group A (prospective studies) and group B (ret-
rospective studies). In group A, the GA at birth was not 
always clearly stated, so the exact interval between ante-
natal culture and delivery culture can not be calculated. 
In group B, the interval is known (calculated afterwards), 
but since one can not know in advance exactly when the 
delivery will take place, it is impossible to determine pre-
cisely when to collect the antenatal culture.
 Interpretation of Results 
 The positive relationship between GA and predictive 
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Gestational age (weeks) 
Kubota [31] (V = 5) 
Regan [33] (V = 4) 
Persson [32] (V = 7) 
Easmon [25] (V = 6) 
Allardice [30] (V = 6) 
Goodman [26] (V = 8) 
Valkenburg [3] (V = 7) 
 Fig. 1. PPV in prospective ( a ) and retro-
spective ( b ) studies. V = Validity score. 
Figure 1: Positive Predictive Values in prospective 
(a) and retrospective (b) studies.V= validity score
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studies, follow-up data could be extracted using information in text or tables, (3;25;26) while 
no follow-up data could be extracted from one study.(33) Of the eight studies with follow-up 
data, three contained a complete follow-up.(20;31;32) Persson et al.(32) followed a randomly 
selected subgroup of the study population from the start of antenatal screening until delivery. 
The mean follow-up percentage of all eight studies was 83.5% (range: 45-100%) (Tables 2a 
and 2b). Total validity scores of the included studies are shown in Table 3. 
All studies were found to have methodological limitations, with a range of 4-8 (with a 
maximum possible validity score of nine). The study of Regan et al. showed serious limita-
tions, with a validity score less than five.(33)
data synthesis 
Figures 1 and 2 show positive and negative predictive values of each study in relation to the 
mean antenatal gestational age at the time of GBS cultures. The figures also give the valid-
 Valkenburg-van den Berg et al.  Gynecol Obstet Invest 2010;69:174–183 180
with the results of earlier retrospective studies by Y ncey 
et al.  [20] and Boyer et al.  [12] . Based on these studies, the 
Centers for Disease Control and Prevention in the United 
States advises collecting rectovaginal cultures during the 
antenatal period at 35–37 weeks’ GA.
 Based on this systematic review, the overall chance of 
a positive GBS result in pregnant women is 19%. Preg-
nant women with antenatal GBS colonization (i.e. a posi-
tive GBS test) have an approximately 70% chance (PPV) 
of being colonized during delivery. This implies that the 
19% a priori chance of GPS increases to 70% with a posi-
tive test result for GBS. On the other hand, the 19% a 
priori chance of GBS decreases to 6% with an initial neg-
ative antenatal test result for GBS.
 A high NPV is needed in order not to miss the chance 
to treat women with GBS colonization during delivery 
and a high PPV is needed in order not o overtreat preg-
nant women for GBS. Accordingly, it is fair to say that an 
NPV of 94% is sufficiently accurate for clinical policy,
i.e. in the dilution in the GBS population, according to 
prevalence, trans ission and ctual EOD, an NPV of 
94% (and not 100%) can be accepted. The NPV is surpris-
ingly constant, and unrelated to prevalence or GA at time 
of culture.
 Screening for GBS between 35 and 37 weeks will pre-
dict GBS colonization at term delivery, but t is screening 
misses the preterm neonatal group, in which GBS sepsis 
is most dangerous. Therefore, all different prevention 
strategies advise antibiotic prophylaxis in cases of pre-
term labor where GBS status is not known. However, 
large-scale IAP may result in unwanted side effects, such 
















Yancey [20] (V = 8) 



















Gestational age (weeks) 
Kubota [31] (V = 5) 
Regan [33] (V = 4) 
Persson [32] (V = 7) 
Easmon [25] (V = 6) 
Allardice [30] (V = 6) 
Goodman [26] (V = 8) 
Valkenburg [3] (V = 7) 
a
 Fig. 2. NPV in prospective ( a ) and retro-
spective ( b ) studies. Figure 2 Negative Predictive Values in prospective 






ity score per study. GBS cultures taken late in pregnancy correspond with higher positive 
predictive values. The negative predictive value remains constant regardless of gestational age.
dISCuSSIon
We reviewed the literature on the predictive value of antenatal cultures during gestation to 
find the optimal timing for collecting antenatal GBS cultures. After primary assessment, nine 
studies were included. Meta-analysis was not conducted; studies were analyzed separately 
because of differences in study design. In seven studies (Group A), culture intervals were 
calculated from gestational age at which the culture was take, to birth. In two studies (Group 
B), culture intervals were calculated retrospectively from birth to the time the culture was 
taken (irrespective of gestational age). Positive predictive values for GBS cultures ranged 
from 43-100 % (mean 69%) and negative predictive values ranged from 80-100% (mean 
94%). The positive predictive values (PPVs) correlate positively with increasing gestational 
age at time of GBS culture. The results of the studies in Group B show that PPV decreases 
when the interval between antenatal culture and delivery culture increases, especially when 
it is more than six weeks. Negative predictive values remain constant and are therefore 
unrelated to the gestational age at which the culture is performed.
GBS disease remains a problem despite IAP, causing significant neonatal morbidity and 
mortality. Inaccurate screening results, improper implementation of IAP or antibiotic failure 
may all contribute to persistent disease. Procedural factors may contribute to false negative 
culture results; these may include improper sampling and culturing, poor swab storage and 
transfer practices, or inappropriate culture media. Furthermore, it is possible that women 
who screened negative early in pregnancy acquired GBS later, since GBS colonization is not 
constant and varies during pregnancy.(5;45;51)
Limits
This systematic review is subject to several methodological limitations. Almost all the 
reviewed studies were published before 2003, which means that recently available highly 
sensitive rapid microbiological diagnostics (PCR) were not taken into account.(55;56) In 
addition, little information about antenatal cultures in the first trimester of pregnancy is 
available.
It is difficult to compare the studies, due to the wide variety of study methods and 
incomplete information on follow up. Some studies reported predictive values in a non-
representative subgroup of the original cohort. Such a selection of patients could result in 
over or underestimation of the true prevalence of GBS. Prevalence rates were also different 
in the studies, making it difficult to compare them, since PPV is dependent on the preva-
lence. The type of broth medium used and the culture site(s) can influence the prevalence. 
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Using selective broth media and sampling several culture sites (i.e., both vagina and rectum) 
improves recovery of GBS up to 50%.(37) Other factors could also affect prevalence and 
predictive values: e.g., ethnicity, socio-economic status, age at beginning of pregnancy, 
duration of pregnancy, or multiparity. In other words, differences in the prevalence of GBS 
could be a reflection of the different risk profiles in the study population.(3;9;13;37;45)
The differences mentioned above are reflected in the differences in the validity of the 
studies (Table 3, Figures 1a and 1b). The validity score reflects both the quality of the spe-
cific studies and the comparability between the studies. All studies showed methodological 
limitations, with validity varying from four to eight (with nine being the maximum score). A 
strong correlation between validity scores and predictive values was not found.
To compare these studies, we divided them into two groups: Group A (prospective stud-
ies) and Group B (retrospective studies). In Group A, the gestational age at birth was not 
always clearly stated, so the exact interval between antenatal culture and delivery culture 
can not be calculated. In Group B, the interval is known (calculated afterwards), but since 
one can not know in advance exactly when the delivery will take place, it is impossible to 
determine precisely when to collect the antenatal culture. 
Interpretation of results
The positive relationship between gestational age and predictive values of GBS cultures 
found in this review corresponds with the results of earlier retrospective studies by Yancey 
et al.(20) and Boyer et al.(12) Based on these studies, the Centers for Disease Control and 
Prevention in the United States advises collecting rectovaginal cultures during the antenatal 
period at 35-37 weeks gestational age.
Based on this systematic review, the overall chance of a positive GBS result in pregnant 
women is 19%. Pregnant women with antenatal GBS colonization (i.e., a positive GBS test) 
have an approximately 70% chance (PPV) of being colonized during delivery. This implies 
that the 19% a-priori chance of GPS increases to 70% with a positive test result for GBS. On 
the other hand, the 19% a-priori chance of GBS decreases to 6% with an initial negative 
antenatal test result for GBS.
A high NPV is needed in order not to miss the chance to treat women with GBS coloniza-
tion during delivery and a high PPV is needed in order not to overtreat pregnant women 
for GBS. Accordingly, it is fair to say that an NPV of 94% is sufficiently accurate for clinical 
policy: i.e. in the dilution in the GBS-population, according to prevalence, transmission 
and actual early-onset disease a NPV of 94% (and not 100%) can be accepted. The NPV 
is surprisingly constant, and unrelated to prevalence or gestational age at time of culture. 
Screening for GBS between 35 and 37 weeks will predict GBS colonization at term 
delivery, but this screening misses the pre-term neonatal group, in which GBS sepsis is 
most dangerous. Therefore, all different prevention strategies advise antibiotic prophylaxis 






result in unwanted side-effects, such as decreased susceptibility or resistance to other 
micro-organisms(57) and disturbance of both the mother’s and the neonate’s intestinal and 
vaginal flora.(58) While IAP during delivery is associated with declines in GBS streptococcal 
infections, there have also been reports of clusters or increases in gram-negative infections 
among newborns as a result of increasing prophylactic treatment.(59-62) In addition, the 
incidence of penicillin allergy (allergic reactions of all severities), specifically in an obstetric 
population, has been reported to vary from 0.7–10%.(63-66) 
In order to minimize IAP while still providing optimal prevention of perinatal GBS infection 
in preterm neonates, it would be beneficial to screen for GBS colonization early in pregnancy, 
as the American Academy of Pediatrics recommended in 1992.(67;68) However, the results 
of early screening are not predictive of colonization during delivery after six weeks, which 
means that when early screening is performed, cultures should be repeated later in pregnancy. 
Because NPV remains high and constant during pregnancy and PPV decreases as the interval 
between antenatal culture and delivery increases beyond six weeks, cultures should only be 
repeated at 35-37 weeks gestation in women who tested positive at 29-31 weeks gestation.
ConCLuSIon
This systematic review confirms the recommendations to screen pregnant women for coloniza-
tion of GBS at 35-37 weeks gestation, but one should be aware of the limitations of screening, 
because 6% of GBS carriers during delivery remain undetected in antenatal cultures. There are 
two options for preventing GBS-EOD in preterm infants: either giving IAP in all premature deliv-
eries or screening all pregnant women early in pregnancy and culturing again later in pregnancy.
Because the studies reviewed for this article had serious methodological limitations, we 
recommend new, well-designed and well-executed studies to determine the best timing of 
antenatal culturing for GBS. These could include longitudinal prospective cohort studies 
with cultures taken at different gestational ages. This would provide more reliable data to 
compare individual differences in GBS colonization, and understand its dynamics, thus 
permitting practitioners to draw more dependable conclusions from culture results.
Rapid molecular diagnostics such as PCR will fill an important need in the near future, 
since bedside testing will help to identify every GBS carrier during delivery.(6;7;56) 
To reduce the serious problem of perinatal GBS disease, a highly-accurate, rapid diag-
nostic test for GBS, as well as the development of a polyvalent GBS vaccine and rapid 
implementation should be high public health priorities.
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Chapter 7
Opportunities for improvement of prevention of GBS-EOD











Despite considerable efforts and economic resources spent on prevention of early-onset 
group B streptococcal disease (GBS-EOD), it is still an important cause of neonatal infection 
and early neonatal mortality within the first seven days of life.
In this article, we identify potential areas for improvement of prevention of GBS-EOD. 
Opportunities for improvement can be found in development and implementation of local 
prevention protocols as well as in optimal timing of screening, the correct choice of sampling 
sites, the best conditions of transport of swabs and culture procedures and the best choice 
of antibiotics. Knowledge about the route to disease and the possible preventive measures 
as well as training in recognizing GBS-EOD is important. Caregivers should be aware that 
there are a lot of little steps in the chain of prevention where improvement of prevention of 
GBS-EOD can be made.
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InTroduCTIon
Invasive Group B streptococcal disease emerged in the 1970’s as a leading infectious cause 
of perinatal morbidity and mortality.(1) Vertical transmission of GBS from mother to child 
occurs during labor. The gastrointestinal tract of the mother has been recognized as the 
source of vaginal GBS colonization. The frequency of GBS colonization ranges from 10% to 
35% in women of reproductive age.(2;3) Studies on vertical GBS transmission in colonized 
mothers during labor report incidences of colonization of the infant between 16 and 69%.
(4-9) Early-onset group B streptococcal disease (GBS-EOD) occurs in approximately 1% of 
newborns who are colonized with GBS and typically presents with sepsis, pneumonia or 
meningitis.(10) Risk factors for acquiring GBS-EOD are prolonged rupture of membranes, 
preterm labor, intrapartum fever, GBS bacteriuria during pregnancy or a previous child with 
GBS.(11)
Because infants with early onset group B streptococcal disease (GBS-EOD) are infected 
during labor, the opportunity for timely prevention is limited. Prevention of disease rather 
than treatment is the focus of attempts to reduce neonatal GBS infections and the burden 
of the disease.
Intrapartum antibiotic prophylaxis (IAP) given to women at risk of transmitting GBS to 
their baby can prevent GBS-EOD.(9;12) Identifying these mothers at risk may be performed 
by screening (taking a culture during pregnancy to detect maternal colonization) and/ or by 
identifying women during labor with one of the established risk factors for GBS-EOD.
Today, after implementation of prevention strategies, the overall incidence of GBS-EOD 
in many countries has declined progressively.(2-5) However, current strategies for preven-
tion of GBS-EOD are still subject of controversy. Despite considerable efforts and economic 
resources spent on prevention of GBS-EOD, it is still an important cause of neonatal infec-
tion and mortality within the first seven days of life.(1-3;6-14)
Factors contributing to ongoing disease
Nowadays, as shown in several recent studies, in countries where culture based screening 
is performed, GBS-EOD mainly occurs in term infants born to mothers screened negative 
for GBS colonization and in preterm infants born to mothers who were not screened and 
did not receive IAP.(3;14;15) Missed opportunities for prevention of GBS-EOD in case of 
a screening based strategy were identified in a recent study by Stoll et al(13) and revealed 
failure to screen all women during pregnancy, failure to provide antibiotics to all colonized 
women or to those who delivered preterm with unknown colonization status, and false 
negative GBS screens among some women who deliver infants with GBS infection. 
Negative GBS screens among women who deliver infants with GBS-EOD are particularly 
troubling and may be attributable to insufficient sampling, delay in processing, suboptimal 






ie wrong timing of antenatal cultures. This, together with several other aspects of antena-
tal and perinatal clinical practice, including lack of guidelines, lack of communication, 
improper implementation of IAP and microbiological factors including antibiotic resistance, 
may all contribute to ongoing disease.
opportunities for improvement of prevention of GBS-eod
With regard to the remaining burden of disease it is important to identify potential areas for 
improvement in the total process from antenatal care to discharge of a healthy women with 
a healthy baby. 
Prevention Strategy
Among all opportunities for improvement, one of the most important factors in decreasing 
GBS-EOD is that there is at least a nationwide guideline for preventing GBS-EOD, ideally 
translated into protocols for each region or each hospital. 
The best prevention strategy maximizes treatment in women who need it, and refrains 
from treatment in women who do not need it. Wilson and Jugner defined in 1968 criteria for 
appraising validity of a screening programme, which still upheld today as classics; the gold 
standard of screening. (Table 1)(14)
However, several adaptations have been made to the classic criteria of Wilson and Jung-
ner, and several new criteria have also emerged. Emerging criteria reflect broader trends that 
have shaped both Western medicine and society more generally over the past generation 
(e.g. increased consumerism, the shift away from paternalism towards informed choice, a 
focus on evidence-based health care, and the rise of managed care models that emphasize 
cost-effectiveness, quality assurance, and accountability of decision-makers.(15) All these 
Table 1 The Wilson-Jungner criteria for appraising the validity of a screening program.(14)
1. The condition being screened for should be an important health problem 
2. The natural history of the condition should be well understood 
3. There should be a detectable early stage 
4. Treatment at an early stage should be of more benefit than at a later stage 
5. A suitable test should be devised for the early stage 
6. The test should be acceptable 
7. Intervals for repeating the test should be determined 
8.  Adequate health service provision should be made for the extra clinical workload resulting from 
screening 
9. The risks, both physical and psychological, should be less than the benefits 
10. The costs should be balanced against the benefits 
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criteria should be taken into account when a nationwide guideline or local protocol is 
established.
Management strategy to prevent GBS-EOD depends on local factors, including the percent-
age of GBS carriers and the percentage of pregnant women with perinatal risk factors within 
the population, the organization of perinatal care and the availability of laboratory facili-
ties. The choice for a prevention strategy is based on rationality, cost-effectiveness, current 
knowledge and implementation and should be in line with criteria for screening. 
In this article, we will not particularly describe pros and cons of different prevention 
strategies of GBS-EOD, but focus on identifying GBS carriage, different aspects of IAP and 
identifying GBS-EOD in newborns.
Improvement of prenatal screening
Accuracy of GBS prenatal screening can be improved. The aim of GBS screening is to predict 
vaginal GBS colonization at time of delivery. Methods that maximize the likelihood of GBS 
recovery are required, and specific culture media are needed. Critical factors that influence 
the accuracy of detecting GBS maternal colonization include anatomic sites of samplng 
the GBS bacteria, timing sampling in pregnancy, transport conditions of swabs and culture 
procedures. In addition, failure to culture GBS may be caused by maternal factors, such as 
use of oral antibiotics before specimen collection.
 Sampling sites
The recommended method of collection of GBS is based on a 1977 study in which was 
shown that the gastrointestinal tract was the primary site of GBS colonization. In 17.9% of 
rectal cultures from pregnant women GBS was found, compared to 10.2% of vaginal cul-
tures.(16) Results from later studies showed that swabs taken from both the anorectum and 
the vaginal introitus increase the likelihood of GBS isolation by 5-27% over vaginal culture 
alone.(19-21) In recent cohort studies similar detection rates were found when the vaginal-
rectal collection method was compared with the vaginal-perianal collection method.(22-24) 
Patients indicated less pain and discomfort with the vaginal-perianal collection method. 
Therefore, vaginal-perianal cultures may be reasonable, patient-preferred alternatives for the 
recommended vaginal-rectal cultures for detection of GBS during pregnancy.(17) 
 Transport
For shipment from outpatient clinics to a microbiology laboratory it is important to know 
how long Group B streptococci in swabs will survive at room temperatures.
The CDC guidelines state specifically that the viability of GBS can be maintained for up 
to 4 days in appropriate transport media, i.e. Amies transport medium.(3) There are few data, 






results if the GBS colony density is low or if the room ambient temperature is relatively high 
(> 300C).(18) Even when appropriate transport media are used, the sensitivity of culture is 
best when the specimen is stored at 4 0C before culture and processed within 24 hours of 
collection.(19) Further research is needed to know more about best transport and storage 
conditions.
 Culture Procedures
The use of selective broth media (i.e. broths containing antimicrobial agents to inhibit com-
peting organisms) is essential. In these media, the yield of screening cultures increases by 
as much as 50%.(28;29) Appropriate selective broth media, either SBM broth or Lim broth, 
are commercially available. Of course, it is important that the person who sends the swab 
to the laboratory clearly indicates that a GBS screening is requested, so that the appropriate 
media are used.
 Timing
In countries were a screening regimen is followed, GBS-EOD mainly occurs in term infants 
born to mothers screened negative for GBS colonization and in preterm infants born to 
mothers who were not screened.(20-22) As GBS carriage is highly variable, antenatal GBS 
cultures are not always good predictors of maternal GBS carriage during delivery. Whether 
these negative cultures were false negative or the mothers acquired GBS in the interval 
between the screening culture and the time of delivery is unknown. Negative GBS screens 
may provide a false sense of reassurance both to the patient and her caregivers. In addition, 
women with GBS may not be colonized at the time of labor and thus receive IAP unneces-
sarily.
After a systematic review we confirmed recommendations to screen all pregnant women 
for colonization of GBS at 35-37 weeks gestation. However, one should be aware of the 
limitations of screening. Positive predictive values for antenatal GBS-cultures at gestation 
of 35-37 weeks ranged from 43-100% (mean 69%) and negative predictive values from 
80-100% (mean 94%). GBS-cultures collected in late pregnancy correspond with high posi-
tive predictive values for colonization during delivery. The negative predictive value is high 
and relatively constant with regard to gestational age, but still 6% of GBS carriers during 
delivery remains undetected.(23)
Several studies have confirmed the benefit of using a reliable, highly sensitive, easy to 
perform, rapid test. To allow a timely and targeted IAP to GBS-positive women screened 
during labor, turnaround time of such tests should be short. These tests should be available 
24 hours a day, 7 days a week. An accurate rapid test for GBS colonization proved difficult 
to develop. Despite the development of antigenic and hybridization-based tests in the last 
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two decades, a rapid and accurate culture method for GBS colonization is still unavailable. 
Although these tests have good specificities, they have disappointing performance with low 
sensitivities, which only increase with heavy colonization.
Communication and Implementation
In a recent prospective surveillance study from the USA all cases of GBS-EOD during 4 years 
in a cohort of 400 000 live births were reported. Despite CDC recommendations for univer-
sal antenatal screening for GBS, only 58% of mothers who delivered infants with GBS-EOD 
were screened. (in 63% of term deliveries and in 44% of preterm deliveries) Only 76% of 
mothers with GBS bacteriuria, 76% with a positive GBS screen and 66% with unknown GBS 
colonization status and a risk factor (gestation < 37 weeks, ROM more than 18 hours before 
delivery, maternal temperature > 38.00C) received intrapartum antibiotics.(13)
Guidelines are adressed to obstetric and neonatal-care practitioners, laboratories and 
labor-and delivery facilities. For ideal implementation of guidelines, good collaboration and 
communication is extremly important. Each hospital should have a protocol for prevention 
of GBS-EOD which is known to all professionals involved in the care of pregnant women. 
This protocol should document the way of selection of mothers to whom administration 
of IAP is advised, complete with documentation of risk factors (in case of risk factor based 
strategy), procedures for collecting specimens for culture of GBS at 35-37 weeks of gestation 
(in case of a screening strategy), transport and laboratory procedures, mode of administering 
IAP, dosage and duration and way of secondary prevention of GBS-EOD among newborn 
infants (i.e. observation vs treatment).
Results should be easily available for clinical workers on the floor, who ideally have 
been trained in the protocol and exactly know what to do in patients with risk factors for 
GBS-EOD or positive screening results. Health-care providers should inform women about 
recommended interventions.
Good implementation of guidelines requires knowledge of and adherence to the protocol 
for both the patient and caregivers.
Choice of antibiotics
Penicillin is the preferred antibiotic for IAP to prevent GBS-EOD. It is the first choice before 
ampicillin or amoxicillin, because of its narrower spectrum of antimicrobial activity, its 
decreased potential for selection of resistant organisms and its likely minor effect on enteric 
bacterial species. The efficiacy of all three agents administered intravenously for the preven-
tion of GBS-EOD has been reported in clinical studies.(12)
Dosage
Proper dosing of antibiotics is essential to prevent the fetus from infection. In various coun-






are currently used. The rationale behind these regimens is not always clear nor evidence 
based. There is strikingly little information available on the pharmacokinetics of antibiotics 
in pregnancy in general and in the peripartal period in particular. Future studies should 
focus on research on pharmacokinetics of antibiotics during pregnancy and childbirth.
The CDC recommends penicillin G in a dosing regimen of 5 million units iv, followed by 
2.5-3.0 million units iv every 4 hours. The range of 2.5-3.0 million units after the first 5 
million units is recommended to achieve adequate drug levels in the fetal circulation and 
amniotic fluid while avoiding neurotoxicity. In order to reduce the need for pharmacies 
to specially prepare doses, the choice of dose should be guided by which formulations of 
penicillin G are readily available.(5)
As an alternative but equally recommended is Ampicillin in a 2 gram initial dose, fol-
lowed by 1 gram every 4 hours until delivery. (Figure 1)
Outside the USA, intravenous amoxicillin is sometimes used in the prevention of neontal 
GBS disease.
Amoxicillin dosing regimens have been derived from studies using ampicillin, a beta-
lactam antibiotic closely related to amoxicillin. Since the consequences of changes in 
Figure 1 Algorithm for intrapartum antibiotic prophylaxis for prevention of GBS-EOD(5)
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antibiotic dosing are unknown, it is not possible to study different regimens in pregnant 
women. Computer-simulations using data of the prescribed regimens are an accepted alter-
native, particularly when detailed information on the pharmacokinetics and the inherent 
inter-individual variation are avilable. 
Muller et al. described in a simulation model in women with preterm prelabor rupture of 
membranes that a dosing regimen of bolus injections of 1 gram amoxicillin every 6 hours 
was predicted to be adequate for the prevention of GBS infection in pregnant patients.
(24) This regimen was described as the usual regimen in a former review of the Cochrane 
Library.(25) After revision, the Library doesn’t provide recommendations for antibiotic dos-
ing regimens anymore. A 2 gram loading dose does not seem to be beneficial and the 1 gram 
doses can safely be administered by bolus injection increasing the comfort of the patient 
and facilitating prophylaxis.(31) The remaining difference between the CDC regimen and 
the former Cochrane regimen is the dosing interval of 4 hours versus 6 hours. Muller advises 
a 4-hour dosing regimen instead of a 6-hour dosing interval, since the common urgency 
of care in delivery rooms can easily result in inaccuracies in the administration. Using a 
4-hour dosing interval results in a higher probability of target attainment, even when doses 
are accidentally skipped. 
Dutch guidelines advise benzylpenicillin, in an initial dose of 2 million Units and subse-
quent doses of 1 million Units every four hours. As an alternative guidelines mention an 
initial dose of 2 gram amoxicillin or ampicillin, followed by 1 gram every four hours until 
delivery.(26)
Alternatives in penicillin-allergic patients
Considering a prevalence of GBS colonization of 20% and a prevalence of penicillin allergy 
of 10%, it is estimated that 2% of the pregnant women is both GBS colonized and penicillin 
allergic. 
Penicillin skin testing can be performed in pregnant women, so that penicillin can be 
administered safely if the result is negative.(27)
To select the antibiotic prophylaxis for penicillin allergic women at high risk of anaphy-
laxis properly , antimicrobial susceptibility testing of GBS isolates is essential and should 
be documented. An antibiotic that is frequently prescribed in women with penicillin allergy 
is clindamycine. However, there is increasing resistance among GBS isolates. Resistance of 
GBS isolates to erythromycin and clindamycin has been reported many times.(28-31)
Resistance to erythromycin and clindamycin in a multicultural population of pregnant 






Nevertheless, susceptibility testing to macrolides is rarely performed ( < 1% of colonized 
women who are allergic to penicillin) and clindamycin is administered to 70% of women 
allergic to penicillin.(21)
CDC guidelines recommend that penicillin-allergic women at high risk for anaphylaxis 
( i.e. a history of anaphylaxis, angioedema, respiratory distress or urticaria following 
administration of a penicillin or a cephalosporin) should receive clindamycine if their GBS 
isolate is susceptible to clindamycine and erythromycin, as determined by antimicrobial 
susceptibilitytesting; if the isolate is sensitive to clindamycin but resistant to erythromycin, 
clindamycine may be used if testing for inducible clindamycin resistance is negative.
However, data on the pharmacokinetics of clindamycine in pregnant women and non 
pregnant individuals are scarce.(39-41) Data suggest that in pregnant women the current 
dosing regimen of 900 mg every 8 hours reach adequate concentrations, but the concentra-
tion-time profiles in the fetus might be inadequate. More pharmacokinetic studies including 
data of both the mother and the neonate are needed to investigate whether the currently 
advised regimen is adequate to prevent GBS-EOD.
Penicillin-allergic women at high risk for anaphylaxis should receive vancomycine if their 
isolate is intrinsically resistant to clindamycin as determined by antimicrobial susceptibility-
testing, if the isolate demonstrates inducible resistance to clindamycin or if susceptibility to 
both agents is unknown. (Figure 1)
Duration of administration of antibiotics
The Centre for Disease Control and Prevention (CDC) issued recommendations for the 
prevention of GBS-EOD specifying that profylaxis is considered adequate only if antibi-
otic administration is started at least 4 hours prior to delivery. Because of various delivery 
circumstances, as many as 50% of GBS carriers women may not get IAP 4 hours before 
delivery.(42) As a consequence, soon after birth healthy-appearing infants born to mothers 
who received inadequate IAP routinely undergo invasive testing (including white blood cell 
count and blood culture) to exclude infection. Only a few studies have evaluated the influ-
ence of timing of profylaxis on neonatal colonization and the reported rates of transmission 
are quite heterogeneous. In a systematic review a rationale for the 4 hour threshold of the 
CDC guidelines was not found.(32) A recent prospective cohortstudy described colonization 
rates of infants born to mothers who received inadequate or no profhylaxis. Among 137 
infants born to mothers who received inadequate prophylaxis, 3.6% were colonized. Eighty-
two women received prophylaxis < 2 hours before delivery and two of their infants (2.4%) 
were colonized. Of 30 infants who were not exposed to prophylaxis, 60% were colonized. 
Colonization was significantly more frequent among infants born to untreated mothers com-
pared with infants born to women who received inadequate profylaxis. This suggests that 
inadequate prophylaxis may effectively interrupt GBS transmission. IAP should therefore 
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always been given to women with higher risk of neonatal GBS-EOD, even if delivery is 
expected to be within a few hours.(44)
To conclude, research on the pharmacokinetics of various antibiotics should be continued 
for optimization of the GBS disease prophylaxis. 
Secondary prevention of GBS-EOD among newborn infants
Prevention strategies will never prevent all cases of GBS-EOD. Rapid detection of neonatal 
infections and initiation of appropriate treatment is needed to minimize morbidity and 
mortality. The detection of GBS-EOD poses certain clinical challenges, because neonatal 
care providers must take into account the clinical appearance of the infant, the presence of 
maternal risk factors for GBS-EOD and infant exposure to intrapartum antibiotics. Figure 2 
describes the algorithm for managing infants with signs of sepsis, infants born to women 
with chorioamnionitis and well-appearing infants exposed to inadequate intrapartum anti-
biotics.(5) 
Detection of disease after IAP
As use of IAP to prevent GBS-EOD increased, concern was expressed that signs of sepsis 
in the newborn could be delayed or masked, impairing the ability of clinicians to detect 
GBS-EOD. (45;46) However, several studies conducted since 1996 did not find significant 
difference in the clinical presentation of GBS-EOD between infants exposed to IAP and 
those not exposed.(22;33-36) Approximately 90% of cases of GBS-EOD continue to mani-
fest within the first 24 hours of life.
Neonatal infection is diagnosed by laboratory tests, i.e. CRP (routinely) or procalcitonin 
(PCT) concentrations (sporadically). The concentrations of both proteins are increased in 
cord blood in response to infection. Measurements of CRP and PCT levels in cord blood 
plasma contribute to the diagnosis EOD.(37-40) There are significant differences between 
infected and uninfected neonates in levels of CRP and PCT levels in cord blood, also when 
prenatal antibiotic therapy was administered.
Knowledge, training and awareness
Training in recognizing GBS-EOD and knowledge about the route to disease and the pos-
sible preventive measures deserve continued attention of all workers in obstetric care, either 
in hospitals or at home. Parents need to be informed about the disease so that they can 






Figure 2 Algorithm for secondary prevention of early-onset group B streptococcal (GBS) disease 
among newborns(5)
* Full diagnostic evaluation includes a blood culture, a complete blood count (CBC) including white 
blood cell differential and platelet counts, chest ra diograph (if respiratory abnormalities are present), 
and lumbar puncture (if patient is stable enough to tolerate procedure and sepsis is suspected). 
† Antibiotic therapy should be directed toward the most common causes of neonatal sepsis, including 
intravenous ampicillin for GBS and coverage for other organisms (including Escherichia coli and other 
gram-negative patho gens) and should take into account local antibiotic resistance patterns. 
§ Consultation with obstetric providers is important to determine the level of clinical suspicion for 
chorioamnionitis. Chorioamnionitis is diagnosed clini cally and some of the signs are nonspecific. 
¶ Limited evaluation includes blood culture (at birth) and CBC with differential and platelets (at birth 
and/or at 6–12 hours of life). 
†† If signs of sepsis develop, a full diagnostic evaluation should be conducted and antibiotic therapy 
initiated. 
§§ If ≥37 weeks’ gestation, observation may occur at home after 24 hours if other discharge criteria 
have been met, access to medical care is readily available, and a person who is able to comply fully 
with instructions for home observa tion will be present. If any of these conditions is not met, the infant 
should be observed in the hospital for at least 48 hours and until discharge criteria are achieved. 
¶¶ Some experts recommend a CBC with differential and platelets at age 6–12 hours.
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ConCLuSIon
To identify potential areas for improvement of prevention of GBS-EOD, training in recogniz-
ing GBS-EOD is important. Opportunities for improvement can be found in development 
and implementation of local prevention protocols as well as in optimal timing of screening, 
a correct choice of sampling sites, the best conditions of transport of swabs and culture 
procedures and the best choice of antibiotics. Knowledge about the route to disease and the 
possible preventive measures deserve continued attention of all workers in obstetric care, 
either in hospitals or at home. Caregivers need to be aware that there are a lot of little steps 
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Chapter 8
The strategy for prevention of GBS-EOD in the Netherlands; 
plea for the combination strategy











Introduction of the Dutch modified risk factor based strategy on prevention of Group B 
streptococcal disease in 1998 resulted in a slight reduction in the incidence of early-onset 
group B streptococcal disease (GBS-EOD), but not in a decrease in severe morbidity and 
case fatality rate. The current Dutch guideline is not effective and a new strategy to prevent 
GBS-EOD is justified. 
We describe several alternative prevention strategies for the Dutch modified risk factor 
based strategy and we hypothesize about the best strategy for the Netherlands.
The combination strategy seems applicable for the Dutch situation and organisation of 
obstetrical care. In this strategy, screening of all pregnant women is combined with IAP only 
for carriers with risk factors for GBS-EOD during labor. This strategy is cost-effective with a 
low number of women that get antibiotics during delivery. Advantage of the combination 
strategy is that GBS status of the mother is always known, which allows caregivers and 
parents to observe babies from GBS positive mothers who did not receive IAP. The combina-
tion strategy will not interfere with the Dutch obstetrical system and will not lead to extra 
hospital referrals. 
Therefore, we plea for the combination strategy as the new Dutch strategy in prevention 
of GBS-EOD.
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InTroduCTIon
Despite decline in incidence of neonatal group B streptococcal disease (GBS-EOD) over 
the past 10 years, GBS continues to be an important cause of neonatal infections and early 
neonatal mortality within the first seven days of life.(1-4) The gastrointestinal tract of the 
mother is the source of vaginal GBS colonization. Transmission from mother to child occurs 
during labor. Prevalence of GBS colonization in women of reproductive age ranges from 
10% to 36%.(5;6) GBS colonization can be transient, intermittent or persistent.(7-9) GBS 
cultures at gestational age of 35-37 weeks are predictive for GBS carriage during labor.
(10;11) Established risk factors for GBS-EOD are preterm birth (before 37 weeks of gestation)
(12-18), prolonged rupture of the membranes(17-22), intrapartum temperature > 38°C(16-
18;21;23;24), maternal GBS bacteriuria during pregnancy(25;26) and a history of a previous 
child with GBS-EOD. (27-29)
Intrapartum antibiotic prophylaxis (IAP) given to women at risk of transmitting GBS to 
their baby can prevent GBS-EOD.(30;31) Identifying these mothers at risk may be performed 
by screening (taking a culture during pregnancy to detect maternal colonization) and/ or by 
identifying women during pregnancy with one of the established risk factors for GBS-EOD. 
The Centres for Disease Control and Prevention (CDC) have recommended screening of all 
pregnant women in the United States at 35-37 weeks’ gestation and IAP during labor for all 
carriers.(32) 
The Dutch Society of Obstetrics and Gynaecology (NVOG) and the Dutch Society of 
Paediatrics (NvK) approved modified risk factor based guidelines for prevention of early-
onset Group B streptococcal disease (GBS-EOD) in 1998. These guidelines on prevention 
of GBS-EOD recommend intrapartum maternal administration of antibiotics in women with 
intrapartum temperature > 38ºC, in women with GBS bacteriuria during current pregnancy 
and in women who previously delivered an infant with early-onset GBS disease, irrespective 
to their GBS status.(33) In women presenting with any of the other risk factors associated 
with early onset GBS disease, i.e. delivery at <37 weeks’ gestation or rupture of membranes 
for more than 24 hrs, screening for GBS carriage is performed first, followed by intrapartum 
antibiotic prophylaxis (IAP) when the culture is positive. In case the delivery occurs before 
the result is available, the obstetrician should decide about antibiotic prophylaxis, based 
on the severity of the risk factor. The choice for this modified risk factor based strategy was 
made in 1998, with the intention to reduce the number of cases of GBS-EOD while few 
women receive antibiotics during delivery. The disadvantages of this strategy are, that 30%-
40% of GBS-EOD may occur in the absence of factors and that in most cases of preterm 
delivery and /or prolonged rupture of membranes delivery occurs before culture results are 
available.(33) 
There has been a disappointing limited decrease in the incidence of proven GBS-EOD 






cerebrospinal fluid combined with physical signs of infection in the neonate. In probable 
sepsis GBS is detected in serious ill children at various sites, but not in blood and/or cere-
brospinal fluid. Incidence of proven sepsis declined from 0.54 per 1000 live births to 0.36 
per 1000 live births.(34) There was no decrease in the incidence of probable early-onset 
GBS sepsis, meningitis or case fatality rate. According to the Netherlands Perinatal Registry, 
which doesn’t distinguish between incidences of proven and probable GBS-EOD, GBS 
sepsis and GBS meningitis seemed to be stable until 2008, with respectively 108 and 15 
reported cases in 2008. In 2009 an unexplained increase was seen, with 172 cases of GBS-
EOD (0.93 per 1000 live births). Between 2000 and 2009 a case fatality rate for GBS-EOD 
of 6.3% was found. 
revision of current dutch guidelines
Since the overall effect of the Dutch guideline on the incidence of GBS-EOD is disappoint-
ing, revision of the Dutch guidelines was considered in 2006. Because of the presumed 
lack of evidence to change towards an alternative strategy, the Dutch prevention strategy 
remained as it was. However, given the on-going burden of GBS-EOD, adaptation of the 
Dutch guidelines should be reconsidered, particularly concerning perinatal mortality in the 
Netherlands, which is high compared to other European countries.(35)
In the USA, guidelines for prevention of GBS-EOD recommend the screening based 
strategy. Extrapolation of prevention strategies from the USA to the Netherlands may be 
inappropriate, since there are differences in for example the organization of perinatal care.
It is important to know that most women colonized with GBS are asymptomatic, so 
screening is needed if these women are to be identified. However, of the women in labor 
who are GBS positive, very few (1%) will give birth to babies who are infected with GBS. 
Hence, giving intravenous antibiotics to all women in labor who are GBS positive will put a 
large number of women and babies at risk of adverse effects unnecessarily.
Alternative strategies
There are several alternatives in prevention strategies for the Dutch modified risk factor 
based strategy.
Risk factor based strategy 
The risk factor based strategy was based on multiple studies indicating that certain clinical 
risk factors were overly represented in mothers of infants who went on to develop GBS-
EOD. With this strategy prenatal screening cultures are not obtained and IAP is directed to 
any women with prolonged rupture of the membranes, gestation < 37 weeks or intrapartum 
fever. Additionally, IAP is given to women with antenatal GBS bacteriuria (a presumed 
marker of heavy colonization and a risk factor for GBS-EOD) and to those who had experi-
enced a previous delivery of a newborn with GBS disease. 
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Screening based strategy
In the screening based strategy, cultures are obtained at 35-37 weeks ’gestation. After onset 
of labor or rupture of membranes, IAP is then given to women who are identified as GBS 
carriers. In case of unscreened women or if the culture result is not available, IAP is given 
as well. As with the risk factor based strategy, IAP is also given to women with intrapartum 
fever, to women with antenatal GBS bacteriuria and to those who have experienced a previ-
ous delivery of a newborn with GBS-EOD. This strategy is recommended by the CDC in the 
USA since 2002.(6;32)
Combined screening/risk factor based strategy 
The combined screening/risk factor based strategy (Combinationstrategy) that originates 
from the Canadian Task Force on Preventive Health Care, consists of a culture taken at 
35-37 weeks of gestation and IAP only for GBS colonized women with risk factors and not 
for those without risk factors. In addition, in this strategy, IAP is given in all cases of preterm 
labor if screening results are not available, in women with intrapartum temperature > 38ºC, 
in women with GBS bacteriuria during current pregnancy and in women who previously 
gave birth to an infant with early-onset GBS disease, irrespective to their GBS status.
disadvantages of screening
Disadvantages of IAP are the medical interference in normal labor and in the neonatal period 
as well as increased demand for prenatal counselling and increased maternal anxiety. In the 
Dutch organization of obstetrical care, a screening based strategy during pregnancy will 
need adjustment and dedication and therefore will take some time until full implementation. 
The potential for causing maternal psychological stress by testing in pregnancy has 
always been a concern for clinicians concerned with maternal welfare. A study among 183 
pregnant Taiwanese women reported significantly greater psychological distress on state-
anxiety scores among women with GBS colonization, but after delivery, anxiety scores did 
not differ between GBS positive and GBS negative women. Among all women screened for 
GBS, those with positive and negative results alike, there was great approval for the test and 
the desire to have screening for their next pregnancy.(36) Clinician concerns about maternal 
anxiety should therefore not be an impediment to test for GBS.
unintended consequences after adoption of a prevention strategy
Although implementation of intrapartum prophylaxis strategies in the USA has been associ-
ated with a substantial decrease in newborn illness and death from GBS, there are concerns 
regarding unintended consequences of the increased use of antimicrobials among pregnant 
women and newborns. 
If a culture based screening would be introduced In the Netherlands, obstetrical inhospi-






IAP. In an era of increased patient autonomy, IAP may be rejected when offered to healthy 
pregnant women. This strategy is at odds with home delivery, because it is unlikely that IAP 
is to be administered at home.
On the other hand, the fact that nowadays more patients are well informed about pos-
sibilities for screening and prevention of GBS-EOD, may also lead to specific requests and 
outrage when testing for GBS carriage is not routinely performed during pregnancy.(37)
Resistance
The widespread use of antibiotics is known to contribute to the development of resistant 
organisms. This is a particular risk when broad-spectrum antibiotics such as ampicillin and 
amoxicillin are used.(3;38;39)
Anaphylaxis
Wider use of antibiotics will also lead to an increase in adverse antibiotic events, potentially 
including anaphylaxis and death. Estimates of these events for anaphylaxis are 1: 10.000 
and for death 1:100.000 treated patients, although the evidence base for these much quoted 
figures is limited.(40)
Anaphylaxis-related mortality is likely to be a rare event because the majority of women 
receiving intrapartum antibiotics will be in hospital settings were rapid intervention is read-
ily available. Allergic reactions occur in an estimated 0.7%-4.0% of all treatment courses 
with penicillin, the most common of which is a maculopapular rash. Maternal anaphylaxis 
associated with GBS prophylaxis was reported in 1990s (41) ; since the release of the 1996 
guidelines, four reports of nonfatal cases of anaphylaxis associated with GBS IAP in the USA 
have been published.(42-45)
Fetal effects of severe anaphylaxis have not been reported. There might be fetal distress 
and injury due to maternal hypoxia and hypotension.
Effects on children on short and long term
One study reported an association between the use of intrapartum antibiotics for preven-
tion of GBS-EOD and late-onset (7-90 days) serious bacterial infections (LOD) caused by 
several micro-organisms.(46) The incidence of postnatal yeast infections may increase with 
the use of intrapartum antibiotics.(47) Possibly acquired abnormalities in early-life bacterial 
colonization may affect the development of the immune system and change the pattern of 
initial colonization of the gut in the first days of life. This may be linked to later development 
of allergic disease.(46;48;49)
Changing patterns of sepsis
Major concerns about IAP comes from reports of clusters or increases in gram-negative 
infections among newborns in association with declines in GBS infections in the context 
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of increasing IAP use.(50-52) A review on this issue suggested no consistent trend toward 
increased incidence of gram-negative or drug-resistant early onset neonatal sepsis.(38) One 
large report of infants with very low birth weight documented a shift from gram-positive 
to gram-negative early onset infections in the context of increased GBS prevention, with 
increases in E. Coli infections.(53) This phenomenon did not extend to the general popula-
tion.(54;55) A recent analysis of babies with E. coli sepsis in the first week of life compared 
with the birth cohort has revealed no increased risk of neonatal sepsis from E. coli associ-
ated with intrapartum antimicrobials.(56) This remains an important issue and emphasizes 
the importance of ongoing neonatal infection surveillance.
Comparison of strategies
There are no randomized controlled trials comparing different screening protocols.
Estimates of the efficacy of the screening strategies are based on observational studies. 
A decision model used to predict outcomes for two strategies in the United States revealed 
that a screening based strategy would result in 31% of pregnant women being offered IAP 
compared with 17% of women with a risk factor based strategy. Screening was predicted to 
prevent 75% of GBS-EOD, whilst the risk factor strategy would prevent 54%.(57;58)
The CDC conducted a retrospective cohort study in eight states of the USA among a birth 
cohort of more than 600.000 and including 312 cases of GBS-EOD, to assess the relative 
effectiveness of the screening based strategy and the risk factor based strategy. Adjusting 
for confounders, women of the cohort of the screening based strategy had a > 50 % lower 
risk of delivering a baby with GBS disease than did those exposed to the risk factor based 
strategy. (RR for GBS-EOD following screening based versus risk factor based IAP 0.46, CI 
0.36-0.60)(59)
Two features seemed to account for the superior effectiveness of screening based strategy. 
First, the screening based strategy prevented disease among women who had no obstetric 
risk factors, who in the pre-prevention era had represented up to 45% of early onset cases.
(60) Secondly, adherence to the protocol as well as eligibility of women for IAP were more 
frequently performed in deliveries in the screening cohort than in the cohort of the risk factor 
based strategy.
Theoretic model for the Netherlands
Table 1 shows a comparison of different strategies with respect to percentage of screening of 
pregnant women, percentage of women who receive IAP, percentage of unprotected deliver-
ies (i.e. no IAP to prevent GBS-EOD) and percentage of infants who acquire GBS-EOD.







The incidence of GBS-EOD without any prevention strategy is 0.15%; in the Netherlands, 
prevalence of GBS carriage among pregnant women is 21%; in 20% of pregnant women 
there is one or more risk factor for GBS-EOD present during labor; 40% of GBS-EOD occurs 
in the absence of risk factors; positive and negative predictive values for antepartum cultures 
are 100% and IAP is always effective in preventing GBS-EOD.
The best preventive strategy maximizes treatment in women who need it, and minimizes 
treatment in women who do not need it. As shown in the table, the combination of the 
screening/risk factor based ( combination) strategy has the lowest number needed to treat, 
i.e. only 47 pregnant women need to receive IAP to prevent one case of GBS-EOD. There is 
an equal percentage of unprotected infants in comparison to the risk factor based strategy. 
However, the great advantage of the combinationstrategy is that GBS status is always known, 
which allows caregivers to observe babies from GBS positive mothers who did not receive 
IAP because there is no risk factor. Parents of these babies can be informed to watch for signs 
of GBS-EOD as well.
In the Dutch obstetrical system, a distinction is made between low and high risk pregnancies 
and deliveries. Low risk pregnancies and deliveries are attended by a “primary caregiver” 
(midwife or general practitioner) and deliveries may take place at home, in a freestanding 
birth clinic or in a hospital. High risk pregnancies and deliveries, defined as the presence 
of conditions that place women and/or newborns at risk during pregnancy and delivery, 
are attended by a secondary care caregiver (obstetrician) and deliveries take place in a 
hospital. Preterm labor, prolonged prelabor rupture of membranes and intrapartum fever are 
indicators for high risk delivery. Women with one of the five risk factors, as described in the 
guidelines, will always be referred to a hospital. Therefore both the risk factor based and the 
combination strategy will not interfere with the Dutch obstetrical system and will not lead 
to extra hospital referrals.
Table 1 Comparison of strategies for prevention of GBS-EOD; a theoretic model
Strategy Screening IAP for Screened 
women
IAP unprotected - 
GBS-eod
nnT
No strategy No Nobody 0% 0% 100% / 0.15%
Risk factor based No Women with RF 0% 20% 40% / 0.06% 222
Screening based Yes Women with GBS+ 100% 21% 0% / 0% 140
Combination Yes Women with GBS+ and RF 100% 4.2% 40% / 0.06% 47
IAP = Intrapartum antibiotic prophylaxis
RF= Risk factor
NNT= Number needed to treat
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Cost effectiveness
In a 2005 study a cost-effectiveness analysis based on different decision models for the 
Dutch situation was performed. The screening strategy, the risk factor based strategy, the 
combined screening/risk factor based strategy and the current Dutch strategy (modified risk 
factor based strategy) were compared with respect to costs and effects.
This study showed that the screening based strategy showed the highest reduction in 
GBS-EOD, but for the highest costs, resulting in a high cost-effectiveness ratio. The risk factor 
based strategy (as recommended by the CDC in 1996) and a combined screening/risk factor 
based strategy are more cost-effective.(61) However, in this study several assumptions have 
been made, which have been criticized later.(62) The higher amount of estimated costs of the 
screening based strategy could partly be explained by the costs of 48 hours clinical observa-
tion of healthy infants of GBS culture positive mothers. The costs of this neonatal observation 
period contribute to more than half of the total costs in the screening approach. Neonatal 
observation is not necessary in the risk factor based strategy. Although 48 hours clinical obser-
vation is recommended in current Dutch guidelines and in the CDC guidelines, the necessity 
for this procedure in the Netherlands may be questioned. In the Netherlands an effective 
postnatal home care system exists, supervised by midwives and specially trained maternity 
nurses, which could replace the need for clinical observation. Omitting the clinical observa-
tion of clinically healthy infants reduces the costs calculated for the screening based strategy.
ConCLuSIon
Introduction of the Dutch modified risk factor based strategy on prevention of GBS-EOD 
resulted in a slight reduction in the incidence of proven GBS-EOD, but not in a decrease 
in severe morbidity and mortality. Latest information even shows increase in cases of GBS 
sepsis per year. Therefore, it is obvious that the current Dutch guideline is not effective and 
a new strategy to prevent GBS-EOD is justified. The combination strategy seems applicable 
for the Dutch situation and organisation of obstetrical care. In this strategy, screening of all 
pregnant women is combined with IAP only for carriers with risk factors for GBS-EOD during 
labor. This strategy is comparable cost-effective with the risk based strategy, but the number 
of women that get IAP much lower. This is of great advantage, since particularly in case of 
preventive interventions, attention should be paid to risks and unintended consequences of 
widespread use of antibiotics. Another great advantage of the combination strategy is that 
GBS status is always known, which allows caregivers and parents to observe babies from 
GBS positive mothers who did not receive IAP. The combination strategy will not interfere 
with the Dutch obstetrical system and will not lead to extra hospital referrals. Future studies 
should focus on implementation of this strategy in the Dutch system of obstetric care with 







 1. Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, et al. The burden of 
invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011 
Nov;30(11.:937-41.
 2. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting para-
digms. Clin Microbiol Rev 1998 Jul;11(3.:497-513.
 3. Stoll BJ, Hansen NI, Sanchez PJ, Faix RG, Poindexter BB, Van Meurs KP, et al. Early onset neo-
natal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011 
May;127(5.:817-26.
 4. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, Cousens S, et al. Group B streptococ-
cal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 
2012 Feb 11;379(9815.:547-56.
 5. Barcaite E, Bartusevicius A, Tameliene R, Kliucinskas M, Maleckiene L, Nadisauskiene R. Preva-
lence of maternal group B streptococcal colonisation in European countries. Acta Obstet Gynecol 
Scand 2008;87(3.:260-71.
 6. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal 
disease. Revised guidelines from CDC. MMWR Recomm Rep 2002 Aug 16;51(RR-11.:1-22.
 7. Lewin EB, Amstey MS. Natural history of group B streptococcus colonization and its therapy 
during pregnancy. Am J Obstet Gynecol 1981 Mar 1;139(5.:512-5.
 8. Hoogkamp-Korstanje JA, Gerards LJ, Cats BP. Maternal carriage and neonatal acquisition of group 
B streptococci. J Infect Dis 1982 Jun;145(6.:800-3.
 9. Hansen SM, Uldbjerg N, Kilian M, Sorensen UB. Dynamics of Streptococcus agalactiae coloniza-
tion in women during and after pregnancy and in their infants. J Clin Microbiol 2004 Jan;42(1.:83-
9.
 10. Yancey MK, Schuchat A, Brown LK, Ventura VL, Markenson GR. The accuracy of late antenatal 
screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet 
Gynecol 1996 Nov;88(5.:811-5.
 11. Valkenburg-van den Berg AW, Houtman-Roelofsen RL, Oostvogel PM, Dekker FW, Dorr PJ, Sprij 
AJ. Timing of group B streptococcus screening in pregnancy: a systematic review. Gynecol Obstet 
Invest 2010;69(3.:174-83.
 12. Quirante J, Ceballos R, Cassady G. Group B beta-hemolytic streptococcal infection in the new-
born. I. Early onset infection. Am J Dis Child 1974 Nov;128(5.:659-65.
 13. Tseng PI, Kandall SR. Group B streptococcal disease. In neonates and infants. N Y State J Med 
1974 Nov;74(12.:2169-73.
 14. Yagupsky P, Menegus MA, Powell KR. The changing spectrum of group B streptococcal dis-
ease in infants: an eleven-year experience in a tertiary care hospital. Pediatr Infect Dis J 1991 
Nov;10(11.:801-8.
 15. Garland SM. Early onset neonatal group B streptococcus (GBS. infection: associated obstetric risk 
factors. Aust N Z J Obstet Gynaecol 1991 May;31(2.:117-8.
 16. Adair CE, Kowalsky L, Quon H, Ma D, Stoffman J, McGeer A, et al. Risk factors for early-onset 
group B streptococcal disease in neonates: a population-based case-control study. CMAJ 2003 
Aug 5;169(3.:198-203.
 17. Benitz WE, Gould JB, Druzin ML. Risk factors for early-onset group B streptococcal sepsis: estima-
tion of odds ratios by critical literature review. Pediatrics 1999 Jun;103(6.:e77.
 18. Oddie S, Embleton ND. Risk factors for early onset neonatal group B streptococcal sepsis: case-
control study. BMJ 2002 Aug 10;325(7359.:308.
 19. Spaans WA, Knox AJ, Koya HB, Mantell CD. Risk factors for neonatal infection. Aust N Z J Obstet 
Gynaecol 1990 Nov;30(4.:327-30.
Prevention of GBS-EOD in the Netherlands 147
 20. Yancey MK, Duff P, Kubilis P, Clark P, Frentzen BH. Risk factors for neonatal sepsis. Obstet Gyne-
col 1996 Feb;87(2.:188-94.
 21. Boyer KM, Gadzala CA, Kelly PD, Burd LI, Gotoff SP. Selective intrapartum chemoprophylaxis 
of neonatal group B streptococcal early-onset disease. II. Predictive value of prenatal cultures. J 
Infect Dis 1983 Nov;148(5.:802-9.
 22. Stewardson-Krieger PB, Gotoff SP. Risk factors in early-onset neonatal group b streptococcal infec-
tions. Infection 1978;6(2.:50-3.
 23. Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease. Risk factors, prevention 
strategies, and vaccine development. Epidemiol Rev 1994;16(2.:374-402.
 24. Schuchat A, Zywicki SS, Dinsmoor MJ, Mercer B, Romaguera J, O’Sullivan MJ, et al. Risk factors 
and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. 
Pediatrics 2000 Jan;105(1 Pt 1.:21-6.
 25. Wood EG, Dillon HC, Jr. A prospective study of group B streptococcal bacteriuria in pregnancy. 
Am J Obstet Gynecol 1981 Jul 1;140(5.:515-20.
 26. Persson K, Christensen KK, Christensen P, Forsgren A, Jorgensen C, Persson PH. Asymptomatic 
bacteriuria during pregnancy with special reference to group B streptococci. Scand J Infect Dis 
1985;17(2.:195-9.
 27. Carstensen H, Christensen KK, Grennert L, Persson K, Polberger S. Early-onset neonatal group B 
streptococcal septicaemia in siblings. J Infect 1988 Nov;17(3.:201-4.
 28. Faxelius G, Bremme K, Kvist-Christensen K, Christensen P, Ringertz S. Neonatal septicemia due 
to group B streptococci--perinatal risk factors and outcome of subsequent pregnancies. J Perinat 
Med 1988;16(5-6.:423-30.
 29. Philipson EH, Herson VC. Intrapartum chemoprophylaxis for group B streptococcus infection to 
prevent neonatal disease: who should be treated? Am J Perinatol 1996 Nov;13(8.:487-90.
 30. Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selec-
tive intrapartum chemoprophylaxis. N Engl J Med 1986 Jun 26;314(26.:1665-9.
 31. Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal coloniza-
tion. Cochrane Database Syst Rev 2009;(3.:CD007467.
 32. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease--revised 
guidelines from CDC, 2010. MMWR Recomm Rep 2010 Nov 19;59(RR-10.:1-36.
 33. Trijbels-Smeulders M, Adriaanse AH, Gerards LJ, Kimpen JL. Strategy to prevent neonatal early-
onset group B streptococcal (GBS. disease in the Netherlands. Reviews in Medical Microbiology 
2003;14:35-9.
 34. Trijbels-Smeulders M, de Jonge GA, Pasker-de Jong PC, Gerards LJ, Adriaanse AH, van Lingen RA, 
et al. Epidemiology of neonatal group B streptococcal disease in the Netherlands before and after 
introduction of guidelines for prevention. Arch Dis Child Fetal Neonatal Ed 2007 Jul;92(4.:F271-
F276.
 35. Mohangoo AD, Buitendijk SE, Hukkelhoven CW, Ravelli AC, Rijninks-van Driel GC, Tamminga 
P, et al. [Higher perinatal mortality in The Netherlands than in other European countries: the 
Peristat-II study]. Ned Tijdschr Geneeskd 2008 Dec 13;152(50.:2718-27.
 36. Cheng PJ, Shaw SW, Lin PY, Huang SY, Soong YK. Maternal anxiety about prenatal screening for 
group B streptococcus disease and impact of positive colonization results. Eur J Obstet Gynecol 
Reprod Biol 2006 Sep;128(1-2.:29-33.
 37. McCartney M. Streptococcus B in pregnancy: to screen or not to screen? BMJ 2012;344:e2803.
 38. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention 
of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. 
Lancet Infect Dis 2003 Apr;3(4.:201-13.
 39. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, et al. Very low birth weight 






continues in the National Institute of Child Health and Human Development Neonatal Research 
Network, 2002-2003. Pediatr Infect Dis J 2005 Jul;24(7.:635-9.
 40. Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. 
Clin Allergy 1988 Nov;18(6.:515-40.
 41. Pylipow M, Gaddis M, Kinney JS. Selective intrapartum prophylaxis for group B streptococcus 
colonization: management and outcome of newborns. Pediatrics 1994 Apr;93(4.:631-5.
 42. Dunn AB, Blomquist J, Khouzami V. Anaphylaxis in labor secondary to prophylaxis against group 
B Streptococcus. A case report. J Reprod Med 1999 Apr;44(4.:381-4.
 43. Gei AF, Pacheco LD, Vanhook JW, Hankins GD. The use of a continuous infusion of epinephrine 
for anaphylactic shock during labor. Obstet Gynecol 2003 Dec;102(6.:1332-5.
 44. Sheikh J. Intrapartum anaphylaxis to penicillin in a woman with rheumatoid arthritis who had no 
prior penicillin allergy. Ann Allergy Asthma Immunol 2007 Sep;99(3.:287-9.
 45. Chaudhuri K, Gonzales J, Jesurun CA, Ambat MT, Mandal-Chaudhuri S. Anaphylactic shock in 
pregnancy: a case study and review of the literature. Int J Obstet Anesth 2008 Oct;17(4.:350-7.
 46. Glasgow TS, Young PC, Wallin J, Kwok C, Stoddard G, Firth S, et al. Association of intrapar-
tum antibiotic exposure and late-onset serious bacterial infections in infants. Pediatrics 2005 
Sep;116(3.:696-702.
 47. Dinsmoor MJ, Viloria R, Lief L, Elder S. Use of intrapartum antibiotics and the incidence of post-
natal maternal and neonatal yeast infections. Obstet Gynecol 2005 Jul;106(1.:19-22.
 48. Bedford-Russell AR. New modalities for treating neonatal infection. Eur J Pediatr 1996 Aug;155 
Suppl 2:S21-S24.
 49. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001 Apr 7;357(9262.:1057-9.
 50. Terrone DA, Rinehart BK, Einstein MH, Britt LB, Martin JN, Jr., Perry KG. Neonatal sepsis and 
death caused by resistant Escherichia coli: possible consequences of extended maternal ampicil-
lin administration. Am J Obstet Gynecol 1999 Jun;180(6 Pt 1.:1345-8.
 51. Towers CV, Carr MH, Padilla G, Asrat T. Potential consequences of widespread antepartal use of 
ampicillin. Am J Obstet Gynecol 1998 Oct;179(4.:879-83.
 52. Joseph TA, Pyati SP, Jacobs N. Neonatal early-onset Escherichia coli disease. The effect of intrapar-
tum ampicillin. Arch Pediatr Adolesc Med 1998 Jan;152(1.:35-40.
 53. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Changes in pathogens 
causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002 Jul 25;347(4.:240-
7.
 54. Baltimore RS, Huie SM, Meek JI, Schuchat A, O’Brien KL. Early-onset neonatal sepsis in the era of 
group B streptococcal prevention. Pediatrics 2001 Nov;108(5.:1094-8.
 55. Hyde TB, Hilger TM, Reingold A, Farley MM, O’Brien KL, Schuchat A. Trends in incidence and 
antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and 
Atlanta. Pediatrics 2002 Oct;110(4.:690-5.
 56. Schrag SJ, Hadler JL, Arnold KE, Martell-Cleary P, Reingold A, Schuchat A. Risk factors for inva-
sive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. 
Pediatrics 2006 Aug;118(2.:570-6.
 57. Benitz WE, Gould JB, Druzin ML. Preventing early-onset group B streptococcal sepsis: strategy 
development using decision analysis. Pediatrics 1999 Jun;103(6.:e76.
 58. Benitz WE, Gould JB, Druzin ML. Antimicrobial prevention of early-onset group B streptococ-
cal sepsis: estimates of risk reduction based on a critical literature review. Pediatrics 1999 
Jun;103(6.:e78.
 59. Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig AS, et al. A population-based compari-
son of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 
2002 Jul 25;347(4.:233-9.
Prevention of GBS-EOD in the Netherlands 149
 60. Rosenstein NE, Schuchat A. Opportunities for prevention of perinatal group B streptococcal 
disease: a multistate surveillance analysis. The Neonatal Group B Streptococcal Disease Study 
Group. Obstet Gynecol 1997 Dec;90(6.:901-6.
 61. Akker-van Marle ME, Rijnders ME, Dommelen P, Fekkes M, Wouwe JP, Amelink-Verburg MP, et 
al. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to 
prevent early-onset group B streptococcal disease. BJOG 2005 Jun;112(6.:820-6.
 62. Wolf H, Wouters MG, Trijbels-Smeulders M. Re: Cost-effectiveness of different treatment strate-




Summary, General Discussion and Future Perspectives

Summary, General Discussion and Future Perspectives 153
Group B Streptococcus (GBS, Streptococcus agalactiae) has been recognized as an impor-
tant cause of perinatal morbidity and mortality.(1-3) The frequency of GBS colonization 
ranges from 10% to 35% in women of reproductive age.(4;5) GBS colonization can be 
transient, intermittent or persistent.(6-8) Vertical transmission of GBS from mother to child 
occurs during labor. Studies on vertical GBS transmission in colonized mothers during labor 
report incidences of colonization of the infant between 16 and 69%.(9-14) Early-onset 
group B streptococcal disease (GBS-EOD) occurs in approximately 1% of newborns who 
are colonized with GBS.(15)
Established risk factors for acquiring GBS-EOD are prolonged rupture of membranes, 
preterm labor, intrapartum fever, GBS bacteriuria during pregnancy or a previous child with 
GBS-EOD.(16) Intrapartum antibiotic prophylaxis (IAP) given to women at risk of transmitting 
GBS to their baby may prevent GBS-EOD.(14;17) Identification of mothers at risk may be 
performed by screening (taking a culture during pregnancy to detect maternal colonization) 
and/ or by identifying pregnancies with one or more of the established risk factors for GBS-
EOD. The Centres for Disease Control and Prevention (CDC) have recommended screening 
of all pregnant women in the United States at 35-37 weeks’ gestation and IAP during labor 
for all carriers.(18) In the Netherlands, the Dutch Society of Obstetrics and Gynaecology 
(NVOG) and the Dutch Society of Pediatrics (NVK) approved a modified risk factor based 
guideline for prevention of GBS-EOD in 1998. This guideline advises IAP for women with 
intrapartum fever (>38°C), GBS bacteriuria during pregnancy or a previous child with GBS 
disease, as recommended worldwide in both screening based and risk factor based strate-
gies. In women with preterm labor (< 37 weeks) or prolonged rupture of membranes (>18 
hours), a culture is taken, followed by IAP when the culture is GBS-positive. Culture results 
are available after 24 to 48 hours. If labor occurs before the result of the culture is available, 
the obstetrician should decide about IAP, based on the severity of the risk factor(s) or by 
symptoms of infection. 
After implementation of prevention strategies, the overall incidence of GBS-EOD in many 
countries over the world has declined progressively.(18-21) However, current strategies for 
prevention of GBS-EOD are still subject of controversy. Despite considerable efforts and 
economic resources spent on prevention of GBS-EOD, it is still an important cause of neo-
natal infection and early neonatal mortality within the first seven days of life.(2;18;20;22;23) 
In the Netherlands, there has been a limited decrease in the incidence of GBS-EOD.(24) 
There is a continuous debate for improvement or change of guidelines, particularly with 
regard to perinatal mortality in the Netherlands, which is high compared to other European 
countries.(25) Limited effectiveness of the present guideline might be explained by the fact 
that in case of occurrence of preterm labor or prolonged rupture of membranes, oppor-






factors contributing to ongoing disease could be insufficient sampling, delay in processing, 
suboptimal laboratory techniques, recent antibiotic use or colonization after screening 
was performed, ie wrong timing of antenatal cultures. These factors, together with several 
other aspects of antenatal and perinatal clinical practice including lack of guidelines, lack 
of communication, improper implementation of IAP and microbiological factors such as 
antibiotic resistance, may all cause that opportunities in the prevention and further decline 
of GBS-EOD are missed. Since the overall effect of the Dutch guideline on the incidence 
of GBS-EOD is disappointing, adaptation of the Dutch guidelines should be reconsidered. 
The aim of this thesis is to contribute to the information needed for the establishment of an 
optimal preventive strategy for GBS-EOD.
This thesis
The best prevention strategy maximizes treatment in women who need it, and minimizes 
treatment in women who do not need it. To be able to optimize the Dutch strategy it is 
essential to start with knowledge about the prevalence of GBS colonization of pregnant 
women in the Netherlands, which may have changed due to recent changes in demograph-
ics, in particular with regard to ethnic background of women living in major cities. In 
our study described in chapter 2, we show that in the multicultural, urban population of 
pregnant women in The Hague, the Netherlands, the prevalence of GBS colonization is 
21%. We found differences between colonized and non-colonized women, but we could 
not demonstrate differences between colonized and non-colonized women with respect to 
age, parity or socio-economic background. Results show that it is not possible to identify a 
subgroup of pregnant women that is at higher risk for GBS colonization. Positive predictive 
value of GBS carriage at 35-37 weeks gestation for carriage at time of parturition was 79% 
and negative predictive value was 93%.
A secondary analysis of our cohort of pregnant women was performed to evaluate whether 
labor before 37 weeks of gestation or prolonged rupture of membranes can predict prenatal 
GBS status. If women with these risk factors are at higher risk to carry GBS, Dutch guidelines 
could be improved by advising direct administration of antibiotics to women with these risk 
factors instead of waiting for culture results before start IAP. We found that occurrence of 
the risk factors preterm birth and/or rupture of membranes for more then 24 hrs does not 
predict GBS colonization. Occurrence of this risk factor in itself is therefore not helpful in 
identifying mothers at higer risk for a baby with GBS-EOD.(Chapter 3)
In the Dutch modified risk factor based guideline on prevention of GBS-EOD, intrapartum 
maternal administration of benzylpenicillin is advised in women eligible for IAP. In case of 
a history of penicillin allergy, clindamycin or erythromycin is recommended as alternative. 
Previous reports have documented universal susceptibility to benzylpenicillin and cepha-
losporins, but resistance of GBS to erythromycin and clindamycin has increased during the 
Summary, General Discussion and Future Perspectives 155
last decade in several countries, with some geographical variations.(26-29) Especially for 
antibiotics used in widespread prophylactic treatment regimens, continuous surveillance 
for resistance and clonal spread of resistant microorganisms is needed. In chapter 4 we 
describe the prevalence of phenotypic and genotypic macrolide-resistance among group 
B streptococci isolated in the Dutch prevalence study as described in Chapter 2 and we 
explore the possibility of clonal spread of resistant GBS isolates in a multicultural popula-
tion. Antimicrobial resistance patterns of 107 GBS isolates were determined using Etests. 
Macrolide resistance genes mef(A), erm(TR) and erm(B) were determined with PCR and a 
subset of 39 isolates, including the 8 isolates harbouring macrolide resistance genes, was 
subjected to RAPD analysis to detect clonal spreading. Resistance to erythromycin and 
clindamycin was found in 8% and 7%, respectively. Macrolide resistance genes mef(A), 
erm(TR) and erm(B) were found in 1, 2 and 5 isolates, respectively; only five of these eight 
isolates exhibited both genotypic as well as phenotypic resistance. One genotype occurred 
in 36% of the subset. Earlier reports on prevalence of phenotypic resistance were confirmed. 
Among the susceptible isolates one clonal type of GBS was clearly predominant; one of the 
resistant isolates shared its genotype. When such clonal types acquire resistance traits in the 
future, GBS disease may become harder to control.
Preterm delivery in GBS colonized mothers is a recognized risk factor for early-onset 
neonatal GBS disease (GBS-EOD)(30), but whether maternal GBS genital colonization is 
related to preterm labor is unclear. In the search for opportunities for timely interventions 
in the prevention of GBS-EOD, we critically reviewed the literature to find any association 
between maternal GBS colonization and preterm delivery. In chapter 5 results of this sys-
tematic review are described. The search strategy yielded studies with different study designs 
and different study periods, from countries with different prevalence of GBS colonization 
and preterm labor. Preterm labor seems positively associated with GBS colonization at the 
time of delivery, but colonization during pregnancy is not associated with occurrence of 
preterm delivery. A positive relationship between colonization and risk of preterm birth 
would provide opportunities for further research regarding antibiotic interventions in the 
prevention of preterm labor caused by GBS. 
In chapter 6 we describe a meta-analysis on the timing of GBS screening in pregnancy 
to determine the best moment to screen for GBS colonization, which may help to establish 
optimal prevention of perinatal GBS infection both in term and preterm neonates. GBS 
colonization can be transient, intermittent or persistent. International studies report that 
the majority of remaining GBS-EOD nowadays occurs in infants whose mothers screened 
negative for GBS colonization.(31) Predictive values of GBS cultures at gestational age of 
35-37 weeks have never been reported to be 100%, and screening in this period will not 
provide information about GBS colonization in the preterm period, when GBS-disease 
in neonates is most dangerous.(32;33) Improving the effectiveness of GBS screening and 






We found that the positive predictive values (PPVs) correlate positively with increasing 
gestational age at time of GBS culture. PPV decreases when the interval between antenatal 
culture and delivery culture increases, especially when it is more than six weeks. Negative 
predictive values remain constant and are therefore unrelated to the gestational age at which 
the culture is performed. Our systematic review confirms the recommendations to screen 
pregnant women for colonization of GBS at 35-37 weeks gestation. However, since 6% of 
GBS carriers during delivery remain undetected in antenatal cultures one should be aware 
of the limitations of screening. There are two options for preventing GBS-EOD in preterm 
infants whose mothers are not yet screened: either giving IAP in all premature deliveries or 
screening of all pregnant women early in pregnancy and culturing again later in pregnancy. 
With regard to the remaining burden of disease it is important to identify potential areas 
for improvement in the total process from antenatal care to discharge of a healthy women 
with a healthy baby. In chapter 7 we indicate opportunities for improvement of prevention 
of GBS-EOD. Training in recognizing GBS-EOD is important. Knowledge about the route 
to disease and the possible preventive measures deserve continued attention of all workers 
in obstetric care, either in hospitals or at home. Caregivers need to be aware that there 
are a lot of small steps in the chain of prevention where improvement can be made. These 
include establishment of national and local prevention guidelines, accuracy of GBS prenatal 
screening, good implementation and communication, correct procedures for laboratory 
techniques, proper dosage and duration of IAP and clear appointments about secondary 
prevention of GBS-EOD among newborn infants. In chapter 8, we describe several strategies 
for prevention of GBS-EOD as alternatives for the current Dutch modified risk factor based 
guideline. As mentioned before, the best preventive strategy maximizes treatment in women 
who need it, and minimizes treatment in women who do not need it. We suggest that chang-
ing the current guideline into a guideline which advocates the combinationstrategy will 
result in a optimimal prevention of GBS-EOD in the Netherlands. In theory, the combination 
of the screening based strategy and risk factor based strategy (combinationstrategy) has the 
lowest number needed to treat, i.e. only 47 pregnant women need to get IAP to prevent one 
case of GBS-EOD. There is an equal percentage of unprotected infants in comparison to the 
risk factor based strategy. However, the great advantage of the combinationstrategy is that 
GBS status is always known, which allows caregivers to be extra alert on babies from GBS 
positive mothers who do not receive IAP because there is no risk factor. Parents of these 
newborns can be informed as well to watch for signs of GBS-EOD. This combination strategy 
will not interfere with the Dutch obstetrical system and will not lead to extra hospital refer-
rals.
Future Perspectives and directions of research
This thesis contributes to the information needed for the establishment of an optimal preven-
tive strategy for GBS-EOD. Although much progress has been made in the prevention of 
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GBS-EOD, important challenges remain. Early-onset disease has declined among all racial 
and ethnic groups, yet disparities persist. Research aimed at better understanding racial or 
ethnic differences in GBS disease might lead to opportunities for more effective prevention 
efforts. Continued monitoring and analysis of cases of GBS-EOD is needed in order to get 
tools for future prevention. The evidence is incomplete for several areas related to GBS 
prevention, including strategies to prevent GBS-EOD among preterm infants, the role of bac-
teriuria as a risk factor in the era of universal screening and effectiveness of recommended 
antibiotics other than penicillin for penicillin allergic women at high risk for anaphylaxis. 
We recommend new, well-designed and well-executed studies to determine the best timing 
of antenatal culturing for GBS. These could include longitudinal prospective cohort studies 
with cultures taken at different gestational ages. This would provide more reliable data to 
compare individual differences in GBS colonization, and understand its dynamics, there-
fore permitting practitioners to draw more dependable conclusions from culture results. 
By identification of most virulent GBS strains, IAP can targeted been given in carriers of 
these specific GBS strains, thereby decreasing the total proportion of women treated with 
antibiotics unnecessarily . The development of a rapid laboratory test to identify GBS will 
bring us closer to the possibility of an intrapartum test for GBS screening. This screening 
test for GBS should consist of a simple bedside kit that enables delivery staff to perform a 
test, have a turn-around time of less than 1 hour and have a sensitivity and specificity of > 
90%. Ideally, a rapid test for intrapartum use also would give information about resistance to 
clindamycin and/or erythromycin in order to guide antibiotic choice for penicillin-allergic 
women. Alternative strategies continue to merit evaluation. These include use of the vaginal 
disinfectant chlorhexidine applied topically during labor, as well as newborn washes with 
chlorhexidine formulation. 
In recognition of the shortcomings of IAP-based prevention strategies, vaccination has 
the most potential for eradicating invasive GBS disease of the neonate and the young infant, 
as well as of the mother. Several other advantages might be anticipated; vaccination would 
avoid antibiotics, screening and labor intrusions and could protect against both early and 
late onset disease. Development of GBS vaccines is scientifically feasible(34) and multiple 
phase II studies, including among pregnant women, have already been conducted. Practi-
cal, legal and business concerns have thus far hindered the achievements of licensure of 
GBS vaccines targeted for use in pregnancy. To ensure effective vaccine development, it will 
be important to monitor the distribution pattern of the prevalent serotypes and sequence 
types in all regions of the world continuously, thereby ensuring the inclusion of the most 
relevant components in a global GBS vaccine.(35) However, a vaccination program is effec-
tive only if the entire target audience is reached, and this will be a continuous challenge for 
anyone involved in the area of prevention of disease. The introduction in 1998 of a Dutch 
national guideline on prevention of GBS-EOD resulted in a slight reduction in the inci-






information even shows increase in cases of GBS sepsis per year. It is therefore clear that 
the current Dutch guideline is not effective enough and a new strategy to prevent GBS-EOD 
is justified, in particular with regard to the fact that perinatal mortality in the Netherlands 
is high compared to other European countries.(25) Until a safe and efficacious vaccine is 
licensed and implemented, areas of research in the Netherlands should include studies on 
cost-effectiveness of several prevention strategies, including trials on vaginal chlorhexidine 
flushing compared to intravenous antibiotics in GBS carriers during term delivery. Cases of 
GBS-EOD in the Netherlands should be monitored and analyzed in order to improve future 
prevention. By evaluating and debating existing guidelines and giving priority to find the 
best prevention strategy for GBS-EOD, it should be possible to further decrease the burden 
of this disease in the Netherlands.
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Groep B Streptokokken (Streptococcus Agalactiae, GBS) zijn in de westerse wereld belang-
rijke verwekkers van vroege en soms zeer ernstig verlopende infecties bij pasgeborenen.
(1-3) Besmetting met GBS vindt plaats van moeder naar kind tijdens de baring (verticale 
transmissie). Er is sprake van GBS-dragerschap bij 10% tot 35% van de vrouwen in de 
fertiele levensfase.(4;5) GBS-dragerschap kan van voorbijgaande aard zijn, maar ook inter-
mitterend of continue.(6-8) Studies naar verticale transmissie bij vrouwen die GBS-drager 
zijn, rapporteren kolonisatie van het kind in 16 tot 69% van de gevallen.(9-14) Neonatale 
groep B streptokokken ziekte (GBS-early onset disease, GBS-EOD) komt voor bij ongeveer 
1% van de pasgeborenen die zijn gekoloniseerd met GBS.(15)
Van een aantal factoren is bekend of wordt aangenomen dat zij, indien GBS in het barings-
kanaal aanwezig is, de kans op een infectie vroeg in de neonatale periode aanzienlijk 
vergroten. Deze risicofactoren zijn 1.vroeggeboorte, 2.langdurig gebroken vliezen, 3.koorts 
van de moeder tijdens de baring, 4.GBS-bacteriurie en 5.GBS-ziekte bij een eerder kind.(16) 
Het is effectief gebleken om -aan vrouwen die risico lopen om een kind met GBS-ziekte 
te krijgen- tijdens de bevalling antibioticaprofylaxe toe te dienen om GBS-ziekte bij de 
pasgeborene te voorkomen.(14;17) Het opsporen van deze zwangeren met een verhoogd 
risico op verticale transmissie, kan door middel van screening (een kweek afnemen tijdens 
de zwangerschap om GBS-kolonisatie op te sporen) (screeningstrategie) en/of door het 
identificeren van zwangerschappen met één of meer van de risicofactoren voor GBS-EOD 
(risicofactorstrategie). 
In de wereld bestaat geen eenduidig beleid voor de preventie van GBS-EOD. In de Verenigde 
Staten bijvoorbeeld, wordt door de ‘Centers for Disease Control en Prevention’ (CDC) aanbe-
volen alle zwangere vrouwen bij een zwangerschapsduur van 35-37 weken te screenen op 
dragerschap en preventief antibiotica tijdens de bevalling te geven aan alle GBS-dragers.(18)
De huidige Nederlandse richtlijn voor preventie van perinatale groep B streptokokken-ziekte, 
geformuleerd door de Nederlandse Vereniging voor Obstetrie en Gynaecologie (NVOG) en de 
Nederlandse Vereniging voor Kindergeneeskunde (NvK), gaat uit van de risicofactorstrategie. 
In de richtlijn wordt geadviseerd tijdens de bevalling intraveneus antibiotica te geven aan 
vrouwen met koorts (> 38°C), zwangeren met GBS-bacteriurie of vrouwen die een eerder 
kind hadden met GBS-infectie. Bij vrouwen met vroegtijdige weeën (<37 weken) of langdurig 
gebroken vliezen (> 18 uur), wordt in de Nederlandse richtlijn geadviseerd een rectovaginale 
kweek af te nemen, gevolgd door intraveneuze antibioticaprofylaxe als de kweekuitslag posi-
tief is. Meestal is de kweekuitslag bekend na 24 tot 48 uur. Wanneer de bevalling plaatsvindt 
vóórdat de uitslag van de kweek beschikbaar is, moet de gynaecoloog beslissen over het al 
dan niet intraveneus toedienen van antibiotica tijdens de bevalling. De beslissing is meestal 







Sinds de implementatie van preventiestrategieën is de totale incidentie van GBS-EOD in 
vele landen over de hele wereld geleidelijk afgenomen,(18-21) maar de huidige strategieën 
voor preventie van GBS-EOD zijn nog steeds onderwerp van discussie. Ondanks aanzien-
lijke inspanning en investeringen in geld besteed aan de preventie van GBS-EOD, blijft het 
een belangrijke oorzaak van neonatale infectie en neonatale sterfte binnen de eerste zeven 
dagen van het leven.(2;18;20;22;23)
In Nederland is er sinds de invoering van de huidige richtlijn ter preventie van perinatale 
groep B streptokokkenziekte sprake van een beperkte daling van de incidentie van GBS-
EOD.(24) Dit geeft aanleiding tot discussie over verbetering of verandering van de richtlijn. 
Deze discussie is actueel naar aanleiding van cijfers over de perinatale sterfte in Nederland, 
die hoog is in vergelijking met andere Europese landen.(25) 
De beperkte effectiviteit van de huidige richtlijn zou kunnen worden verklaard door het 
feit dat in geval van het optreden van vroeggeboorte of langdurig gebroken vliezen, moge-
lijkheden tot preventie kunnen worden gemist als gevolg van vertraging bij het verkrijgen 
van kweekresultaten. Andere factoren die bijdragen aan het voortbestaan van GBS-ziekte 
zijn onjuiste kweekafname, vertraging in de verwerking van kweken, suboptimale labo-
ratoriumtechnieken, recent gebruik van antibiotica of optreden van kolonisatie nadat de 
screeningskweek werd uitgevoerd, onder andere door een verkeerde timing van de afname 
van de kweek. Ook factoren zoals het ontbreken van (lokale) richtlijnen, gebrek aan com-
municatie van alle betrokkenen bij pre-en perinatale zorg of onjuiste uitvoering van de 
richtlijn en microbiologische factoren zoals resistentie tegen antibiotica, kunnen leiden tot 
het missen van mogelijkheden tot preventie en daarmee tot het uitblijven van een verdere 
daling van GBS-EOD. 
Omdat het totale effect van de Nederlandse richtlijn op de incidentie van GBS-EOD 
teleurstellend is, dient aanpassing van de Nederlandse richtlijn plaats te vinden. Het doel 
van dit proefschrift is een bijdrage te leveren aan de informatie die nodig is voor het opstel-
len van een optimale preventie strategie voor GBS-EOD.
dit proefschrift
De beste preventiestrategie maximaliseert de behandeling bij vrouwen die het nodig heb-
ben, en minimaliseert de behandeling bij vrouwen die het niet nodig hebben. Alvorens 
de Nederlandse strategie te kunnen optimaliseren, is het essentieel om kennis over de 
prevalentie van GBS-kolonisatie van zwangere vrouwen in Nederland te verkrijgen. Pre-
valentie van dragerschap zou veranderd kunnen zijn als gevolg van recente demografische 
veranderingen, in het bijzonder met betrekking tot de etnische achtergrond van vrouwen 
die in grote steden wonen. In onze studie beschreven in hoofdstuk 2 tonen we aan dat 
onder de multiculturele, randstedelijke bevolking van de zwangere vrouwen in Den Haag, 
Nederland, de prevalentie van GBS-kolonisatie 21% is. We vonden ethnische verschillen 
tussen gekoloniseerde en niet-gekoloniseerde vrouwen, maar we konden geen verschillen 
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aantonen tussen gekoloniseerde en niet-gekoloniseerde vrouwen met betrekking tot leeftijd, 
pariteit of sociaal-economische achtergrond. De resultaten van deze studie laten zien dat 
het niet mogelijk is een subgroep van zwangere vrouwen die een hoger risico op GBS-
kolonisatie hebben, te identificeren. De positief voorspellende waarde van GBS-dragerschap 
bij 35-37 weken zwangerschap voor dragerschap op het moment van de bevalling was 79% 
en de negatief voorspellende waarde was 93%.
Een secundaire analyse van ons cohort van zwangere vrouwen werd uitgevoerd om na te 
gaan of het optreden van vroeggeboorte vóór 37 weken zwangerschapsduur of het optreden 
van langdurig gebroken vliezen kan voorspellen wat de prenatale GBS-status is. Als vrouwen 
met deze risicofactoren een hoger risico lopen om GBS-drager te zijn, kan de Nederlandse 
richtlijn worden verbeterd door het adviseren van directe toediening van antibiotica aan 
vrouwen met deze risicofactoren, in plaats van te wachten tot kweekresultaten bekend zijn 
voordat antibioticaprofylaxe wordt gestart. We vonden dat het optreden van de risicofac-
toren vroeggeboorte en/of gebroken vliezen langer dan 24 uur niet voorspellend is voor 
GBS-kolonisatie. Het optreden van deze risicofactor op zich is dus niet te gebruiken bij het 
identificeren van moeders met een hoger risico op een baby met GBS-EOD. (hoofdstuk 3)
In de Nederlandse richtlijn voor preventie van perinatale GBS-ziekte wordt aangeraden 
intraveneus benzylpenicilline te geven aan vrouwen die in aanmerking komen voor profy-
lactisch antibiotica tijdens de bevalling. Indien er sprake is van penicilline-allergie, wordt 
clindamycine of erytromycine aanbevolen als alternatief. Diverse studies rapporteren uni-
versele gevoeligheid voor benzylpenicilline en cefalosporines, maar de resistentie van GBS 
voor erytromycine en clindamycine is in de loop van de laatste tien jaar in verschillende 
landen toegenomen.(26-29) 
Wanneer antibiotica op grote schaal gebruikt wordt ter preventie van ziekte, is waakzaam-
heid geboden met betrekking tot de ontwikkeling van antibiotica-ongevoeligheid en klonale 
verspreiding van resistente micro-organismen.
In hoofdstuk 4 beschrijven we de prevalentie van fenotypische en genotypische resisten-
tie tegen macroliden bij groep B streptokokken die werden geïsoleerd in de Nederlandse 
prevalentiestudie, zoals beschreven in hoofdstuk 2. Wij onderzochten de mogelijkheid 
van klonale verspreiding van resistente GBS isolaten in een multiculturele populatie. De 
antimicrobiële resistentie patronen van 107 GBS isolaten werden bepaald met behulp van 
Etests. Door middel van PCR-onderzoek werd aanwezigheid van macrolide resistentie-
genen mef (A), erm (TR) en erm (B) bepaald. Een subgroep van 39 isolaten, waaronder 
de 8 isolaten met macrolide resistentiegenen, werd onderworpen aan RAPD-analyse om 
klonale verspreiding te detecteren. Resistentie tegen erytromycine en clindamycine werd 







en erm (B) werden gevonden in respectievelijk 1, 2 en 5 isolaten; slechts vijf van deze acht 
isolaten vertoonden zowel genotypische als fenotypische resistentie. Van de geanalyseerde 
subgroep behoorde 36% tot eenzelfde genotype. Eerdere berichten over de prevalentie 
van fenotypische resistentie werden bevestigd. Onder de gevoelige isolaten was duidelijk 
één GBS-kloon overheersend en één van de resistente isolaten had eenzelfde genotype 
als deze GBS-kloon. Wanneer dergelijke klonen in de toekomst resistentie verwerven, kan 
GBS-ziekte moeilijker te controleren worden.
Vroeggeboorte bij moeders die GBS-drager zijn is een erkende risicofactor voor GBS-
ziekte(30), maar of maternaal GBS-dragerschap is gerelateerd aan vroeggeboorte is onduide-
lijk. Een positieve relatie tussen GBS-kolonisatie en optreden van vroegtijdige geboorte zou 
mogelijkheden bieden voor verder onderzoek met betrekking tot antibiotische interventies 
bij de preventie van vroeggeboorte als gevolg van GBS.
In de zoektocht naar mogelijkheden voor tijdige interventie in de preventie van GBS-
EOD, werd een literatuurstudie verricht om een  samenhang tussen GBS-dragerschap en 
vroeggeboorte te vinden. In hoofdstuk 5 worden de resultaten van deze systematische 
review beschreven. De zoekstrategie leverde studies op met uiteenlopende studieopzet in 
verschillende studieperiodes, uit landen met verschillende prevalentie van GBS-dragerschap 
en vroeggeboorte. Vroeggeboorte lijkt positief geassocieerd met GBS-kolonisatie op het 
moment van bevalling, maar dragerschap tijdens de zwangerschap is niet geassocieerd met 
het optreden van vroeggeboorte. 
In hoofdstuk 6 worden de uitkomsten van een meta-analyse naar het optimale tijdstip van 
GBS-screening in de zwangerschap beschreven. GBS-kolonisatie kan van voorbijgaande 
aard zijn, maar ook intermitterend of continue aanwezig zijn. Onderzoeksresultaten van 
meerdere landen laten zien dat het merendeel van de GBS-ziekte tegenwoordig voorkomt 
bij zuigelingen van wie de moeder bij screening GBS negatief was.(31) De voorspellende 
waarde van GBS-kweken afgenomen bij een zwangerschapsduur van 35-37 weken is in 
geen enkele studie 100% gebleken. Bovendien, door screening rondom deze amenorroe-
duur zal geen informatie worden verkregen over GBS-dragerschap in de preterme periode, 
terwijl GBS-ziekte juist bij preterm geboren kinderen het meest gevaarlijk is.(32;33) Ver-
betering van de effectiviteit van GBS-screening en het bewustzijn van de beperkingen zou 
kunnen helpen bij het verder verminderen van de incidentie van GBS-EOD. Uit analyse 
blijkt dat de positief voorspellende waarde (PPV) positief correleert met toenemende zwang-
erschapsduur ten tijde van de GBS-kweek. De PPV neemt af wanneer het interval tussen 
de prenataal afgenomen kweek en de kweek afgenomen bij de bevalling toeneemt, vooral 
wanneer het interval meer is dan zes weken. De negatief voorspellende waarde blijft con-
stant en staat daarom los van de zwangerschapsduur waarbij de kweek is uitgevoerd. Onze 
systematische review bevestigt de internationale aanbevelingen om GBS-screening tijdens 
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de zwangerschap te verrichten rond 35-37 weken zwangerschapsduur. Omdat 6% van de 
vrouwen die GBS-drager is tijdens de bevalling, onopgemerkt blijft tijdens de antenatale 
kweken moet men zich bewust zijn van de beperkingen van de screening. Er zijn twee 
opties voor het voorkomen van GBS-EOD bij premature zuigelingen van wie de moeder 
nog niet gescreend is: ofwel antibiotica geven aan alle vrouwen met een vroeggeboorte, of 
screening van alle zwangere vrouwen in het begin van de zwangerschap en het herhalen 
van de kweken later in de zwangerschap.
Om de mortaliteit en morbiditeit ten gevolge van GBS-ziekte verder terug te kunnen 
dringen, is het van belang aanknopingspunten voor verbetering te identificeren. Hierbij 
dienen mogelijkheden voor verbetering te worden onderzocht in het totale proces van 
prenatale zorg voor de zwangere tot en met ontslag van een gezonde moeder met een 
gezonde baby. In hoofdstuk 7 worden mogelijkheden voor verbetering van de preventie 
van GBS-EOD beschreven. Training in het herkennen van GBS-ziekte is belangrijk. Kennis 
over de pathologie van het ziektebeeld en de mogelijke preventieve maatregelen verdienen 
blijvende aandacht van alle zorgverleners in de keten. Zorgverleners moeten zich ervan 
bewust zijn dat er in de keten van preventie vele kleine stappen zijn waar verbetering kan 
worden bewerkstelligd. Hierbij valt te denken aan het opstellen van nationale en lokale 
preventie-richtlijnen, juiste timing en techniek van afname van GBS-kweken, een goede 
implementatie en communicatie, de juiste procedures voor laboratorium technieken, de 
juiste dosering en duur van antibioticaprofylaxe en duidelijke afspraken over de secun-
daire preventie van GBS-ziekte bij pasgeboren baby’s. In hoofdstuk 8 zijn verschillende 
strategieën voor de preventie van GBS-EOD genoemd als alternatieven voor de huidige 
Nederlandse richtlijn die op de risicofactorstrategie is gebaseerd. Zoals eerder vermeld, 
is de beste preventieve strategie een strategie die behandeling geeft aan vrouwen die het 
nodig hebben, en geen behandeling aan vrouwen die het niet nodig hebben. We adviseren 
aanpassing van de huidige richtlijn en pleiten voor de combinatiestrategie als optimale 
preventiestrategie ter preventie van perinatale GBS-ziekte in Nederland.
In theorie heeft deze combinatie van zowel op screening als op risicofactoren geba-
seerde strategie (de combinatiestrategie) het laagste ‘number needed to treat’, dat wil zeggen 
slechts 47 zwangere vrouwen moeten tijdens de bevalling intraveneus antibiotica krijgen 
om één geval van GBS-ziekte te voorkomen. Er is een gelijk percentage onbeschermde 
zuigelingen in vergelijking met de risicofactor strategie. Echter, het grote voordeel van de 
combinatiestrategie is dat de GBS-status altijd bekend is. Dit maakt het mogelijk dat zorg-
verleners extra alert zijn bij baby’s van GBS-positieve moeders die geen antibiotica kregen 
tijdens de bevalling omdat er geen risicofactor was. Ouders van deze pasgeborenen kunnen 
extra worden geïnformeerd en instructies krijgen om op tekenen van GBS-EOD te letten. 
Deze combinatie strategie zal niet interfereren met het huidige Nederlandse verloskundige 







Toekomstperspectieven en richtingen van onderzoek
Dit proefschrift draagt  bij aan de informatie die nodig is voor het opstellen van een optimale 
preventiestrategie voor GBS-EOD.
Hoewel er veel vooruitgang is geboekt in de preventie van GBS-EOD, blijven er grote 
en belangrijke uitdagingen bestaan. De incidentie van GBS-ziekte is afgenomen onder alle 
rassen en etnische groepen, maar verschillen blijven bestaan. Onderzoek gericht op een 
beter begrip van etnische verschillen in het optreden van GBS-infectie kan leiden tot moge-
lijkheden voor meer doeltreffende inspanningen met betrekking tot preventie. Voortdurend 
toezicht op en analyse van kinderen met GBS-EOD is nodig om handvatten te krijgen voor 
preventie in de toekomst. Er is nog onvoldoende onderzoek gedaan op verschillende ter-
reinen die verband houden met GBS-preventie, zoals studies naar strategieën om GBS-EOD 
te voorkomen bij te vroeg geboren baby’s, de rol van bacteriurie als risicofactor en de effec-
tiviteit van de aanbevolen antibiotica bij vrouwen met penicillineallergie en hoog risico 
op anafylaxie. Er dienen nieuwe, goed ontworpen en goed uitgevoerde studies te worden 
verricht om de beste timing van prenatale kweken voor GBS te bepalen. Daartoe behoren 
onder meer longitudinale prospectieve cohortstudies waarbij kweken worden afgenomen 
tijdens verschillende momenten in de zwangerschap. Dit levert meer betrouwbare gegevens 
op om individuele verschillen in GBS-kolonisatie te vergelijken en meer betrouwbare con-
clusies te trekken uit kweekresultaten. 
Door identificatie van de meest virulente GBS-stammen, kan gericht antibiotica worden 
gegeven aan dragers van deze specifieke GBS-stammen, waardoor het totale aantal vrouwen 
dat onnodig wordt behandeld tijdens de bevalling kan afnemen. De ontwikkeling van een 
snelle laboratoriumtest om GBS te identificeren zal mogelijk maken dat pas op het moment 
van de bevalling zelf getest wordt op GBS-dragerschap. Deze screeningstest voor GBS dient 
te bestaan  uit een eenvoudige “bedside kit” die binnen een uur betrouwbaar uitsluitsel geeft 
over GBS-dragerschap. 
Alternatieve strategieën voor preventie van GBS-ziekte dienen te blijven worden onder-
zocht. Hierbij kan bijvoorbeeld gedacht worden aan het gebruik van het vaginale ontsmet-
tingsmiddel chloorhexidine tijdens de bevalling.
Met het besef van de tekortkomingen van alle strategieën waarbij antibiotica worden 
gebruikt ter preventie van GBS-ziekte, heeft als alternatief waarschijnlijk vooral vaccinatie 
het grootste potentieel voor de bestrijding van invasieve GBS-infectie van de pasgeborene en 
het jonge kind. Er zijn hierbij verschillende voordelen; vaccinatie maakt antibioticagebruik 
onnodig, voorkomt de noodzaak van screening en biedt bescherming tegen zowel de vroege 
als de latere ontstane GBS-ziekte. De ontwikkeling van GBS-vaccins is wetenschappelijk 
haalbaar(34) en meerdere fase II studies, ook onder zwangere vrouwen, zijn al uitgevoerd. 
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Praktische, juridische en zakelijke bezwaren hebben tot nu toe het verwerven van licentie 
voor GBS-vaccins voor gebruik tijdens de zwangerschap verhinderd. Om een effectief vaccin 
te kunnen ontwikkelen, is het belangrijk om het verspreidingspatroon van de voorkomende 
serotypen in alle delen van de wereld te volgen, zodat gezorgd kan worden dat een globaal 
GBS-vaccin de meest relevante componenten bevat.(35) Een vaccinatieprogramma is alleen 
effectief als de gehele doelgroep wordt bereikt en dit zal een voortdurende uitdaging zijn 
voor iedereen die betrokken is bij de preventie van ziekten. 
De introductie van een Nederlandse landelijke richtlijn voor de preventie van GBS-EOD 
in 1998 resulteerde in een lichte daling van de incidentie van bewezen GBS-EOD, maar 
niet in een daling van ernstige morbiditeit en mortaliteit. Recente informatie toont zelfs 
toename van het aantal gevallen van GBS-sepsis per jaar. Het is dus duidelijk dat de huidige 
Nederlandse richtlijn niet effectief genoeg is en dat de ontwikkeling van een nieuwe stra-
tegie om GBS-EOD te voorkomen gerechtvaardigd is, in het bijzonder met betrekking tot 
het feit dat de perinatale sterfte in Nederland hoog is in vergelijking met andere Europese 
landen.(25) Tot een veilig en werkzaam vaccin is ontwikkeld en kan worden gebruikt, moet 
onderzoek in Nederland zich richten op kosteneffectiviteit van verschillende preventiestra-
tegieën, waaronder het gebruik van vaginale chloorhexidine spoeling in vergelijking met 
intraveneuze antibiotica voor GBS-dragers tijdens de bevalling. Kinderen met GBS-EOD in 
Nederland moeten worden geanalyseerd om toekomstige preventie te verbeteren. Door de 
evaluatie van en discussie over bestaande richtlijnen en het geven van hoge prioriteit aan 
de zoektocht naar de beste preventiestrategie voor GBS-EOD, moet het mogelijk zijn om 
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De schrijfster van dit proefschrift werd op 27 september 
1974 geboren in Delft. Na het behalen van haar VWO-
diploma met klassieke talen (1992) aan het Christelijk 
Lyceum te Delft volgde zij het Basisjaar aan de Evangeli-
sche Hogeschool te Amersfoort. 
In 1993 begon zij aan haar studie Geneeskunde aan 
de Erasmus Universiteit van Rotterdam. Keuzeonderzoek 
werd verricht op de afdeling Neonatologie van het Sophia 
Kinderziekenhuis te Rotterdam. Hier werkte zij mee aan een 
vroegtijdig interventieprogramma ter preventie van groei- en 
ontwikkelingsstoornissen bij prematuur geboren kinderen 
met een laag geboortegewicht. In 1997 vertrok ze naar 
Afrika, voor een klinische stage van enkele maanden in het 
Presbyterian Church of East Africa Kikuyu Hospital te Kikuyu 
in Kenia. Daarna was zij tijdens haar afstudeeronderzoek betrokken bij de ontwikkeling van een 
meetinstrument voor het meten van de kwaliteit van leven van ouders van een kind met een 
aangeboren aandoening. Dit onderzoek vond plaats op de afdelingen Medische Psychologie en 
Kinderchirurgie van het Sophia Kinderziekenhuis te Rotterdam. 
Na haar doctoraalexamen in 1998 begon zij aan haar co-schappen. Zij maakte kennis 
met de Verloskunde en Gynaecologie tijdens haar co-schap in het Westeinde Ziekenhuis te 
Den Haag. Hier werd definitief de liefde voor dit vak geboren. Tijdens het keuze-coschap 
Verloskunde en Gynaecologie participeerde zij in de follow-up van een prospectieve studie 
naar onder andere de prevalentie van Humaan Papilloma Virus bij geringe cytologische 
afwijking in het uitstrijkje van de cervix. 
Na het behalen van het artsexamen (najaar 2000) werkte zij als AGNIO (assistent genees-
kundige niet in opleiding) op de afdeling Verloskunde en Gynaecologie van het Westeinde 
Ziekenhuis te Den Haag. In 2002 begon zij als AGIKO (assistent geneeskundige in opleiding 
tot klinisch onderzoeker) aan het in dit proefschrift beschreven onderzoek in het Westeinde 
Ziekenhuis te Den Haag. In 2004 startte zij in dit ziekenhuis, inmiddels Medisch Centrum 
Haaglanden, met de opleiding tot gynaecoloog (opleiders prof. dr. P.J. Dörr en mw. dr. M.J. 
Kagie), gevolgd door het academisch deel van de opleiding in het Leids Universitair Medisch 
Centrum te Leiden (opleiders prof. dr. H.H.H. Kanhai, mw. prof. dr. G.G. Kenter en prof. dr. 
J.M.M. van Lith). In augustus 2011 begon ze als gynaecoloog aan het fellowship Perinatologie 
in het VU Medisch Centrum te Amsterdam, waar zij tot heden met veel plezier werkzaam is.
Als laatste genoemd, maar ten diepste de belangrijkste mijlpalen uit schrijfsters levens-
loop tot nog toe: in 1998 trouwde zij met Arco Valkenburg en werden in hun gezin Job 














Tussen de dag dat ik voor het eerst besefte wat groep B streptokokken kunnen aanrichten bij 
pasgeborenen en de dag dat ik “Het GBS-onderzoek” zoals beschreven in dit proefschrift 
kan verdedigen, werd een behoorlijk pad afgelegd waarop onderweg van alles gebeurde. 
Het was geen rechte weg en zeker niet één die zich gemakkelijk liet vinden. Dat het eind-
punt uiteindelijk bereikt kon worden, is dankzij vele mensen die onderweg voor kortere of 
langere tijd om mij heen waren. Het is moeilijk om zo velen persoonlijk te bedanken, maar 
feit is wel dat alle steun, inspiratie, aanmoediging en hulp op welke manier dan ook, voor 
mij van grote waarde is geweest.
Er werd onderweg hard gewerkt, gezongen, gelachen, gehuild, gebaard, gezucht, gerend, 
gestruikeld, bij de pakken neergezeten, gejuicht en gehaast. Steeds waren daar toeschouwers, 
aanmoedigers, helpers en dragers, toevallige passanten, meelopers, aanjagers, verzorgers, 
trainers en belangstellenden. Hele stukken van de weg werden afgelegd in zonneschijn, 
maar soms regende het of kwam de mist op, zodat de weg alleen maar hobbelig leek en 
moeilijk begaanbaar. Steeds bleef het verlangen naar het eindpunt en het uitzicht, maar ook 
onderweg werd regelmatig op het pad stilgestaan om van de omgeving en onverwachte 
vergezichten te genieten. Het was goed om steeds te kunnen vertrouwen op de bagage die 
mij ooit werd meegegeven en bovendien voor alles terug te kunnen vallen op hen waarmee 
ik arm in arm liep.
En zo kwam ik samen met velen daar waar ik nu ben. De afgelegde afstand zorgt voor 
vreugde en trots, maar vooral ook voor dankbaarheid. Ere Wie ere toekomt! 
Lieve mama en daddy, jullie stonden aan het begin, hielpen mij op weg en zijn altijd 
blijven aanmoedigen. Allerliefste Ar, bij jou is het steeds weer goed thuiskomen. Ik hoop dat 
we samen met Job, Saar, Mees en Noor nog vele mooie wegen zullen gaan!
Lieverds, het boekje is klaar. Op weg naar morgen!



